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Zusammenfassung 
Ivorenolide A und B sind Vertreter einer neuartigen Klasse von polyacetylenischen Naturstoffen, 
welche ein in ein makrozyklisches Gerüst eingebettetes 1,3-Diin-Motiv aufweisen. Biologische 
Studien ergaben, dass beide Naturstoffe vielversprechende immunosuppressive Aktivität aufweisen 
und somit als mögliche Leitstrukturen für die Entwicklung neuartiger Medikamente in Frage 
kommen. 
Die Anwendung der kürzlich publizierten Ringschluss-Alkin-Metathese von 1,3-Diinen (RCDM) 
erlaubte die Zyklisierung einer Vielzahl von verschienden acyclischen Substraten. Die Verwendung 
dieser Methode ermöglichte die Totalsynthese von Ivorenolide A und B, wobei die Synthese von 
Ivorenolide B die erste unsymmetrische RCDM zwischen einem terminalen und einem methyl-
verkappten 1,3-Diin darstellte. Die Totalsynthese von Ivorenolide A ist das erste Beispiel einer 
Zyklisierung eines bis-propargylischen 1,3-Diines.  
 
Rhizoxin D und verwandte Verbindungen gehören zu einer Klasse von polyketidischen Makroliden, 
welche ein breites Spektrum an biologischen Eigenschaften aufweisen. Eine neue Strategie, welche 
den Zugang zu dieser Klasse von Verbindungen ermöglicht, wurde erarbeitet. Diese Route basiert auf 
der RCDM als Schlüsselschritt und einer eigens entwickelten Synthese von (E,E)-1,3-Dienen durch 
eine hydroxy-dirigierende trans-Hydrostannierung von 1,3-Diin-Verbindungen. 
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Das hoch funktionalisierte makrozyklische Gerüst von Rhizoxin D weist eine Vielzahl von Sauerstoff-
funktionalitäten sowie mehrere ungesättigte Positionen auf und besitzt durch das annulierte δ-
Lakton sowie durch die (E)-konfiguerierte Doppelbindung eine signifikante Ringspannung. Die 
Zyklisierung eines solchen Substrates stellte somit eine große Herausforderung für die neue 
Methodik dar. 
 
Nach den Synthesen beider Fragmente, sowie deren erfolgreicher Verknüpfung,  erlaubte die 
Verwendung des Molybdänalkylidin-Komplexes C5 die problemlose Zyklisierung des Substrates. 
Dieses Beispiel verdeutlicht die Vielseitigkeit dieser Methodik und stellt somit eine wertvolle 
Ergänzung zu etablierten Methoden wie der Olefin-Metathese dar.    
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Abstract 
Ivorenolide A and B are representatives of a novel class of polyacetylenic natural products featuring a 
1,3-diyne motif embedded in a macrocyclic core. Biological surveys revealed their promising 
immunosuppressive activity. Both compounds might serve as possible lead structures in the 
evolutionary process of developing novel highly active drugs. 
The application of the recently reported ring-closing alkyne metathesis of 1,3-diynes (RCDM) allowed 
the cyclization of a broad variety of acyclic 1,3-diynes. Application of this methodology culminated in 
the total syntheses of ivorenolide A and B. The total synthesis of ivorenolide B represented the first 
unsymmetrical RCDM between a terminal and a methyl capped 1,3-diyne and the total synthesis of 
ivorenolide A was the first cyclization of a bis-propargylic 1,3-diyne. 
 
Rhizoxin D and related family members are a class of polyketide macrolides which exhibit a wide 
array of interesting biological properties. A novel strategy for the total synthesis of this class of 
antitumor macrolides was established. The strategy relied on RCDM as the key transformation 
followed by a specifically developed selective conversion of the resulting 1,3-diyne to the 
corresponding (E,E)-1,3-diene via hydroxyl group directed trans-hydrostannation. 
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The highly decorated macrocyclic core of rhizoxin D represented a remarkably challenging substrate 
for RCDM as it exhibits a multitude of oxygen functionalities as well as several sites of unsaturation 
and significant ring strain due to the annulated δ-lactone as well as to the (E) configured olefin. 
 
After the syntheses of both fragments and their successful assembly, the utilization of molybdenum 
alkylidyne complex C5 allowed the RCDM to proceed smoothly to give the cyclized 1,3-diyne. This 
example highlights the versatility of this transformation, rendering it a valuable alternative to 
established methods such as olefin metathesis. 
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1. Introduction  
1.1 Natural product synthesis 
The necessity for the development of new and more efficient drugs in a rapidly changing and aging 
society provides a major challenge for life sciences. Substances isolated from natural sources play a 
significant role in this process, either as drugs or as possible lead structures in the evolutionary 
process of finding new highly biologically active compounds.[1] Natural products (NP) are often 
secondary metabolites isolated from a great variety of sources including plants,[2] microbes,[3] fungi[4] 
and marine sponges.[5] They undergo specific interactions with target enzymes or receptors and 
exhibit a wide variety of potentially interesting biological properties. Their often remarkable activity 
makes them interesting objects for interdisciplinary research. In addition natural products often 
exhibit structural features which are not regularly found in synthesis-based screening libraries. The 
span of their biological activity ranges from drugs for the treatment of different sorts of cancer, HIV, 
malaria and flu to compounds which are used for the treatment of mental disorders like Alzheimer or 
schizophrenia.[6] Their importance as potential drug candidates is demonstrated by the fact that in 
the time frame from January 2008 until December 2013 a total of 25 NP and NP-derived drugs have 
been approved for marketing.[1a] Prominent representatives of natural products or compounds based 
on natural products used as drugs include paclitaxel (1) (Taxol[TR], drug for the treatment of different 
sorts of cancers),[7] artemisin (2) (malaria treatment),[8] or erythromycin (3) (antibiotic).[9]  
 
Scheme 1: Selected examples of natural products or natural product-derived drugs.  
2 
 
Despite the steady improvements of methods for the isolation and purification of compounds 
deriving from natural sources, total or semisynthesis often remains the method of choice for efficient 
and reliable material supply. This is owed to the fact that natural sources might be rare, hardly 
accessible or under environmental protection. The isolation often only yields trace amounts of 
substances, which make the structure determination particularly challenging and can lead to 
mistakes. Although analytical methods have rapidly developed and became more sophisticated in the 
last decades, wrong assignments of structurally demanding molecular frameworks are not 
uncommon and can result in severe consequences.[10] Since its early achievements, starting with the 
synthesis of urea by Friedrich Wöhler in 1828,[11] the field of total synthesis of natural products has 
rapidly grown and had an enormous impact on chemistry and on the human society. Milestones like 
the synthesis of vitamin B12 by Woodward and Eschenmoser[12] or the first synthesis of taxol by K. C. 
Nicolaou in 1994[13] have not only led to important developments in the field of organic chemistry, 
they also produced a plethora of synthetic methods for the assembly of molecular frameworks. In a 
reverse manner the total synthesis of complex targets represents a “challenging environment” for 
newly developed synthetic methods. A prominent example for such synergistic effects is the total 
synthesis of the complex polyether macrolide halichondrin B (4) by Kishi et al. in 1992.[14] It showed 
the utility of Nozaki-Hyama-Kishi coupling (NHK-coupling) and eventually led to the development of 
the structurally simplified halichondrin B derivative eribulin (5), a highly potent drug for the 
treatment of breast cancer.[15] 
1.2 Naturally occuring polyacetylenes 
The class of polyacetylenic natural products has recently attracted much attention not only because 
of their wide spectrum of structural diversity but also due to their promising biological properties.[16] 
According to F. Bohlmann, the first isolated polyacetylenic natural product was dehydromatricaria 
ester 6, which was isolated but not fully characterized in 1826 from an Artemisia species.[16-17] In the 
following nearly two centuries over 1000 naturally occurring polyacetylenes have been isolated and 
characterized from a wide array of sources including bacteria, insects, higher fungi, plants, moss and 
lichens, marine sponges and corals.[16] These often unstable compounds tend to decompose by 
oxidative, photolytic or pH-dependent pathways, which make their isolation and characterization 
challenging. Polyacetylenic natural products have been used in traditional medicine for the 
treatment of a variety of diseases.[16, 18]  
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Scheme 2: Representative examples for polyacetylenic natural products. 
The structural diversity includes 1,3-diynes like thiarubrine B (7), a natural occurring pigment which 
has been isolated from the giant ragweed Ambrosia trifida in 1964/1965.[19] It contains a rather 
unstable 1,2-dithiin motif and can be found in several plants which are used to treat skin infections 
and intestinal parasites.[20] Diacetylenic spiroacetals like Al-2 (8) have been isolated from plants of 
the Asteracae family (Artemisia lactiflora) and exhibit promising antitumor activity.[21] Among the 
isolated polyacetylenic natural products are also several glucosides, such as bidensyneoside C (9), 
isolated from species of the genus B. parviflora. Biological studies revealed their ability to inhibit 
histamine release and nitric oxide production.[22] In addition to naturally occurring 1,3-diynes, several 
triynes and tetraynes have been identified. (-)-Ichthyothereol (10) has been isolated in 1965 from 
Dahlia coccinea and has been used as a fish poison by the natives of the Lower Amazon Basin.[23] The 
terminal tetrayne caryoynencin (11) was isolated from the plant pathogen Pseudomonas caryophylli. 
Biological tests of the unstable compound demonstrated antimicrobial activity against Gram-positive 
and Gram-negative bacteria.[24] 
1.3 Synthetic methods for the preparation of 1,3-diynes 
The construction of bis-acetylenic motifs found in naturally occurring polyynes relies nearly exclusive 
on the transition metal assisted or catalyzed coupling of two alkyne fragments. The first coupling of 
two identical alkyne fragments, for the construction of a 1,3-diyne, was demonstrated by Glaser et al. 
in 1869.[25] He observed that copper(I)phenylacetylide (12) underwent dimerization under oxidative 
conditions to the corresponding diphenylbuta-1,3-diyne (13). Thirteen years later Baeyer et al. 
utilized Glaser´s observations for the synthesis of indigo (16), a naturally occurring blue dye.[26] 
Important contributions from Eglington, Galbraith (17 Æ 18)[27] and Hay (19 Æ 20)[28] further 
improved the synthetic utility of this transformation, making it the method of choice for the 
dimerization of acetylenic fragments (scheme 3).[29] 
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Scheme 3: Selected examples for the preparation of symmetrical and unsymmetrical 1,3-diynes: a.) O2, NH4OH, EtOH; b.) 
H2O, Δ; c.) EtOH, CuCl, NH4OH; d.) K3[Fe(CN)6], H2O; e.) H2SO4, (NH4)2S; f.) Cu(OAc)2, pyridine, MeOH (high dilution), 20 – 
40%; g.) CuCl·TMEDA; h.) CuCl, NH2OH·HCl, MeOH, EtNH2, N2.
[29] 
The coupling of two different alkyne fragments was reported in the 1950´s by Cadiot and 
Chodkiewicz and relies on the condensation of a 1-haloalkyne 21 and a terminal alkyne 22 in 
presence of a suitable Cu(I) salt and an amine base (scheme 3).[30] Since these early findings, 
modifications have been developed in terms of employed solvents, temperature, bases and 
acetylenes. Although other procedures for the construction of 1,3-diynes have been reported, the 
methods above mentioned and their modifications were the methods most utilized in present 
literature.[29] 
1.4 Alkyne metathesis 
In 2012 Tamm and co-workers published a novel approach for the preparation of symmetrical and 
unsymmetrical 1,3-diynes based on alkyne metathesis. The reaction of a 1,3-diyne 24 in presence of 
catalytic amounts of tungsten benzylidyne complex C1a resulted in the formation of product 25 
(scheme 4).[31] In 2014 the unsymmetrical version of this transformation was reported by the same 
group.[32]  
 
Scheme 4: Construction of symmetrical 1,3-diynes via tungsten-catalyzed alkyne metathesis: a.) C1a (cat.), toluene, 5 Å MS. 
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This contribution further expanded the already remarkable scope of alkyne metathesis and granted 
access to a new class of substrates. Alkyne metathesis was first reported in the late 1960´s by Penella 
et al.[33] In their contribution they observed scrambling of 2-pentyne with a heterogenous catalyst, 
namely WO3 immobilised on SiO2. The rather harsh reaction conditions  
(240 °C – 450 °C) and competing polymerization reactions prevented the method from being broadly 
applied. Mortreux and Blanchard reported in 1974 the first use of a homogenous catalytic system, 
consisting of  [Mo(CO6)] and resorcinol, for the dimerization of bis-arylacetylene 26 (scheme 5).[34]  
 
Scheme 5: First demonstration of a homogenously catalyzed alkyne metathesis reaction: a.) [Mo(CO)6] (cat), resorcinol, 
decalin, 3 h, 160 °C. 
The mechanism was first proposed by Katz and McGinnis in the following year and is closely related 
to the Chauvin cycle for olefin metathesis.[35] The reactive metal alkylidyne A undergoes a formal 
[2+2] cycloaddition with the alkyne substrate forming a metallacyclobutadiene which can be best 
described by the two resonance structures B and B´. Cyclorevision releases the product and 
regenerates the active metal alkylidyne species, which undergoes the same elementary steps again 
(scheme 6).[36] 
 
Scheme 6: Proposed and commonly accepted mechanism for the alkyne metathesis. Ancillary ligands are omitted for 
clarity.  
Since these early discoveries plenty of effort was invested in the development of more efficient and 
functional group tolerant catalysts. In a series of important contributions the group of Schrock 
reported the preparation and use of molybdenum and tungsten alkylydine complexes such as C2 and 
C3 as active alkyne metathesis catalysts (scheme 7).[37] The molybdenum complex C4 originally 
developed for the activation of N2[38] proved to be a highly active alkyne metathesis catalyst after 
activation with CH2Cl2.[39] Fürstner and co-workers introduced the latest generation of remarkably 
active molybdenum complexes such as C5 possessing a high functional group tolerance.[40] The 
complex C5 could be made bench-stable by forming the adduct with an appropriate nitrogen donor 
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ligand such as 1,10-phenantroline. The resulting adducts C6a/b are highly crystalline and can be 
activated by stirring with a mild Lewis acid such as MnCl2 or ZnCl2 to release the active species.[40] All 
well-defined catalysts up to now are high valent tungsten(VI) and molybdenum(VI) Schrock alkylidyne 
complexes (scheme 7). 
 
Scheme 7: Alkyne metathesis catalysts. 
The rise of alkyne metathesis started with the application to forge medium and large-size cyclic 
systems via ring-closing alkyne metathesis (RCAM) representing a new and valuable alternative to 
established methods such as macrolactonization or ring closing olefin metathesis (RCM).[41] In 
particular the selective transformation of the resulting alkyne to either the E or Z alkene, a common 
motif in natural occurring macrolides, made this method particularly attractive.[42] In addition several 
other post-metathetic transformations were developed and successfully applied, which increased the 
product portfolio and provided access to new structural motifs.[43] The multitude of post-metathetic 
transformations combined with the excellent functional group tolerance, high reactivity and the 
convenient handling of the latest generation of catalysts rapidly led to many applications culminating 
in several total syntheses of complex biologically active molecules and applications in material 
science.[41a, 43-44]  
The mechanism of alkyne metathesis for 1,3-diynes, as proposed by Tamm and co-workers in their 
first report, is in accordance with the established mechanism for regular alkyne metathesis.[31] 
Although initial studies already revealed the potential of ring-closing alkyne metathesis of 1,3-diynes 
(RCDM) for the preparation of cyclic 1,3-diynes, no detailed investigation of this transformation has 
been reported.  
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The objective of this thesis was to identify the scope and limitations of RCDM and to find possible 
applications. In the following chapter of this work the systematical investigation of the RCDM will be 
presented.  
 
Scheme 8: Schematical description of transformations discussed in this work. 
Initial studies for the cyclization of a model compound led to the identification of suitable catalysts 
and conditions for the desired transformation. Differently substituted precursors were prepared and 
cyclized. Application of these conditions to structurally demanding substrates culminated in the total 
syntheses of ivorenolide A and B (29). In addition, employment of transition metal catalyzed post-
metathetic transformations of cyclic 1,3-diynes provided access to the synthesis of cyclophanes (30). 
Furthermore a novel strategy, based on RCDM, allowed the synthesis of the highly decorated 
macrocyclic core of rhizoxin D (31) and will be outlined in the second half of this work. 
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2. The ivorenolide family 
2.1 Isolation, structure elucidation and biological properties 
In 2012 the group of Ying Li and Jian-Min Yue reported the isolation and structure elucidation of 
ivorenolide A, a new type of macrocyclic lactone which features a structurally novel bis-acetylenic 
unit within a macrocyclic core.[45] Ivorenolide A (32) and ivorenolide B (33), which was reported two 
years later, were isolated from the well-known African mahagony tree khaya Ivorenesis A. chev. 
(Meliacae).[46] The isolation group obtained 8 mg of crystalline ivorenolide A and 15 mg of ivorenolide 
B out of 4.8 kg of air-dried plant material. 
 
Scheme 9: Ivorenolide A and B. 
The crude extracts of the stem bark have been used in traditional medicine for the treatment of 
malaria and other tropical diseases. Biological surveys revealed the anti-plasmodial and anti-
inflammatory activity of these extracts.[47] Furthermore, the most recent biological studies by the 
isolation group demonstrated significant immunosuppressive activity and remarkably high inhibition 
of concavalin A-induced T-cell proliferation. Immunosuppressive therapy is commonly applied in 
modern medicine for lowering the immune response during organ transplantations to avoid the 
rejection of the newly transplanted organ. Additionally immunosuppressive agents are used for the 
treatment of severe autoimmune diseases including psoriasis and multiple sclerosis.[48] The isolation 
group showed that ivorenolide A possesses selectivity comparable to the standard reference 
cyclosporin A (table 1).[45] All major immunosuppressive drugs currently used in medicine are either 
natural product derived or natural products themselves (present state).[49] 
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Table 1: Immunosuppressive effects of ivorenolide A and B (analogues included) on murine lymphocyte proliferation 
induced by ConA (5 µg/mL) or LPS (10 µg/mL).[a]  
  ConA-induced T-cell 
proliferation 
LPS-induced B-cell 
proliferation 
Cmpd CC50 (µM) IC50(µM) SI IC50(µM) SI 
         32 >100 4.80 >20.83 8.12 >12.32 
32b >100 2.86 >34.97 4.55 >21.98 
         33 20.7 >10 - 7.2 2.9 
33b N N - N - 
33c N N - N - 
33d N N - N - 
CsA 4.79 0.11 44.80 0.33 14.50 
PSA 18.85 0.68 27.72 2.17 8.69 
 
 
 
 
 
 
 
[a] CsA = cyclosporin A, PSA = periplocoside A, N = inactive (defined as inhibition rates lower than 30% at 10 µM). The 
selectivity index (SI) is defined as the ratio of the concentration of the compound that reduced cell viability to 50% (CC50) to 
the concentration of the compound needed to inhibit the proliferation by 50% to the control value (IC50). 
The structure of ivorenolide A was elucidated using 2D-NMR-techniques (scheme 10), high-resolution 
positive-ion-mode electrospray ionization mass spectrometry [HR-ESI(+)-MS] and circular dichroism 
(CD-Spectroscopy). The relative stereochemistry was assigned via single-crystal-X-ray diffraction, but 
due to lack of absolute structure parameters the absolute configuration could not be assigned. 
Ivorenolide A features a 18-membered macrocyclic lactone exhibiting five stereogenic centers and a 
bis-acetylenic motif. The crystal structure revealed that the molecule is nearly planar and that two or 
three molecules are regularly overlapped in the unit cell. Intramolecular hydrogen bonds are formed 
between, the C16 hydroxy group and the ester moiety and between the C11 hydroxy group and the 
epoxide motif.  
 
Scheme 10: Selected 1H – 1H COSY and 1H – 13C HMBC correlations for the structure determination of ivorenolide A and B. 
Single crystal X-Ray structure of ivorenolide A. 
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The same methods were employed for the structure determination of ivorenolide B (scheme 10), 
although the gum-like consistency of the compound prevented the use of single-crystal-X-ray 
diffraction. Ivorenolide B possesses four stereogenic centers and the same bis-acetylenic moiety 
within the 17-membered macrocyclic core. The structural features and the promising biological 
properties made both compounds interesting targets for the synthetic community. 
2.2 Previous syntheses 
2.2.1 Synthesis of ent-ivorenolide A by Li and Yue 
The single crystal did not refract well enough to unambigously determine the absolute configuration 
of ivorenolde A. For this reason the isolation group carried out a total synthesis to establish the 
absolute configuration.  
 
Scheme 11: Retrosynthetic analysis of putative ivorenolide A.[45] 
The disconnections were based on the macrolactonization of acyclic precursor 34 followed by 
deprotection and late-stage epoxidation. The acyclic precursor was planned to be assembled via 
Cadiot-Chodkiewicz coupling of terminal alkyne 35 with bromo alkyne 36. Bromo alkyne 36 should be 
prepared from commercially available 8-bromooctanoic acid (37), and propargyl alcohol via a 
sequence of standard transformations. Terminal alkyne 35 should be accessible by an alkynylation 
reaction of aldehyde 38 derived from methyl-D-lactate (scheme 11).  
The forward synthesis commenced with the protection of literature known propargylic alcohol 39, 
which was prepared in four steps from methyl-D-lactate.[50] The propargylic hydroxy group was 
protected as the corresponding MOM-ether 40 followed by subsequent removal of the alkyne 
protecting group with the aid of K2CO3/MeOH to yield the desired terminal alkyne 35. 
 
 
11 
 
 
Scheme 12: Preparation of terminal the alkyne fragment (35): a.) MOMCl, i-Pr2Net, CH2Cl2, 12 h 98%; b.) K2CO3, MeOH, 2 h, 
93%.[45] 
Coupling of 8-bromooctanoic acid (37) with propargyl alcohol, followed by methyl ester formation 
and hydrogenation of the alkyne under Lindlar conditions[51] yielded cis-allylic alcohol 41. Through a 
four step sequence consisting of IBX-oxidation, TMS-acetylene addition, Dess-Martin oxidation (DMP-
oxidation) and bromination of the alkyne, alcohol 41 was converted to ketone 42. The stereoselective 
CBS-reduction of 42 yielded fragment 36 in good yield and with excellent selectivity (scheme 13). 
 
Scheme 13: Total synthesis of ent-ivorenolide A: a.) IBX, DMSO, CH2Cl2, 0 °C, 24 h 92; b.) TMS-acetylene, n-BuLi, THF, -78 °C, 
3 h, 95%; c.) DMP, CH2CL2, 14 h, 95%; d.) NBS, AgNO3, acetone, 3 h, 96%; e) CBS, BH3·SMe, THF, -40 °C, 40 min, 89%, ee 
>99%; f.) CuCl, BuNH2, H2O, NH2OH·HCl, CH2Cl2, 30 min, 70%; g.) MOMCl, i-Pr2Net, CH2Cl2, 12 h, 99%; h.) TBAF, THF, 0 °C, 18 
h, 97%; i.) aq. LiOH (2.0 M), t-BuOH, 12 h, 98%; j.) 2,4,6-Cl3C6H2COCl, Et3N, THF, 0 °C, then toluene DMAP, 75 °C, 90%; k.) aq. 
HCl (3.0 M), EtOH, 80 °C, 2 h, 67%; l.) m-CPBA, CH2Cl2, 12 h 84%.
[45] 
The Cu-catalyzed coupling of bromo alkyne 36 with terminal alkyne 35 afforded the required 1,3-
diyne 43. Standard transformations including MOM-protection of the free hydroxy group followed by 
removal of the TBS protecting group and hydrolysis of the methyl ester led to the acyclic seco-acid 
44. The cyclization was accomplished under conditions developed by Yamaguchi[52] providing the 
cyclic 1,3-diyne 45. Simultaneous deprotection of the bis-MOM-ether with HCl at elevated 
temperature followed by epoxidation with m-CPBA completed the synthesis, which needed fifteen 
steps as the longest linear sequence and produced sufficient amounts of material for the 
determination of the absolute configuration of all five stereogenic centers. Comparison of the NMR 
data of synthetic ent-32 matched those of the isolated compound but comparison of the CD-spectra 
and optical rotation revealed that the synthesized product was the enantiomer of ivorenolide A.  
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2.2.2 Synthesis of ivorenolide B by Li and Yue 
The first synthesis of ivorenolide B 33 was reported, together with the isolation protocol, in 2014 by 
Ying Li and Jian-Min Yue.[46] The complete determination of the stereochemistry required the 
preparation of the four most likely stereoisomers 33, 33b, 33c, 33d which were synthesized and the 
recorded spectroscopic data were compared with the data of the isolated product. 
 
Scheme 14: Retrosynthetic analysis of ivorenolide B.[46] 
The main features of the utilized strategy were similar to those reported by the authors for the 
synthesis of ent-ivorenolide A (ent-23), except that the macrocycle 48 was prepared via RCM of diene 
49. The metathesis precursor was planned to be assembled via Cadiot-Chodkiewicz coupling of 
terminal alkyne 50 with bromo alkyne 51. The requisite alkyl fragment should be obtained via 
acylation of 50 with 9-decenoic acid (52) (scheme 14).  
 
Scheme 15: Total synthesis of ivorenolide B: a.) NBS, AgNO3, 97%; b.) DCC, DMAP, CH2Cl2, Δ, (S,R)-98%; c.) TBAF, THF, (S)-
97%, (R)-95%; d.) CuCl, BuNH2, H2O, NH2OH·HCl, 0 °C, (S)-90%, (R)-86%; e.) Grubbst 1
st. gen, CH2Cl2, (16S)-93% (Z : E = 1.0 : 
1.5), (16R)-90% (Z : E = 1.0 : 1.5); f.) m-CPBA, CH2Cl2, (16S)-92%, (16R)-91% g.) TBAF, THF, (16S)-90%, (16R)-88%.
[46] 
The synthesis started with the preparation of bromo alkyne 51. D-Mannitol was converted to the 
suitable protected intermediate 53[53], which was then transformed in six steps to alkyne 54.[54] 
Subsequent bromination with NBS yielded the desired bromo alkyne 51. In an analogous way, ent-51, 
was prepared from L-mannitol. Both enantiomers of literature-known alcohol 55[55] were treated 
with 9-decenoic acid (52) under Steglich conditions[56] to obtain acylation product 56. Deprotection of 
the alkyne with TBAF and subsequent coupling with 51 (ent-51) yielded 1,3-diyne 49. With respect to 
the RCM elevated temperatures and high dilution were required to obtain the macrocyclic product in 
good yield as a mixture of stereoisomers (Z : E = 1.0 : 1.5), favoring the undesired E-isomer. 
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Epoxidation with m-CPBA followed by deprotection with TBAF gave the desired compounds. 
The recorded spectroscopic data were compared to the data obtained from the isolated compound 
(scheme 15, 16).  
 
Scheme 16: Putative structures of ivorenolide B. 
In this way the configuration at C16 was unambiguously determined and the structure of ivorenolide 
B was assigned as shown in scheme 16.   
2.2.3 Synthesis of ivorenolide A by Yadav 
In 2015 Yadav and co-workers reported the first total synthesis of ivorenolide A, employing a strategy 
similar to the previous synthesis of ent-ivorenolide A (ent-32).[57] Retrosynthetic analysis envisaged 
that the macrocycle is forged by macrolactonization applying conditions developed by Shiina,[58] 
followed by deprotection and epoxidation to yield ivorenolide A (32). The acyclic precursor 58 
containing the bis-acetylenic motif should be prepared via palladium-catalyzed coupling of alkyne 59 
with bromo alkyne 60. The bromo alkyne should derive from aldehyde 63. Terminal alkyne 59 should 
be accessible from (+)-2,3-O-isopropylidene-L-threitol 62 and nonyl phosphorane 64 (scheme 17). 
 
Scheme 17: Retrosynthesis of ivorenolide A by Yadav et al.[57] 
The synthesis started with the preparation of terminal alkyne 59 from (+)-2,3-O-isopropylidene-L-
threitol. Selective protection of one of the hydroxy groups, followed by Dess-Martin oxidation of the 
free alcohol yielded aldehyde 65, which underwent Wittig olefination with the PMB-protected nonyl 
phosphorane 64 to furnish olefin 66. Removal of the primary TBS group with TBAF and chlorination 
under Appel conditions afforded chloro-compound 67. Conversion of 67 to alkyne fragment 59 was 
accomplished via the Fritsch-Buttenberg-Wiechell rearrangement followed by protection of the 
resulting propargylic hydroxy group as the corresponding MOM-ether (scheme 18).  
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Scheme 18: Yadav´s synthesis of the terminal alkyne fragment (59): a.) TBS-Cl, NaH, THF, 45 min, 0 °C, 98%; b.) DMP, CH2Cl2, 
0 °C; c.) 64, LiHMDS, HMPA, -78 °C, 78%; d.) TBAF, THF, 0 °C, 97%; e.) CCl4, PPh3, 5 h, 91%; f.) n-BuLi, THF, -78 °C, 87%; g.) 
MOMCl, i-Pr2NEt, DMAP (cat), CH2Cl2, 95%.
[57] 
The preparation of bromo alkyne 60 started from methyl-L-lactate (scheme 19). Protection of the 
hydroxy group with TBS-Cl followed by reduction of the ester with DIBAL-H afforded aldehyde 63. 
Two carbon homologation using a Horner-Wadsworth-Emmons olefination (HWE olefination) 
followed by DIBAL-H reduction of the α,β-unsaturated ester and Sharpless epoxidation led to allylic 
epoxide 68. Compound 69 was obtained by using the above described sequence: chlorination 
followed by base-induced elimination and Fritsch-Buttenberg-Wiechell rearrangement.  
Protection of 69 as the corresponding MOM-ether followed by bromination under standard 
conditions gave bromo alkyne 60. The assembly of both fragments was accomplished through a Pd-
catalyzed Sonogashira coupling furnishing the desired 1,3-diyne 70.  
 
Scheme 19: Total synthesis of ivorenolide A by Yadav et al.: a.) Ph3P=CHCO2Et, toluene, 60 °C, 2 h 93%; b.) DIBAL-H, CH2Cl2,  
-78 °C, 1 h; c.) (+)-DIPT, Ti(i-PrO)4, TBHP, CH2Cl2, -20 °C, 84% (over two steps); d.) CCl4, TPP, 5 h; e.) n-BuLi, THF, -78 °C (82% 
over two steps); f.) MOMCl, iPr2Net, DMAP (cat), CH2Cl2 0 °C, 95%; g.) NBS, AgNO3, acetone, 1 h, 97%; h.) Pd(PPh3)2Cl2, CuI,  
i-Pr2Net, THF 1 h, 74%; i.)  TBAF, THF, 0 °C, 1 h 97%; j.) DDQ, pH~7 buffer, CH2Cl2, 0 °C, 2 h, 92%; k.) PIDA, TEMPO, CH2Cl2,  
0 °C, NaClO2/NaH2PO4 2-methyl-2-butene, t-BuOH/H2O, 0 °C, 1 h, 91%; l.) MNBA, DMAP, toluene, 12 h, 84%; m.) aq.  
HCl, EtOH, 70 °C, 4 h, 74%; n.) m-CPBA, CH2Cl2, 12 h 84%.
[57] 
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The seco-acid 58 was obtained by removal of the silyl protecting group followed by deprotection of 
the primary alcohol using DDQ in a buffered CH2Cl2 solution. Selective oxidation of the primary 
alcohol with PIDA in presence of TEMPO, followed by Pinnick oxidation[59] of the resulting aldehyde 
furnished the carboxylic acid. The cyclization was carried out under modified Shiina conditions 
yielding the 18-memberd lactone 71.[60] The final transformations consisted of simultaneous 
deprotection of the MOM-ethers followed by epoxidation as previously described (scheme 19). A 
sixteen step longest linear sequence was necessary to yield ivorenolide A. The spectroscopic data of 
the obtained product were in agreement with those reported in the isolation paper.  
2.3 Motivation 
The aim of the project was to evaluate the recently reported ring-closing alkyne metathesis of 1,3-
diynes (RCDM) in terms of substrates, reaction conditions and catalysts. The latest generation of 
molybdenum complexes developed in the Fürstner group should be applied and the scope and 
limitations of this transformation were first studied on a simplified model substrate. Ivorenolide A 
and B were chosen as suitable targets to demonstrate the utility of this method, culminating in 
concise total syntheses of both natural products with the RCDM as the key transformation. The 
versatility of the obtained cyclic 1,3-diynes was further proven by application of different types of 
post-metathetic transformations.   
2.4 Model studies 
Di(hepta-3,5-diyn-1-yl) adipate (72), was chosen as a model compound for the examination of the 
RCDM. The preparation of 72 was accomplished utilizing the route described by Tamm and co-
workers (scheme 20).[31] But-3-yn-1-ol (73) was converted to the corresponding THP-ether 74, which 
was coupled with propargyl bromide to obtain the skipped diyne 75. Base catalyzed rearrangement 
to the 1,3-diyne 76 followed by acid mediated THP deprotection yielded the desired hepta-3,5-diyn-
1-ol (77). The reaction of this alcohol with adipoyl dichloride 78 in presence of pyridine afforded the 
desired model compound 72 (scheme 20).  
 
Scheme 20: Synthesis of model substrate 72 for the investigation of the RCDM: a.) p-TSA, DHP, CH2Cl2, 0 °C, 1.5 h, 97%; b.) 
EtMgBr, CuBr, propargyl bromide, THF, 50 °C to 65 °C, 3 h, 60%; c.) t-BuOK, THF, -40 °C, 2 h, 93%; d.) p-TSA, MeOH, 2 h, 
89%; e.) Pyridine, CH2Cl2, 20 h, 89%. 
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The RCDM survey started with the evaluation of C5, which has been the state-of-the-art catalyst in 
terms of RCAM applications. The catalyst converted 72 to the cyclic 1,3-diyne 79a in 84% yield at a 
loading of 10 mol%. The reaction could be conducted at ambient temperature as well as at slightly 
elevated temperature with the same result. During the course of the reaction no dimerization of the 
starting material was observed. The molybdenum complex C4 was next investigated. The catalytically 
active species was obtained by treatment of C4 with stoichiometric amounts of CH2Cl2, which then 
yielded the desired product in 59% yield. To reach full conversion a catalyst loading of 20 mol% and 
slightly elevated temperatures were required. 
 
Table 2: Screening of the influence of different catalysts on the outcome of the model reaction.[a] 
 
Entry Catalyst Conditions Yield [%] 
1    C1a (4 mol%,)[31] rt, 16 h 90 
2 C5 (10mol%)[b] rt, 16 h 84 
3 C5 (10mol%)[b] 60 °C, 3 h 84 
4       C4 (20 mol%) 70 °C, 10 h 59 
[a] All reactions were carried out in toluene [10 mM] in presence of 5 Å molecular sieves. [b] The catalyst loading was not 
optimized.  
      
The next step was the variation of termini in the substrate. The methyl capped 1,3-diyne was 
replaced by the corresponding TMS-protected 1,3-diyne, which represents a more challenging 
substrate for the catalyst in terms of steric repulsion. The streamlined synthesis of the TMS-capped 
model substrate 80 commenced with the copper-catalyzed coupling of 4-iodobut-3-yn-1-ol (81) with 
TMS-acetylene.[61] The obtained hexa-3,5-diyn-1-ol 82 was again treated with adipoyl dichloride 78 
and pyridine to give the desired cyclization precursor 80. The TMS group was cleaved under mild 
conditions resulting in the formation of the bis-terminal 1,3-diyne cyclization precursor 83, which 
proved to be highly unstable (scheme 21).  
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Scheme 21: Preparation of RCDM precursors (80, 83): a.) KI, TBHP, MeOH, 6 h, 95%; b.) TMS-acetylene, CuI, piperidine 0 °C,  
1 h, 80%; c.) Pyridine, CH2Cl2, 0 °C to rt, 16 h, 91%; d.) TBAF, THF, 0 °C, 61%. 
Both substrates were subjected to standard conditions for the RCDM involving the use of C5, toluene 
as the solvent and 5 Å molecular sieves. The TMS-protected substrate 80 required rather harsh 
conditions and long reaction times to reach full conversion. The cyclized product 79a was obtained 
together with an inseparable side product which was identified as the ring contracted product 79b. 
The rather unstable terminal 1,3-diyne substrate 83 was converted to the cyclized 1,3-diyne under 
standard conditions in excellent yield (table 3).   
 
Table 3: Screening of the influence of different termini on the outcome of the model reaction.[a] 
 
Entry Substrate Catalyst Conditions Yield [%] 
1 80 C5 (20mol%[c]) 70 °C, 24 h 53[c] 
2 83 C5 (10mol%[c]) rt, 16 h 88 
[a] All reactions were performed in toluene [10 mM] in presence of 4 Å and 5 Å MS. [b] The loading was not optimized.  
[c] 79a : 79b = 2.3 : 1  
       
The obtained results marked the endpoint of the model studies for the RCDM. The use of C5 allowed 
the preparation of cyclic 1,3-diyne 79a from a variety of differently substituted acyclic precursors 
under relatively mild conditions with good yields.  
2.4.1 Post-metathetic transformations 
1,3-Diynes are valuable substrates which had been recently employed in a multitude of different 
reactions such as Pauson-Khand,[62] hexadehydro-Diels-Alder[63] and reductive couplings.[64] The 
successful synthesis of the cyclic model 1,3-diyne 79a allowed the investigation of possible post-
metathetic transformations. The regioselective addition of nucleophiles to the activated 1,3-diyne 
enabled the preparation of heterocyclic cyclophane motifs (scheme 22). 
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Scheme 22: Proposed strategy for the activation mode of 1,3-diynes.[65]  
First the gold-catalyzed hydration of cyclic 1,3-diyne 79a was investigated. The desired 
transformation was accomplished with [(SPhos)AuNTf2], which converted the 1,3-diyne to the 
corresponding meta-bridged furan derivative 84 in 61% yield.[65] By switching the nucleophile to 
pyrrole the structurally demanding para-indolophane 85 was obtained.[66] This compound proved to 
be prone to degradation, which made the isolation and characterization challenging. The removal of 
the pyrrole starting material, which needed to be used in excess to reach full conversion, required 
HPLC purification and resulted in a low yield of 21%. Reaction of cyclic 1,3-diyne 79a with enyne 86 in 
presence of catalytic amounts of [Pd(PPh3)4] yielded the benzo-annulated product 87 in 85% yield.[67] 
 
Scheme 23: Post-metathetic transformations of cyclic model 1,3-diyne 79a: a.) [(SPhos)AuNTf2] (cat), H2O, THF, 60 °C, 16 h, 
61%; b.) [(BrettPhos)Au(MeCN)]SbF6 (cat), pyrrole, 1,2-DCE, 80 °C, 6 h, 21%; c.) [Pd(PPh3)4] (cat), THF, 65 °C, 85%. 
These examples demonstrate the utility of cyclic 1,3-diynes as valuable building blocks for the 
synthesis of cyclophane derivatives and showcase the wide structural outreach of post-metathetic 
transformations.  
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2.5 RCDM: Synthesis of model compound (96) and initial attempt for the total synthesis of 
ivorenolide A 
The project started with the retrosynthetic analysis of ivorenolide A (32). The strategy was based on 
the use of a RCDM reaction as the key transformation to forge the macrocyclic core. The obtained 
results for the cyclization of model compounds 80 and 83 suggested and allowed the use of TMS-
capped 1,3-diynes, which could either serve as the RCDM precursor themselves or being 
conveniently converted to the terminal 1,3-diynes.  
 
Scheme 24: Retrosynthetic analysis of ivorenolide A. 
The required metathesis precursor 88 should be accessible by cross-coupling of alkyl bromide 89 with 
alkenyl iodide 90. The alkyl bromide should be prepared by asymmetric alkynylation of aldehyde 91 
with TMS-protected buta-1,3-diyne 92. Aldehyde 91 should derive from esterification of 
commercially available 8-bromooctanoic acid (37) with allylic alcohol 94. Reduction of commercially 
available ethyl (Z)-3-iodoacrylate (95) to the corresponding aldehyde 93 followed by asymmetric 
alkynylation with 92 should provide alkenyl iodide 90. 
In order to rule out possible interference of the catalytic system with propargylic oxygen 
functionalities, as present in ivorenolide A, the conditions previously employed for the cyclization of 
model compounds 72, 80 and 83 (table 2 and 3) were first tested on a more elaborated substrate. 
Therefore compound 96 was prepared exhibiting already the same 18-membered macrocyclic core of 
ivorenolide A, but lacking the stereogenic centers at C16 and C17 (scheme 25).  
 
Scheme 25: Ivorenolide A and model compound (96). 
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The preparation of model compound 96 started with the careful DIBAL-H reduction of ethyl (Z)-3-
iodoacrylate at -80 °C yielding the unstable and volatile aldehyde 93.[68] Due to the high instability, 
the crude aldehyde was not purified; rather it was dissolved in anhydrous toluene and kept under Ar 
atmosphere. The solution could be stored at -20 °C for at least 3 - 4 weeks without noticeable 
decomposition or isomerization of the double bond. With aldehyde 93 in hand, the focus was laid on 
the asymmetric alkynylation reaction. Preparation of the TMS-protected 1,3-diyne 92 was 
accomplished by treatment of bis-TMS-1,3-butadiyne with MeLi followed by careful protic work-up. 
The desired compound was obtained by destillation in 61% yield on several gram scale.[69] The 
asymmetric alkynylation was accomplished with ZnMe2 and (R,R)-ProPhenol following a procedure 
described by Trost and co-workers.[70] Subsequent protection of the hydroxy group as the TBS-ether 
yielded alkenyl iodide 90 (scheme 26). The requisite coupling partner 98 was prepared by treatment 
of hepta-3,5-diyn-1-ol 77 with 8-bromooctanoic acid 37 under standard Steglich conditions.[56]  
 
Scheme 26: Synthesis of model compound (96). a.) DIBAL-H, CH2Cl2, -80 °C, 30 min, 85%; b.) 74, ZnMe2, Ph3P=O, (R,R)-
ProPhenol, toluene, 0 °C, 4 h 86% 89% ee c.) TBS-Cl, 1-methylimidazole, I2, CH2Cl2, 3 h, 98%; d.) DCC, DMAP, CH2Cl2, 16 h , 
86%; e.) Zn, I2, DMF, 75 °C, 4 h; (ii) 71, PdCl2, P(o-tol)3, THF, 4 h, 36%; f.) C5, 4 Å MS/ 5 Å MS, toluene, 16 h, 82%; g.) m-CPBA, 
CH2Cl2, 16 h, 74%; h.) TBAF, THF, 0 °C, 10 min, 83%. 
The assembly of both fragments was accomplished via Negishi cross-coupling of alkenyl iodide 90 
with the organozinc species derived from alkylbromide 98. Zinc was activated with iodine and treated 
with the alkyl bromide at 75 °C in DMF.[71] Subsequent coupling using PdCl2 and P(o-tolyl)3 gave the 
desired compound 99 in poor yield.[72] It was reasoned that the rather low outcome of the reaction is 
owed to the fact that the employed alkenyl iodide is prone to degradation and the 1,3-diyne motif of 
the organozinc compound is far from being innocent. Despite the disappointing yield of the cross-
coupling reaction, sufficient quantities of material were carried forward to test the cyclization. The 
reaction was carried out under previously described conditions which converted metathesis 
precursor 99 to the desired cyclic 1,3-diyne 100 in good yield. Remarkably no dimerization was 
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detected during the course of the reaction, which was conducted at ambient temperature with a 
catalyst loading of 10 mol%. The subsequent treatment of cyclic 1,3-diyne 100 with m-CPBA followed 
by reaction with TBAF yielded model compound 96 (scheme 26). 
The successful synthesis of the model compound comprised already the requisite alkenyl iodide 90, 
which could be used for the total synthesis of ivorenolide A as well. The preparation of alkyl bromide 
89 commenced with the one-carbon homologation of (S)-2-methyloxirane 101 using 
trimethylsulfonium iodide and n-BuLi.[73] The obtained allylic alcohol 94 proved to be highly volatile 
which made the isolation process difficult; purification was always accompanied by loss of significant 
amounts of material. As a consequence a one-pot procedure was developed which avoided the 
isolation of the alcohol. The crude solution was directly treated with 8-bromooctanoic acid 37 in 
presence of DCC and DMAP, which furnished the desired ester 102 in 66% yield over two steps. 
Subsequent ozonolysis of the olefin gave the desired aldehyde 91, which was then subjected to 
different asymmetric alkynylation conditions. Initial attempts were based on a methodology reported 
by Carreira et al. in their total syntheses of strongyldiol A and B.[74] They described the asymmetric 
addition of 1,3-diynes to aldehydes with the use of Zn(OTf)2 and (±)-N-methyl ephedrine. The 
advantage of this methodology was the use of only one equivalent 1,3-diyne compared to other 
methodologies which require excess of the 1,3-diyne. Unfortunately the reaction gave no desired 
product and only led to recovery of starting aldehyde 91. The alkynylation was then carried out 
under Trost conditions[70] and the product was obtained as an inseparable mixture together with the 
1,2-acyl migration (89a) compound. Alkyl bromide 89 was obtained in pure form by conversion of the 
hydroxy group to the corresponding TBS-ether which could then be separated from the byproduct 
(scheme 27). 
 
Scheme 27: Synthesis of alkyl bromide 85: a.) Me3SI, n-BuLi, THF, -10 °C 3 h; b.) 8-bromoctanoic acid, DCC, DMAP, THF 16 h 
66% over two steps; c.) O3, CH2Cl2, - 78 °C, then DMS; 16 h, 81%; d) 74, ZnMe2, Ph3P=O, (R,R)-ProPhenol, toluene 0 °C 16 h; 
e.) TBS-Cl, 1-methylimidazole, I2, CH2Cl2, 49% (over two steps).  
Negishi cross-coupling of 89 with alkenyl iodide 90 afforded fragment 103. The activation of zinc with 
TMS-Cl and 1,2-dibromethane in the presence of LiCl as reported by Knochel et al.[75] did not yield the 
desired organozinc species, which was instead obtained by treatment of alkyl bromide 89 with zinc, 
activated with iodine. The zinc-insertion occurred only sluggishly and examination of a hydrolysed 
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sample indicated the formation of several byproducts during the insertion reaction.The use of 
different palladium-based catalytic systems gave only low yields of the desired product (table 4).[72] 
 
Table 4: Screening of the Negishi cross-coupling reaction.[a] 
 
Entry Conditions Yield [%] 
1 Zn, LiCl, THF, 50 °C[75] - 
2 PdCl2, P(o-tolyl)3, THF, rt. 15[a] 
3 Pd(PPh3)Cl2, TMEDA, THF, rt. 17[a] 
4 Pd(PPh3)Cl2, THF, rt. 5<[a] 
[a] The insertion was done with Zn dust (activated with 5 mol% I2) in DMF [0. 5 M] at 80 °C for 4 h.  
       
Therefore the Suzuki-Miyaura sp3-sp2 cross-coupling reaction was tested as an alternative to the 
Negishi coupling. The alkyl bromide 89 was subjected to Li/Br exchange conditions in presence of 
9-(MeO)-9-BBN (104), but no formation of the desired borate was observed according to 11B-
NMR.[76] Deprotonation of the ester might occur faster than the lithium/bromide exchange and 
result in decomposition of the compound. 
 
Scheme 28: Attempted preparation of the borate complex: a.) t-BuLi, Et2O/pentane, -78 °C. 
The obtained results led to a revision of the retrosynthetic strategy as shown in scheme 29. The 
assembly of RCDM precursor 88 should be accomplished by esterification of alcohol 105 and 
carboxylic acid 106. The acid should be accessible from methyl ester 107 via alkyl cross-coupling 
reaction with alkenyl iodide 90. The alcohol 105 should derive from a Cadiot-Chodkiewicz 
coupling of bromo alkyne 108 with propyne (scheme 29). 
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Scheme 29: Retrosynthetic revision of ivorenolide A. 
Methyl-L-lactate 109 was protected as the corresponding benzyl ether and treated with DIBAL-H to 
afford aldehyde 110. Diastereoselective addition of TMS-acetylene yielded the propargylic alcohol 
111 in good yield and with good selectivity (9:1, d.r.). The propargylic alcohol underwent bromination 
using NBS in presence of catalytic amounts of AgNO3, and the unstable bromo alkyne 108 was 
subjected to Cadiot-Chodkiewicz conditions in order to obtain the 1,3-diyne. Initial attempts for the 
coupling of 108 with propyne relied on the employment of piperidine as the solvent and proved 
unsuccessful. Changing the solvent to aq. BuNH2 (30% in water) and raising the temperature to 0 °C 
yielded the desired 1,3-diyne. Protection of the free hydroxy group as the TBS-ether 112, followed by 
removal of the PMB-group using DDQ in a buffered solution of CH2Cl2 gave the desired alcohol 105. It 
proved crucial for the success of the reaction that the temperature was kept at 0 °C and that 
prolonged stirring was avoided (scheme 30).  
 
Scheme 30: Preparation of alcohol fragment 105: a.) PMB-trichloroacetimidate, TfOH, Et2O, -78 °C to rt, 16 h, 88%;  
b.) DIBAL-H, CH2Cl2, -78 °C, 1 h, 89%; c.)  TMS-acetylene, Et2Zn, Ti(i-PrO)4, (R)-BINOL, Et2O, 16 h , 71%, 9:1 d.r.; d) NBS, 
AgNO3, acetone, 16 h, 76%; e.) propyne, CuCl, aq. BuNH2 (30% in water), 0 °C, 1 h, 67%; f.) TBS-Cl, 1-methylimidazole, I2, 
CH2Cl2, 2 h, 84%; g.) DDQ, CH2Cl2/aq. buffer (pH~7), 0 °C, 2 h, 64%. 
The synthesis of acid fragment 106 started with the preparation of literature-known alkyl iodide 107 
from 8-bromooctanoic acid.[77] Recently reported examples revealed that coupling between mixed 
halogen species sometimes results in diminished yields of the coupling product.[72] For this reason the 
alkyl iodide 107 was used as the coupling partner of alkenyl iodide 90.[72] Insertion of zinc into the C-I 
bond proved to be more successful without the 1,3-diyne motif and coupling with alkenyl iodide 90 
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was successfully achieved using Pd(PPh3)Cl2 in presence of TMEDA (scheme 31). It proved essential 
for the reproducibility and success of the reaction that the employed TMEDA was rigorously dried 
before use. The coupling product 113 was then subjected to basic hydrolysis conditions to liberate 
the carboxylic acid 106. During the course of the reaction the TMS-group was cleaved and partial loss 
of the TBS-group was observed. The acid fragment bearing the terminal 1,3-diyne proved prone to 
degradation. The assembly of alcohol fragment 87 and acid fragment 106 was accomplished via 
esterification using modified Steglich conditions (scheme 31).[78]  
 
 
Scheme 31: Synthesis of metathesis precursor (88): a.) Zn, I2, DMF, 75 °C, 4 h, (ii) 90, Pd(PPh3)Cl2, TMEDA, THF, 68%; b.) 
LiOH THF/H2O, 6.5 h, 78%; c.) 105, EDC·HCl, DMAP, CH2Cl2 16 h, 58%. 
The metathesis precursor 88 was then subjected to RCDM. The use of molybdenum catalysts C4 and 
C5 only gave recovered starting material. Even at high temperatures no cyclized product was 
observed. The use of 2,4-hexadiyne as an initiator for the cyclization failed. Switching from 
molybdenum catalysts C4 and C5 to tungsten alkylydine C1b did not change the outcome either 
(table 5). Simultaneous removal of both propargylic TBS-ethers was attempted with the aid of TBAF 
at low temperature but only led to decomposition of the starting material.  
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Table 5 : Screening of conditions and catalysts for the RCDM.[a] 
 
Entry Catalyst Temp.[°C] Additive Yield [%] 
1 C4 70 - sm 
2 C4 110 - - 
3 C5 rt - sm 
4 C5 70 - sm 
5 C5 110 - - 
6 C5 60 2,4-Hexadiyne sm 
7 C5 110 2,4-Hexadiyne - 
8 C1b 70 - sm 
[a] All reactions were performed with a catalyst loading of 20 mol% in toluene [10 mM] in presence of 4 and 5 Å MS. sm = 
recovered starting material; - = decomposition of starting material.  
         
Despite the positive results obtained with all the previously employed cyclization precursors (72, 80, 
83, 100), substrate 88 failed to cyclize. One reason for these unsuccessful attempts might be the 
additional propargylic oxygen functionality at C16, which not only provides another possible 
coordination site for the catalyst, also the steric bulk derived from the second protecting group could 
prohibit the required arrangement of the catalyst and the substrate. Therefore the focus shifted 
towards ivorenolide B, which lacks the second propargylic oxygen functionality.   If this hypothesis 
proved to be correct and the cyclization of ivorenolide B would be possible, a second attempt for the 
synthesis of ivorenolide A was planned utilizing a different strategy.  
2.6 Total synthesis of ivorenolide B 
The project started with the idea in mind to utilize the same carboxylic acid fragment 106 as 
previously used for the attempted synthesis of ivorenolide A. The fragments should be assembled by 
an esterification reaction between carboxylic acid 106 and alcohol 115 to obtain the requisite 
metathesis precursor 114. Alcohol 115 should be accessible from propionyl chloride (117) via a 
Friedels-Crafts type reaction followed by enantioselective reduction (scheme 32). 
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Scheme 32: Retrosynthetic analysis of ivorenolide B. 
The synthesis of alcohol 115 commenced with the preparation of literature known alkynone 118 
from propionyl chloride (117) and bis-TMS-acetylene 119 by an AlCl3-mediated Friedel-Crafts type 
reaction. The subsequent reduction of the ketone using Noyori transfer hydrogenation conditions 
yielded the desired alcohol 120 in good yield and with excellent enantioselectivity.[55b] The 1,3-diyne 
115 was obtained by bromination of the TMS-alkyne with NBS in the presence of catalytic amounts 
of AgNO3, followed by copper-catalyzed Cadiot-Chodkiewizc coupling with propyne. The alcohol and 
the acid fragment were connected by esterification to yield metathesis precursor 114. Gratifyingly, 
the metathesis proceeded smoothly to the cyclic 1,3-diyne 121 with the use of standard catalyst C5 
at ambient temperature. The product was obtained in good yield and no dimerization was observed, 
although fairly high catalysts loading were required to drive the reaction to full conversion. The 
example represents the first unsymmetrical RCDM between a terminal 1,3-diyne and a methyl 
capped 1,3-diyne (scheme 33).  
 
Scheme 33: Total synthesis of ivorenolide B: a.) AlCl3, CH2Cl2, 0 °C, 2 h, 97%; b.) [(p-cymene)RuCl2]2, (S,S)-Ts-DPEN, KOH, 
CH2Cl2; ii) 118, iPrOH, 89% (97% ee); c.) NBS, AgNO3, acetone, 2 h, 88%; d.) propyne, CuCl, aq. BuNH2 (30% in water), 
NH2OH·HCl, -5 °C to rt. 1 h, 62%; e.) EDC·HCl, DMAP, CH2Cl2, 16 h, 62%; f.) C5, 4 Å MS/ 5 Å MS, toluene, 16 h, 82%;  
g.) m-CPBA, CH2Cl2, 8 h, 80%; h.) TBAF, THF, 0 °C, 74%. 
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The cyclic 1,3-diyne 121 was epoxidized with m-CPBA and the resulting epoxide was treated with 
TBAF at low temperature to remove the TBS protecting group yielding ivorenolide B (33) as a 
colorless viscous oil (scheme 32). Comparison of the obtained spectroscopic data with those reported 
in the literature confirmed the correct structure (table 9a). In conclusion, ivorenolide B was 
synthesized in ten steps in the longest linear sequence by applying the RCDM of a terminal 1,3-diyne 
with a methyl capped 1,3-diyne as the key step.[79]  
2.7 Total synthesis of ivorenolide A 
The use of substrates bearing bis-propargylic oxygen functionalities have been a long standing issue 
for RCAM.[41a, 80] Until recently such compounds have never been cyclized. Most notably only 
substrates bearing one propargylic oxygen functionality and one “regular alkyne” have been 
successfully used in RCAM. The challenge for a catalytic system to construct a macrocycle bearing a 
propargylic alcohol motif arises from several possible decomposition pathways Alkyne metathesis 
catalysts are Schrock alkylidynes, which possess a high Lewis acidity; if not properly adjusted by an 
ancillary ligand. The high Lewis acidity could lead to decomposition via pathways A and B at any 
activated position. Another challenge arises from the steric bulk of protected propargylic alcohol 
functionalities (scheme 33).  
 
Scheme 34: Challenges for the cyclization of 1,3-diynes bearing propargylic functionalities. 
The recently developed catalytic system consisting of molybdenum complex C7 and the multivalent 
ancillary ligand L1 allowed for the first time to react substrates bearing two propargylic hydroxy 
groups (scheme 34, table 6).[80] It was assumed that a chelating cross linking ligand such as L1 
provides a higher resistance towards protic functionalities and a higher thermal stability, which is 
advantageous since high temperatures are often required for the metathesis of bis-propargylic 
substrates.  
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Table 6:  Performance of the novel catalytic system C7/L1 compared to standard catalyst C5.[80][a] 
 
Entry         Substrate           Product Yield [%] 
   C5 C7/L1 
1  
 
 
 
R1 = MOM, R2 = OH 0 67 
2 R1 = R2 = TES 0 71 
3 R1 = TES, R2 = OH 0 64 
4 R1 = R2 = OH 0 58 
5 R1 = R2 = Ac 0 0 
[a] All reactions were performed with a catalyst loading of 20 mol% in refluxing toluene [1mM].  
The promising results obtained using the new catalytic system for RCAM moved the attention back to 
ivorenolide A. It was rationalized that a change in the protecting group strategy might facilitate the 
cyclization. Therefore the bulky TBS-groups on both sides of the metathesis precursor were replaced 
by sterically less demanding MOM-groups. Additionally, the termini of the metathesis precursor were 
adjusted. Although the successful conversion of substrate 114 proved that the cyclization of an 
unsymmetrically substituted 1,3-diyne proceeds well (scheme 33), the termini of the acyclic 
metathesis precursor in the second attempt were changed to the methyl-capped ones. It was 
considered that this change should facilitate the synthesis of the metathesis precursor in terms that 
building block 122 could be employed for the elaboration of both fragments (scheme 35).  
The second approach towards ivorenolide A started with the preparation of 1,3-pentadiyne 122 for 
the asymmetric alkynylation reaction. Despite the fact that this compound has never been used for 
such a transformation, its use would be beneficial in terms of step economy compared to the 
previous applied strategy consisting of TMS-acetylene addition, bromination and Cadiot-Chodkiewicz 
coupling with propyne. The difficult preparation protocol of 1,3-pentadiyne and the high volatility 
and instability of the compound made the preparation of sufficient quantities of 122 challenging.[81] 
Asymmetric alkynylation of aldehyde 110, derived from methyl-L-lactate, afforded the desired 
product 123 in 61% yield. Subsequent protection of the free hydroxy group as the MOM-ether and 
removal of the PMB-group under oxidative conditions furnished the free alcohol fragment 124 for 
the planned esterification (scheme 35).  
 
Scheme 35: Preparation of alcohol (124): a.) 122, Me2Zn, (R,R)-ProPhenol, Ph3P=O, toluene, 0 °C, 61% (2.5: 1 d.r.); b.) 
MOMCl, i-Pr2Net, CH2Cl2, 85%; c.) DDQ, CH2Cl2/ aq. Buffer (pH~7), 0 °C, 72%. 
The asymmetric alkynylation of (Z)-3-iodoacrylaldehyde 93 was carried out under the same 
conditions as described for the alkynylation with TMS-buta-1,3-diyne 92. The product was obtained 
in good yield but only with moderate enantiomeric excess (table 7). 
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 It was assumed that the rather poor selectivity is owed to the fact that 1,3-pentadiyne 122 lacks any 
steric bias which proved essential to obtain good enantiodiscrimination.[62b, 70]  
 
Table 7 : Screening of conditions for asymmetric alkynylation of (Z)-3-iodoacrylaldehyde.  
 
Entry Conditions Yield [%] 
1[70] ZnMe2, Ph3P=O, (R,R)-ProPhenol, toluene, 0 °C 86 (70% ee) 
  2[62b] ZnEt2, Ti(i-PrO)4, (R)-BINOL, Cy2NH, Et2O 90 (63% ee) 
3[74] Zn(OTf)2, (-)-N-methylephedrin, Et3N, toluene - 
 
         
The free hydroxy group was protected as the corresponding MOM-ether 126 using standard 
conditions. Subsequent coupling with the organozinc species derived from alkyl iodide 107 yielded 
alkene 127. The necessary organozinc species was prepared using the protocol reported by Knochel 
and co-workers[75] and the coupling to the desired product proceeded without any noticeable 
isomerization of the double bond. Hydrolysis of the methyl ester under basic conditions produced 
the carboxylic acid 128 in nearly quantitative yield. Gratifyingly, no loss of the MOM-group was 
observed under the applied conditions. The assembly of both fragments via Yamaguchi esterification 
gave the desired tetrayne 129 in 79% yield.  
 
Scheme 36: Total synthesis of ivorenolide A: a.) 122, Me2Zn, (R,R)-ProPhenol, Ph3P=O, toluene, 0 °C, 86% (70% ee); b.) 
MOMCl, i-Pr2Net, CH2Cl2, 86%; c.) 107, Zn, LiCl, THF, 40 °C, 5 h (ii) Pd(PPh3)2Cl2, TMEDA, THF, 50 °C, 45 min, 75%; d.) LiOH, 
THF/MeOH (2:1), 95%; e.) 2,4,6-trichlorbenzoic acid chloride, Et3N, then 124, DMAP, toluene 0 °C to rt, 79%; f.) C7/L1, 
toluene, 5 Å MS, 60 °C, 78%; g.) aq. HCl, EtOH, 70 °C, 64%; h.) m-CPBA, CH2Cl2, 85%.  
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The metathesis precursor 129 was subjected to RCDM conditions using C5 at elevated temperatures 
but the desired cyclic 1,3-diyne 130 was observed only in poor yields. Fairly high catalyst loadings and 
long reaction times were required to reach full conversion. Upon switching to the novel catalytic 
system C7/L1, the reaction proceeded cleanly to give the desired product in 78% yield; no dimeric 
species was observed. The reaction was done in less than 1 h and the catalyst loading could be 
decreased to 20 mol% (table 8).  
 
Table 8: Screening of the influence of different catalysts for the cyclization.[a] 
 
Entry Catalyst Conditions Yield [%] 
1 C5 (35 mol%) 60 °C, 4 h 38% 
2 C5 (35 mol%) 110 °C, 4 h 33% 
3 C7/L1 (20 mol%) 60 °C 1 h 78% 
4 C7/L1 (20 mol%) 110 °C  1 h< 75% 
[a] All reactions were performed in toluene [8 mM] in presence of 5 Å molecular sieves.  
       
Ivorenolide A (32) was obtained via a two step sequence from the cyclic 1,3-diyne 130 consisting of 
simultaneous removal of both MOM protecting groups with aq. HCl at elevated temperature 
followed by subsequent epoxidation employing m-CPBA (scheme 36). Comparison of the obtained 
analytical data was in excellent agreement with those reported in the literature (table 9b).  
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2.8 Summary 
This study represents the first systematical investigation of RCDM. Model studies revealed that the 
use of molybdenum alkylydine complex C5 allowed the efficient cyclization of differently substituted 
acyclic precursors (72, 80, 83, 100) to cyclic 1,3-diynes 79a and 96 (scheme 37). Application of the 
conditions obtained during the model studies provided access to the naturally occurring cyclic 1,3-
diynes ivorenolide A and B.  
 
Scheme 37: Compounds prepared by RCDM. 
Concise total syntheses of ivorenolide A and B were accomplished, each in a ten step longest linear 
sequence from commercially available starting material.[79-80] Both syntheses represent the shortest 
access to these structurally unique natural products known to date. Moreover the total synthesis of 
ivorenolide B represents the first unsymmetrical RCDM between a terminal 1,3-diyne and a methyl 
capped 1,3-diyne (scheme 33). The total synthesis of ivorenolide A illustrates the utility of the novel 
catalytic system C7/L1 for the cyclization of bis-propargylic substrates. Although the cyclization of 
acyclic precursor 129 to the corresponding cyclic 1,3-diyne 130 was possible, the use of C7/L1 
improved the yield from 38% to 78% (scheme 36, table 7). The conducted surveys proved that RCDM 
is a valuable tool for the construction of macrocyclic compounds, offering a promising alternative to 
classical methodologies for the total synthesis of cyclic natural products.  
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Table 9a: Comparison of synthetic and natural ivorenolide B. 
  
  Isolated 13C Isolated 1H Synthetic 13C Synthetic 1H 
1 173,2 Carbonyl 173,2  
2 34,8 2,43(m, 2H) 34,8 2,43 (m, 2H) 
3a 
3b 
27,0 1,68 (m) 
1,64 (m) 
27,0 1,68 (m) 
1,64 (m) 
4a 
4b 
28,7 1,47 (m) 
1,36 (m) 
28,6 1,47 (m) 
1,36(m) 
5 30,8 1,23 (m, 2H) 30,7 1,23(m) 
6a 
6b 
30,5 1,32 (m) 
1,22 (m) 
30,5 1,32(m) 
1,22(m) 
7a 
7b 
26,4 1,56 (m) 
1,30 (m) 
26,3 1,53(m) 
1,30(m) 
8a 
8b 
29,6 1,98 (m) 
1,38 (m) 
29,6 1,98 (m) 
1,36(m) 
9 56,8 3,11 (ddd) 56,8 3,11 (ddd,) 
10 62,0 3,60 (dd) 62,0 3,60 (dd) 
11 62,8 4,87 (d) 62,8 4,87 (d) 
12 80,5  80,5  
13 70,0  70,0  
14 70,0  69,9  
15 79,0  79,0  
16 65,7 5,49 (t) 65,7 5,49 (t) 
17 27,6 1,79 (dq, 2H) 27,6 1,79 (dq, 2H) 
18 9,8 0,94 (t, 3H) 9,8 0,94 (t, 3H) 
-OH  8,48  8,48 
Table 9b: Comparison of synthetic and natural ivorenolide A. 
  
  Isolated 13C   Isolated 1H Synthetic 13C Synthetic 1H 
1 172.9 Carbonyl 172.9  
2 34.9 2.43 (2H, m) 35.0 2.47 – 2.37 (2H, m) 
3a 
3b 
25.6 1.81 (m) 
1.55 (m) 
25.6 1.81 (m) 
1.54 (m) 
4a 
4b 
29.0 1.42 (2H, m) 29.1 1.43 (2H, ddd, 11.6, 9.3, 6.2) 
5 30.0 1.23 (2H, m) 30.0 1.25 (2H, m) 
6a 
6b 
29.8 1.29 (m) 
1.23 (m) 
29.8 1.29 (m) 
1.23 (m) 
7a 
7b 
26.1 1.47 (m) 
1.36 (m) 
26.2 1.45 (m) 
1.34 (m) 
8a 
8b 
28.5 
 
1.99 (m) 
1.32 (m) 
28.6 1.99 (m) 
1.33 (m) 
9 57.0 3.10 (m) 57.0 3.09(ddd, 10.1, 4.3, 3.0) 
10 61.0 3.53 (dd, 8.1, 4.2) 61.1 3.51 (dd, 8.1, 4.2) 
11 62.0 4.77 (d, 8.1) 62.2 4.79 – 4.67 (m, 2H) 
12 78.5  78.5  
13 68.7  68.7  
14 70.3  70.3  
15 81.3  81.3  
16 65.4 4.74 (d, 8.3) 65.5 4.79 – 4.67 (2H, m) 
17 72.7 5.45 (dq, 8.3, 6.2) 72.8 5.44(dq, 8.2, 6.2) 
18 17.6 1.50 (3H, d, 6.2) 17.7 1.48 (3H, d, 6.2) 
-OH  8.44 
8.37 
 8.27(2H, s) 
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3 The rhizoxin family 
3.1 Isolation and structure elucidation  
The polyketide macrolide rhizoxin (131) was isolated three decades ago from the plant pathogenic 
fungus Rhizopus chinensis by Iwasaki and co-workers in a case study aimed at revealing the origin of 
the economically costly rice seedling blight disease.[82] Congeners of rhizoxin like the didesepoxy 
compound rhizoxin D (132), which is the putative biosynthetic precursor of the parent compound 
rhizoxin, were isolated from the same fungus shortly after the original report.[83] Tremendous efforts 
were devoted to elucidate the structure of this complex class of macrolides. These efforts included 
NMR-studies, X-ray crystallography, mass spectroscopy, IR-spectroscopy and degradation methods. 
The unprecedented structure of rhizoxin exhibits eleven stereogenic centers, a δ-lactone annulated 
in a 16-membered macrocyclic lactone, two epoxides and a triene side chain which is terminated 
with a methyl substituted oxazole heterocycle.[82b, 84]  
 
Scheme 38: Antitumor macrolides from Rhizopus chinensis.  
Initial biosynthetic studies by the isolation group revealed the origin of all carbon atoms via 
incorporation of 13C enriched biosynthetic precursors. The enriched building blocks were fed to 
Rhizopus chinensis grown on a nutrition medium.[82b] NMR studies showed that O-acetyl-L-serine acts 
as the starter unit for the synthesis of the polyketide chain C1 to C22 and that all methyl groups as 
well as the methylated hydroxy group at C17 originated from 6 eq. of methionine.[85] The exception is 
the C26a methyl group which is derived from an acetate unit, which is also the supposed origin of the 
annulated δ lactone. [85] 
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Scheme 39: Initial biosynthetic studies towards the origin of all carbon atoms in rhizoxin. 
In 2005 Hertweck and co-workers revealed that rhizoxin is not produced by the fungus itself but is 
instead synthesized by a bacteria that lives symbiotically inside the fungus.[86] The bacteria from the 
genus Burkholderia lives in a remarkably complex relationship to the host fungus. Early isotope 
labelling studies uncovered the involvement of a polyketide synthase (PKS) for the biosynthesis of 
rhizoxin.[85] Hertweck et al. were unable to detect any fungal PKS genes in the genome of the rhizoxin 
producing fungus via polymerase chain reaction (PCR).[87] Instead they were able to amplify bacterial 
16S rDNA via PCR from the fungal genome. A database search showed that these amplified genes are 
most likely belonging to a type of polyketide synthase (“trans-AT” PKS) which is exclusively known 
from bacteria.[88] The use of the antibiotic ciprofloxacin allowed them to cultivate the Rhizopus 
fungus with complete suppression of rhizoxin production. Isolation of the bacteria and re-
introduction into the symbiont-free culture led to a stable rhizoxin production, which ultimately 
proved their fungus symbiont hypothesis.[86, 89]   
3.2 Biological properties 
Early biological studies already demonstrated the great potential of this class of polyketide 
macrolides as antimitotic agents. Iwasaki and co-workers showed the antimitotic activity of rhizoxin 
by assaying the mycelium growth inhibition activity against a variety of phytopathogenic fungi.[82b] 
The mode of action is believed to occur via binding to the structural protein β-tubulin which 
interferes with the cell cycle and blocks cell division leading to the death of the plant. These results 
prompted researchers to explore the ability of rhizoxin and related compounds as potential 
chemotherapeutic agents. Inhibition of the mitosis of the tumor cells follows a similar pathway as 
known for the Vinca alkaloids such as vincristine, which is used as a chemotherapeutic agent.[90] 
Rhizoxin has been found to be less toxic and more potent than vincristine against L1210 and P388 
leukemia cells.[91]   
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Table 9: Cytotoxicity of rhizoxin and vincristine in mouse and human tumor cell lines sensitive and resistant to vincristine 
and adriamycin.[91] 
 
IC50 (nm) 
Compound P388 P388/VCR P388/ADM K562 K562/VCR 
Rhizoxin 0.91 ± 0.01[a] 3.84 ± 0.39(4.2)[b] 4.13 ± 0.49(4.5) 0.51 ± 0.04 1.28 ± 0.05 (2.5) 
Vincristine 2.10 ± 0.10 32.4 ± 2.3(15.4) 54.0 ± 2.3(25.7) 2.68 ± 0.25 56.3 ± 1.3 (21.0) 
[a] Mean ± SD of three determinations [b] Numbers in parentheses, degree (x-fold) of resistance as compared to parent 
cells. VCR = vincristine, ADM = Adriamycin, P388/VCR = leukemia resistant to VCR, P388/ADM = leukemia resistant to ADM, 
K562 = human myleogenous leukemia, K562/VCR = human myleogenous leukemia resistant to VCR. 
  
Most notably, rhizoxin has significant efficacy against vincristine and adriamycin resistant human 
tumor cells in-vitro and in-vivo. Further studies were conducted and pre-clinical evaluation 
demonstrated moderate to good in-vivo activity against murine tumors such as B-16 melanoma, 
M5076 sarcoma and human xenografts LOX melanoma, MX1 breast cancer and A549 non-small lung 
cancer.[91-92] The absence of cross-reactivity with other chemotherapeutic agents was confirmed by 
the in-vivo activity against small cell lung cancers such as LXFS 605 and LXFS 650, which were 
vincristine sensitive and –resistant, respectively. [92b] The promising properties and the observed 
activities of rhizoxin initiated Phase I and II clinical trials, in the US by the NCI, in Japan by Fujisawa 
and in Europe by the EORTC, but no therapeutic advantages compared to other chemotherapeutics 
were observed and surveys were shut down.[93]  
Rhizoxin acts by binding to β-tubulin thus causing the inhibition of tubulin polymerization. The 
inhibition prevents the formation of microtubule, the key components of the cytoskeleton, leading to 
the death of the cell. Binding studies revealed that the rhizoxin binding site is identical with that of 
ansamitocin p-3, a maytansine derivative, but differs significantly from those of colchicin.[94] The 
binding is reversible and it is believed that interaction mainly occurs via the macrocyclic structure 
which is also present in ansamitocin p-3.[91, 94b, 95] The recent success of antibody drug conjugates 
(ADC´s) led to a revived interest in microtubule destabilizing compounds like rhizoxin. Altmann and 
co-workers examined the binding modalities of rhizoxin, maytansine and PM060184, a phase I drug. 
Maytansine, which exhibits only poor efficacy in in-vivo experiments, is now part of an ADC recently 
approved by the FDA for the treatment of breast cancer.[96] In their survey they were able to obtain 
ligand-tubulin complexes which were suitable for X-ray crystallography and proved that maytansin, 
rhizoxin and PM060184 bind to the same site of β-tubulin and that this binding site differs from the 
Vinca alkaloids site (scheme 39).[97] 
Altmann et al. proposed a more specified mode of action for the microtubule destabilizing effect of 
rhizoxin and related compounds (maytansine, PM060184).[97] The steric clash of a ligand bound to 
the maytansine site (rhizoxin site) of β-tubulin stabilizes the curved tubulin oligomers. As a 
consequence of this stabilization the curved oligomers prevent the formation of longitudinal tubulin-
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tubulin interactions, which are necessary for the formation of straight tubulin structures found in the 
microtubule.[97]  
 
Scheme 40: Microtubule destabilizing agents (A). Overall (B) and close-up (C) view of the tubulin–rhizoxin F interactions (B 
and C adapted from Altmann et al.[97]). 
 
SAR studies revealed that the epoxides at C2 – C3 and C11 – C12 can be replaced by double bonds as 
in rhizoxin D, without any loss of activity. The side chain is required for hydrophobic interactions 
between rhizoxin and adjacent hydrophobic pockets formed by helices and loops of β-tubulin. 
Implementation of polar substituents like hydroxy or carbonyl groups led to loss of activity. The 
oxygen functionalities at C5b, C7 and C1 are required for hydrogen bonding between the active site 
of β-tubulin and rhizoxin. The hydroxy group at C13 is also essential for hydrogen bonding and the 
methyl group C8a is required for hydrophobic interactions. The C17 methoxy group is not essential 
and could be replaced by a hydroxy group, without loss of activity.[90, 92a, 97-98]    
3.3 Previous syntheses 
The structural complexity of this polyketide and its interesting biological properties attracted much 
attention from the synthetic community. This attention culminated in one total synthesis of rhizoxin 
(131) by Ohno et al.[99] nine total syntheses of rhizoxin D (132)[100] and one total synthesis of rhizoxin 
F (WF-1360F, 134).[42d] The total synthesis of rhizoxin by Ohno and co-workers is outlined in detail in 
the following chapter.[99a] The most recent synthesis of rhizoxin F by the Altmann group is based on a 
RCAM approach and will be discussed in-depth in the following chapter as well.[42d] The synthesis of 
Ohno and co-workers serves as a guideline for the brief discussion of the other accomplished 
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syntheses of rhizoxin D, since these syntheses exhibit significant similarities. The key features will be 
discussed, similarities and differences will be emphasized in the next chapters. 
3.3.1 The synthesis of rhizoxin by Ohno and co-workers 
The first and so far only total synthesis of rhizoxin was reported by Ohno and co-workers in 1993.[99] 
Retrosynthetic analysis divided the molecule in three parts 137, 138 and 139, which were assembled 
via Julia or HWE olefination. The main fragment 138 was further disconnected in two subunits 
consisting of Weinreb amide 141 and alkenyl compound 142. Fragment 139 could be accessed by 
double hydroboration of the diene 145. The literature known chromophore side chain was prepared 
via a sequence of standard transformations starting from the commercially available oxazole building 
block 140. 
 
Scheme 41: Retrosynthetic analysis of rhizoxin by Ohno and co-workers.[99a] 
The synthesis commenced with the preparation of fragment 138 from commercially available (S)-
Roche ester 146. Benzyl protection of the free alcohol, followed by Claisen-type reaction with 
diethyl-ethyl phosphonate and deprotection of the primary alcohol gave the phosphonate 147. 
Subsequent HWE olefination yielded the trisubstituted olefin which was then converted to the diol 
by Zn(BH4)2 reduction followed by selective protection of the primary alcohol as the corresponding 
trityl-ether 148. The secondary alcohol was methylated using CH3I and NaH and subsequent cleavage 
of the trityl group followed by Swern oxidation afforded chiral aldehyde 149. The aldehyde was 
transformed to the Weinreb amide 150 in three steps and the second trisubstituted olefin was 
introduced by lithiation of alkenyl bromide 142 and addition to the Weinreb amide. The resulting 
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ketone 151 was then reduced using Evans-Saksena conditions to obtain the 1,3-anti-diol, which was 
converted to the corresponding TBS-ether. Removal of the THP protecting group furnished the allylic 
alcohol which was converted to the desired fragment 138 via MnO2 oxidation. 
 
Scheme 42: Ohno´s synthesis of aldehyde 138: a.) PhCH2OCH2Cl, iPr2Net, 0 °C to rt, 12 h, 100%; b.) (EtO)2P(O)CH2CH3, n-
BuLi, THF, -78 °C, 10 min, 86%; c.) H2/Pd, EtOH, 12 h, 100%; d.)MPMOCH2CHO, LiCl, iPr2Net, CH3CN, 24 h, 72%; e.) Zn(BH4)2, 
Et2O, 0 °C,  30 min, 94%; f.) TrBr, pyridine, CH2Cl2, 12 h, 97%; g.) MeI, NaH, THF, 12 h, 100%; h.) CSA, MeOH, CH2Cl2, 12 h, 
97%; i.) (COCl)2, DMSO, iPr2Net, CH2Cl2, -60 °C, 98%; j.) CH3CONCH2(OCH3), LDA, THF, -78 °C, 20 min, 92%; k.) (COCl)2 DMSO, 
iPr2Net, CH2Cl2, -60 °C, 88%; l.) L-Selectride, THF, -78 °C, 30 min, 91%, m.) E-CH3CHBrCHCH2OTHP (142), t-BuLi, Et2O/THF, -
100 °C to -78 °C, 20 min, 75%; n.) CH3NBH(OAc)3, CH3CN, AcOH, -20 °C, 24 h, (ii) PPTS, MeOH, 12 h, 78%; o.) (CH3)3CCOCl, 
pyridine, CH2Cl2 12 h, 90%; p.) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 15 min, 81%; q.) LiAlH4, Et2O, 0 °C, 30 min, 99%; r.) MnO2, 
CH2Cl2, 30 min, 97%.
[99] 
The construction of the second fragment started with the desymmetrization of meso-diester 152 
with the aid of pig liver esterase. Reduction with LiBH4 and dehydration with Ac2O gave the δ-lactone 
153, which was converted to aldehyde 154 via a sequence of five steps involving basic hydrolysis of 
the lactone followed by esterification of the resulting carboxylic acid. The methyl ester was reduced 
to the alcohol and converted to the corresponding selenide which yielded, after Grieco elimination 
and ozonolysis, the desired aldehyde 154. Reaction of aldehyde under Still-Gennari conditions 
afforded the α,β-unsaturated ester, which was treated with DIBAL-H followed by subsequent TBDPS 
protection of the resulting alcohol. Hydroboration of the diene followed by oxidation yielded the diol 
156. A bicyclic transition state 155a for the hydroboration was proposed to explain the obtained 
selectivity. Fétizon oxidation of the diol 156 afforded lactone 157, which was converted to the 
requisite fragment 139 in nine additional steps.  
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Scheme 43: Ohno´s synthesis of the eastern fragment 139: a.) Pig liver esterase, 0.1 mol/l KPB, (pH~8), 10% acetone, quant. 
(>91% ee); b.) LiBH4, MeOH, DME, 1 h, (ii) Ac2O, pyridine, CH2Cl2, 81%; c.) KOH, MeOH, 0 °C, 1 h, (ii) CH2N2, MsCl, Et3N, 0 °C, 
88%; d.) (PhSe)2, NaBH4, EtOH, 0 °C to reflux, 1 h, 85%; e.) LiAlH4, Et2O, 0 °C, 30 min, 95%; f.) BnBr, NaH, THF, DMF, 12 h, 
91%; g.) O3, CH2Cl2 -78 °C, 45 min, (ii) DMS, Et3N, CH2Cl2, reflux, 1 h, 50%; h.) (CF3CH2O)2POCH(CH3)CHCO2Et, KHMDS, 18-
crown-6, THF, -78 °C, 30 min, 95%; i.) DIBAL-H, CH2Cl2, -78 °C, 20 min, 98%; j.) TBDPS-Cl, imidazole, 0 °C to rt, 2 h, 98%; k.) 
thexylboran, THF,  -78 °C to 0 °C, 12 h, then NaOH, H2O2, 0 °C, 30 min, 70% (7:1); l.) Ag2CO3/Celite, C6H6, reflux, 12 h, 88%; 
m.) TBAF, AcOH, 12 h, 96%; n.) MsCl, Et3N, CH2Cl2, 0 °C to rt, 1 h, 98%;  o.) PhSO2Na, DMF, 100 °C, 12 h, 86%; p.) H2/Pd(OH)2, 
12 h, 100%; q.) TBDPS-Cl, imidazole, 0 °C to rt, 6 h, 99%; r.) Me3Al, (CH2SH)2, 12 h, (ii) PPTS, CH2Cl2 3 h, 98%; s.) TBAF, THF, 3 
h, 98%; t.) C2H2OCHCH2, PPTS, CH2Cl2, 12 h, 100%.
[99] 
The end game started with the assembly of both fragments through Julia olefination, which furnished 
the (E,E)-diene 158. Both silyl protecting groups were removed with the aid of TBAF followed by 
selective protection of the allylic alcohol. The remaining hydroxy group was then treated with 
diethylphosphonoacetic acid to afford the corresponding phosphonate 159. Removal of the 1,3-
dithiolane, followed by deprotection of the ethoxyethyl acetal and Swern oxidation yielded the 
desired aldehyde. Macrocyclization was achieved via intramolecular HWE reaction to give the α,β-
unsaturated lactone 160 in 73% yield. The final transformations started with the stereoselective and 
regioselective epoxidation of the α,β-unsaturated lactone motif. Ohno and co-workers rationalized 
that during the biosynthesis the epoxidation occured after formation of the macrocyclic ring; 
therefore a selective epoxidation should be possible. The use of the lithium salt derived from TBHP 
and a quaternary ammonium salt gave the desired epoxide. The TBDPS protecting group was 
removed with the aid of HF·Pyr to liberate the hydroxy group which was required for the directed 
vanadium-catalyzed second epoxidation to yield 161. Deprotection of the PMB group followed by 
oxidation of the allylic alcohol to the aldehyde set the stage for the attachment of the side chain.  
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Scheme 44: Completion of Ohno´s synthesis of rhizoxin: a.) 139 n-BuLi, -78 °C to 0 °C, 30 min, then 138, -78 °C to 0 °C 2 h; 
b.) Ac2O, pyridine, DMAP, CH2Cl2, 12 h; c.) 5% Na-Hg, Na2HPO4, MeOH, -20 °C, 1 h, 56% (over three steps); d.) TBAF, THF, 12 
h, 86%; e.) TBDPS-Cl, imidazole, 0 °C to rt, 12 h, 81%; f.) (EtO)2P(O)CH2CO2H, EDC·HCl, DMAP, 0 °C to rt, 12 h, 97%; g.) PPTS, 
EtOH, 12 h, 97%; h.) HgCl2, CaCO3, CH3CN, H2O, 1 h, 88%; i.) (COCl)2, DMSO, i-Pr2Net, -60 °C, 75%; j.) K2CO3, 18-crown-6, 
toluene, reflux, 24 h, 73%; k.) t-BuOOLi, Me4NClO4, THF, 4 days; l.) HF·Pyr, pyridine, 40 °C, 12 h, 49% (over two steps); m.) t-
BuOOH, VO(acac)2, 0 °C to rt, 10 min, 86%; n.) DDQ, CH2Cl2, H2O, 1 h, 82%; o.) MnO2, CH2Cl2, 30 min, 76%; p.) 137 KHMDS, 
THF, -78 °C to 0 °C 30 min, 80%.[99] 
The necessary phosphine oxide 137 was prepared from oxazole carboxylate 140 in a seven step 
sequence and assembled with the macrocyclic core through a HWE olefination. Rhizoxin (131) was 
obtained via a longest linear sequence consisting of thirty-nine steps.  
3.3.2 Total syntheses of rhizoxin D 
3.3.2.1 Late stage transformations 
The first asymmetric synthesis of naturally occurring didesepoxyrhizoxin (rhizoxin D, 132) was 
accomplished in 1995 by Kende et al.[100a] Two years later Williams and co-workers reported their 
successful approach towards this 16-membered macrolide. [100b] In the following years Leahy,[101] 
Keck,[100d] Pattenden,[100d] White,[100f] Burke,[100g] Ardisson[100h] and most recently Altmann and co-
workers[42d] reported the total synthesis of didesepoxyrhizoxin. The disconnections for the 
construction of the macrocyclic lactone as well as for the attachment of the chromophoric side chain 
are outlined in scheme 43. 
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Scheme 45: Retrosynthetic analysis of rhizoxin D: Disconnection of the macrocyclic core structure and the chromophore 
side chain. 
Comparison of the reported strategies shows that seven out of nine approaches were based on a 
disconnection between the C2 - C3 olefin to forge the macrocyclic lactone. The method of choice was 
the HWE olefination reaction of the C2 phosphonate with the C3 aldehyde (scheme 45). In all cases 
the phosphonate was prepared by esterification of the C15 hydroxy group with the corresponding 
phosphonoacetic acid in yields between 49% and 84% (table 11). In contrast to the HWE approach 
Pattenden and co-workers used a Stille coupling between C10 alkenyl stannane and C11 alkenyl 
iodide for the macrocyclic closure which provided only moderate yield of the desired (E,E)-diene 
(table 11).  
Table 11: Comparison of conditions for the macrocyclic closure. 
 
Entry Conditions Yield [%] 
Kende LiCl, i-Pr2Net, MeCN 55 
Williams LiCl, DBU, MeCN 84 
Leahy Ba(OH)2, THF, H2O 49 
Keck LiCl, i-Pr2Net, MeCN 87 
Pattenden Pd2dba3, AsPh3, DMF, 70 °C 48 
White LiCl, i-Pr2Net, MeCN 57 
Burke LiCl, DBU, MeCN 80 
Ardisson LiCl, DBU, MeCN 50 
Altmann C6a, 5 Å MS, toluene, 125 °C 69 
 
The construction of the triene side chain relied on three different disconnections. Leahy et al. used 
the disconnection between C18 - C19, whereas Kende, White and Altmann used a C19 - C20 Stille 
coupling. A C20 - C21 disconnection was utilized by Williams, Pattenden, Burke, Ardisson and Keck. 
Leahy and co-workers used a HWE olefination between oxazole aldehyde 162 and the phosphonate 
163 to construct (E)-olefin 164. In contrast to the other approaches, Leahy and Keck introduced the 
side chain prior to formation of the macrocycle in an early stage of the synthesis. 
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The C19 – C20 bond connection was established between oxazole-dienylstannane 165 and alkenyl 
iodide 166 via Pd-catalyzed Stille coupling. 
 
Scheme 46: Attachment of the side chain to the core structure.[99] 
The C20 – C21 disconnection was accomplished by three different olefinations. Williams and 
Pattenden used a Wittig-Horner reaction between the oxazole containing phosphine oxide 137 and 
aldehyde 168. The strategies of Burke and Ardisson were based on the HWE olefination (170 + 171) 
whereas Keck used a Julia olefination (173 + 174) to construct the olefinic C20 – C21 double bond 
(scheme 46). The conditions and yields are summarized in table 12.  
Table 12: Comparison of conditions for side chain attachment. 
 
                        Entry             Conditions Yield [%] 
Kende B [Pd(MeCN)2]Cl2, DMF 95 
Williams C KHMDS, THF 44 
Leahy A Ba(OH)2·8H2O, THF 85 
Keck E LiHMDS, THF, (ii) Ac2O, DMAP, (iii) DBU, THF (iiii) 
SmI2, DMPU, MeOH/THF 
73 
Pattenden C KHMDS, THF 38 
White B [Pd(MeCN)2]Cl2, DMF 84 
Burke D t-BuOK, DME 39 
Ardisson D t-BuOK, DME 30 
Altmann B [Pd(MeCN)2]Cl2, DMF 68 
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3.3.2.2 Fragment synthesis 
Many of the published syntheses pursued a similar strategy for the fragment preparation. For this 
reason the elaboration of the stereogenic centers at C7 and C8 were chosen as representative 
examples for the extensive use of Evans aldol chemistry. Six out of nine reported syntheses relied on 
the use of this method, demonstrating their importance and reliability (scheme 47). The exceptions 
were Ardisson, who applied an allylation reaction, and White who used copper-catalyzed 
regioselective epoxide opening to construct the desired structural motif. Ardisson used the Brown 
allylation of aldehyde 176, which provided the desired product in good yield and excellent 
selectivity.[102] After initially using the Keck allylation, White and co-workers switched to the 
regioselective opening of epoxide 188, which avoided tedious chromatographic separation. 
 
Scheme 47: Construction of the C7, C8 structural element via Evans aldol reaction, Brown allylation and epoxide opening: 
 a.) n-Bu2BOTf, Et3N (Leahy,Kende = i-Pr2NEt), CH2Cl2, -78 °C: Kende 92%; Williams 95%; Leahy 80%; Keck 86%; Pattenden 
79%; Burke 88%; b.) t-BuOK, n-BuLi, (Z)-2-butene, (-)-IPc2BOMe, BF3·OEt2, THF, -78 °C, 4 h, 82%; c.) CH2=CHMgBr, CuI (cat), 
Et2O/THF, -78 °C to -20 °C, 90%.
[42d, 99]  
Williams et al. introduced a novel strategy for the construction of the C5 δ-lactone stereogenic 
center. An elegant sequence consisting of the oxidative cleavage of diol 190, derived from OsO4-
catalyzed dihydroxylation of an early intermediate, led to the formation of an anomeric mixture of δ-
lactols. This mixture could be conveniently converted to the desired lactone 191 through Fétizon[103] 
or Ley-Griffith oxidation.[104] This strategy relied upon the thermodynamic differentiation of the 
diastereotopic aldehydes resulting from the diol cleavage (scheme 48). It was assumed that a chair 
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like transition state is applicable to explain the observed selectivity. In this case the diequatorial 
deployment of the side chains is favored over the axial alignment, leading to the desired isomer. This 
strategy was subsequently employed by Keck and Burke.[100d, 100g]  
. 
Scheme 48: Synthesis of the δ-lactone 191 by Williams and co-workers: a.) NaIO4, THF/H2O; b.) TPAP, NMO, 4 Å MS, CH2Cl2, 
67% (over two steps).[100b] 
The construction of the (E,E)-diene was accomplished with the aid of three different types of 
transformations. Kende and White used Wittig or Wittig-type transformations to prepare the (E,E)-
diene. Ardisson and Pattenden employed palladium-catalyzed reactions, whereas the method of 
choice for Williams, Leahy, Keck and Burke was a Julia type reaction. Kende et al. used the HWE 
olefination between phosphonate 192 and aldehyde 193 to afford diene 194 in 56% yield  
(scheme 49). The Wittig-olefination of aldehyde 195 with the stabilized phosphorane 196 was utilized 
by White and co-workers (scheme 49). 
   
Scheme 49: Synthesis of the (E,E)-diene by Kende and White: a.) LiHMDS, 0 °C to rt, 56%; b.) THF, Δ, 77%.[100a, 100f] 
Ardisson utilized Jeffrey-Heck conditions for the Pd-catalyzed coupling of the exo-olefin 198 with the 
requisite alkenyl iodide 199 yielding the desired product 200 in 55% yield (scheme 50).[105] The 1,3-
diene in Williams´s synthesis was prepared via the alkylation of α-sulfone 201 with allyl bromide 202 
followed by subsequent base induced elimination (scheme 51). 
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Scheme 50: Synthesis of the (E,E)-diene by Ardisson: a.) Pd(OAc)2, PPh3, K2CO3, n-Bu4NCl, DMF/H2O (10:1), 40 °C, 12 h, 
55%.[99h]  
Leahy and co-workers initially attempted to prepare the macrocyclic core of rhizoxin D via Julia 
olefination. This approach failed and they moved to the strategy shown in scheme 45. Prior to the 
cyclization they prepared the 1,3-diene via Julia-Kociensky reaction (scheme 51). This strategy was 
adapted by Burke and co-workers employing the same conditions. A slight variation of this 
transformation was utilized by Keck et al. who applied Julia-Lythgoe conditions with SmI2 as the 
reducing agent (scheme 51). 
 
Scheme 51: Synthesis of the (E,E)-diene by Williams, Leahy, Keck and Burke: a.) LDA, HMPA, THF, -78 °C, 88%; b.) DBU, 
toluene, 105 °C, 70%. c.) LiHMDS, Leahy 79%, Burke 80%; d.) n-BuLi, THF, -78 °C, ii.) Ac2O, DMAP, pyridine, iii.) DBU, THF, 
iiii.) SmI2, DMPU, MeOH, THF, 84% (over four steps).
[99b-d,99g] 
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In summary the presented strategies demonstrate the pertinence of this class of polyketides natural 
products. Although isolated nearly three decades ago, rhizoxin and its congeners still remain 
challenging targets for synthetic chemists to evaluate novel methodologies and eventually get 
deeper insights into the structure-activity relationship of this class of compounds.  
3.3.3 The synthesis of rhizoxin F by Altmann 
The most recent synthetic approach towards members of the rhizoxin family was reported in 2013 by 
the Altmann group and demonstrated the significance of this target.[42d] Their initial attempt relied on 
the closure of the macrocycle by RCM (210), which proved to be unsuccessful. Therefore their focus 
was shifted towards a strategy based on RCAM of metathesis precursor 211, which should be 
accessable via HWE olefination of aldehyde 212 with phosphonate 213. Further disconnections of 
both fragments led to advanced intermediates 214, 215, 216 and 217, the preparations of which are 
described in this chapter (scheme 52).  
 
Scheme 52: Retrosynthetic analysis by Altmann and co-workers and unsuccessful attempt to forge the macrocyclic lactone 
via RCM.[42d] 
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The synthesis started with the preparation of phosphonate 213 from 2-butynol 218. Oxidation with 
MnO2 followed by Wittig olefination gave the α,β-unsaturated ester 220. Subsequent reduction 
afforded the allylic alcohol which underwent upon treatment with MnO2 oxidation to the aldehyde 
221. The preparation of the requisite coupling partner started from 2-propynol which was 
transformed in a six step sequence to the methyl ketone 224. The ketone was treated with (+)-DIP-Cl 
to furnish the chiral boron enolate and the subsequent Paterson aldol reaction yielded the desired 
product in 70% yield. Evans-Saksena reduction of the β-hydroxy ketone afforded the 1,3-anti-diol, in 
which the allylic position was selectively protected as the corresponding TIPS-ether. Subsequent 
treatment with diethylphosphonoacetic acid resulted in the formation of desired phosphonate 213 in 
a longest linear sequence of ten steps (scheme 53).  
 
Scheme 53: Altmann´s synthesis of the phosphonate fragment (213): a.) MnO2, CH2Cl2; b.) 219, CH2Cl2, reflux 45% (based on 
219); c.) LiAlH4, Et2O, 0 °C; d.) MnO2, CH2Cl2, 82% (over two steps); e.) Cp2ZrCl2, Me3Al, then I2, Et2O, -30 °C, 60%; f.) MnO2, 
Et2O, 0 °C, 89%; g.) (R)-4-benzylpropionyloxazolidin-2-one, n-Bu2BOTf, Et3N, CH2Cl2, -78 °C 77%; h.) MeNH(OMe)·HCl, Me3Al, 
CH2Cl2, 0 °C, 85%; i.) NaH, MeI, THF/DMF 3:1, 0 °C, 99%; j.) MeMgCl, THF, -20 °C to 0 °C, 93%; k.) (+)-DIP-Cl, Et3N, CH2Cl2, -78 
°C to -25°C; l.) Me4NBH(OAc)3, AcOH, MeCN, -40 °C to -20 °C, 66% (over two steps); m.) TIPSOTf, 2,6-lutidine, CH2Cl2, -78 °C, 
97%; n.) CME-carbodiimide-TsO, DMAP, (EtO)2P(O)CH2COOH, CH2COOH, CH2Cl2, 0 °C to rt, 82%.
[42d]  
The synthesis of the δ-lactone fragment commenced with benzyl protection of butane-1,4-diol (225), 
followed by subsequent Swern oxidation and in situ α-methylenation by a procedure originally 
reported by Ogasawara.[106] The resulting aldehyde was then reduced to the allylic alcohol 226 and 
subsequent treatment with CCl4 gave allylic chloride 227. The allylic chloride was converted to the 
corresponding Grignard reagent which was treated with Bu3SnCl to furnish stannane 228. 
Transmetalation with Corey´s bromoborane complex 229,[107] followed by treatment with chiral 
aldehyde 230[108] at low temperature afforded the allylic alcohol 231 with good diastereoselectivity 
(d.r. 10 : 1). The allylic alcohol was treated with acryloyl chloride and the corresponding acryl ester 
underwent RCM with the aid of 2nd generation. Hoveyda-Grubbs catalyst.[109] The obtained 
dihydropyrone 232 was hydrogenated with Pearlman´s catalyst[110] to the lactone. After reduction 
with DIBAL-H the resulting hemiacetal was protected with TBDPS chloride. Removal of the primary 
TBS protecting group followed by oxidation and Corey-Fuchs homologation gave the acetylide which 
was trapped with MeI to furnish the methyl capped alkyne. The silyl protecting groups were removed 
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by treatment with TBAF and the lactol 234 was oxidized with PIDA/TEMPO to the desired aldehyde 
212 (scheme 54). The δ-lactone fragment was synthesized in a seventeen steps longest linear 
sequence.  
    
Scheme 54: Altmann´s synthesis of the δ-lactone fragment (212): a.) BnBr, NaH, THF, 0 °C, 95%[111]; b.) (COCl)2, DMSO, Et3N, 
CH2Cl2, -78 °C to 0 °C, then CH2N(CH3)2Cl, DBU, 86%; c.) LiAlH4, THF, 0 °C, 96%; d.) CCl4, PPh3, MeCN, 95%; e.) Mg, Bu3SnCl, 
THF, ultrasound, 0 °C to rt, quant. (80% purity); f.) 229, CH2Cl2 18 h, then 230, -78 °C, 74% (over two steps, d.r. 10 : 1); g.) 
acryloyl chloride, i-Pr2Net, CH2Cl2,  -40 °C, 85%; h.) Hoveyda-Grubss 2
nd gen. DCE, reflux, 89%, i.) H2 (9 bar), Pd(OH)2/C, 
EtOAc, 98%; j.) DIBAL-H, CH2Cl2, -78 °C; k.) TBDPS-Cl, imidazole, CH2Cl2 90% (over two steps); l.) NaIO4, THF/H2O (4:1), 87%; 
m.) (COCl)2, DMSO, Et3N, CH2Cl2, -78 °C to rt, 96%; n.) CBr4, PPh3, CH2Cl2, -78 °C, 99%; o.) n-BuLi, MeI, THF, -78 °C to rt, 94%; 
p.) TBAF, AcOH, THF, 0 °C to rt, quant. q.) TEMPO, PIDA, Yb(OTf)3 (cat), CH2Cl2, 0 °C to rt, 62%.
[42d] 
The endgame started with the assembly of both fragments via HWE olefination, affording the 
requisite metathesis precursor 211. The cyclization was carried out with Fürstner´s catalyst C6a/b, 
which yielded, after activation with MnCl2, the corresponding macrocyclic lactone 235 in good yield. 
The reduction of the triple bond failed and no transition-metal catalyzed procedure achieved the 
desired transformation. Altmann and co-workers ultimately needed to prepare the 
acetylenehexacarbonyl dicobalt complex which gave, after reductive cleavage, the undesired (Z)-
olefin 236. Three reaction cycles were necessary to achieve full conversion. The isomerization of the 
(Z)-olefin to the desired configuration was finally accomplished with AIBN/PhSH to yield the (E,E)-
diene 237. Deprotection of the TIPS group with HF·Pyr followed by Stille coupling to attach the side 
chain yielded rhizoxin D which was then converted to rhizoxin F (134) via hydroxy directed 
epoxidation using VO(acac)2 and TBHP (scheme 55).  
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Scheme 55: Completion of the rhizoxin F synthesis by Altmann and co-workers: a.) LiCl, DBU, THF/MeCN, 3:1, 0 °C to rt, 81% 
(88% brsm); b.) C6a or C6b, MnCl2, toluene, 5 Å MS, 125 °C, C6a : 69%, C6b = 63% (67% brsm); c.) [Co2(CO)8], CH2Cl2, (ii) 1-
ethylpiperidine hypophosphite, C6H6, reflux, 74% over 3 cycles, (Z)-alkene only; d.) AIBN, PhSH, C6H6, reflux, 88% (E/Z = 
20:1) e.) [PdCl2(MeCN)2], DMF, 68%; f.) HF·Pyr, pyridine, THF, 0 °C to rt, 54%; g.) t-BuOOH, [VO(acac)2], C6H6, 0 °C to rt, 65%, 
29% after prep. RP-HPLC. 
In summary Altmann and co-workers accomplished the total synthesis of rhizoxin F by the use of 
RCAM as the key transformation. The natural product was obtained through a longest linear 
sequence of twenty-four steps.[42d] The strategy allowed the preparation of several derivatives, which 
were used for biological tests. This approach demonstrated the utility of the latest generation of 
alkyne metathesis catalysts developed in the Fürstner group. 
 3.4 Objective 
Rhizoxin D was chosen as a potential target for the application of the RCDM due to its structural 
complexity and its interesting biological properties, particularly because of the revived interest in 
microtubule destabilizing compounds. The structurally challenging polyketide would provide the 
ultimate testing ground for the utility of RCDM. Notably the problems with the conversion of enyne 
235 to the corresponding (E,E)-diene 237 in Altmann´s synthesis of rhizoxin F (scheme 55) 
encouraged us to develop a novel strategy for the conversion of 1,3-diynes to differently substituted 
1,3-(E,E)-dienes. The chosen strategy should further be concise, enable access to several members of 
the family and should allow the preparation of analogues for biological evaluation. In view of the 
50 
 
requirements the planned route should be reliable, scalable and rely on catalytic and stereoselective 
transformations to establish an efficient pathway to the required scaffold. 
3.4.1 Preliminary studies 
Recently the Fürstner group reported a series of ruthenium-catalyzed trans-hydrometalation 
reactions of alkynes[112] which culminated in total syntheses of brefeldin A and 5,6-
dihydrocineromycin B.[113] The selective conversion of an alkyne to the corresponding alkenyl 
stannane proved to be the most robust and successful transformation in terms of functional group 
tolerance and practicability. The use of unsymmetrically substituted alkynes in hydrometalation 
reactions usually leads to a mixture of regioisomers. In order to obtain good selectivity for one 
regioisomer, a protic directing group, for instance a hydroxy group, was found to be crucial. These 
findings allowed the preparation of alkenyl stannanes with good proximal to distal selectivity (293a : 
293b, scheme 56). The selectivity is achieved through the interaction of the propargylic hydroxy 
group and the [Ru-Cl] unit of the catalyst (scheme 53). Spectroscopic data suggest that the chloride 
forms a hydrogen bond which aligns and blocks the orientation of the alkyne. At the same time the 
incoming stannane is predispositionally orientated by an additional interaction with the [Ru]-catalyst 
to ensure the selective trans-addition to the alkyne.[112c, 112d, 113b]    
 
Scheme 56: Trans-hydrostannation reaction and possible explanation for the observed regioselectivity: a.) [Cp*RuCl2]n, 
Bu3SnH, CH2Cl2, 88% (Z : E 99:1, proximal : distal 97:3).
[112d]  
The methodology was successfully applied as the key step in the recently reported synthesis of 5,6-
dihydrocineromycin B. The regioselective trans-hydrostannation of alkyne 239, followed by 
subsequent Pd-catalyzed Stille coupling with MeI, yielded the desired trisubstituted alkene 241, a 
structural element present in several natural products. 
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Scheme 57: Keystep in Fürstner´s total synthesis of 5,6-dihydrocineromycin B: a.) [Cp*RuCl2]n, Bu3SnH, CH2Cl2, 83%; b.) 
[Pd(PPh3)4], [Ph2PO2][NBu4], CuTc, MeI, DMF, 92%.
[113b] 
The extension of this methodology to 1,3-diynes should allow the differentiation between the two 
triple bonds. The conversion of the triple bond adjacent to the directing protic group into the 
trisubstituted alkene, followed by a second trans-hydrometalation reaction would give access to 
(E,E)-dienes such as present in members of the rhizoxin familiy. 
For the evaluation of this hypothesis a structurally simple acyclic model substrate was prepared, 
which mimicked the C8 – C13 subunit of the proposed cyclic 1,3-diyne 242 (scheme 58).  
 
Scheme 58: Preparation of the acyclic model compound (245): a.) CuCl, NH2OH·HCl, aq. BuNH2 (30% in water), 81%. 
Test substrate 245 was prepared via copper-catalyzed coupling of literature known bromo alkyne 
244[114] with 3-methylbut-1-yne (scheme 58). With the model substrate in hand the attention was laid 
on the regioselective hydrostannation reaction. The tetrameric complex [Cp*RuCl4] (C8a) and the 
polymeric complex [Cp*RuCl2]n (C8b) were chosen as catalysts, which provided the best results in 
previous studies.[112c, 112d, 113b] After optimization of several reaction parameters such as addition time 
and amount of Bu3SnH, the desired product 246 was obtained in 74% yield along with 20% of the bis-
stannane 247 (table 13). It was found that slow addition was necessary to reach full conversion of the 
starting material. Unfortunately the formation of the bis-stannylated side product 247 could not be 
suppressed by variation of the reaction parameters. NMR studies revealed that the trans-addition 
products were obtained exclusively. The most indicative parameter for this assignment was the 
observed 1H – 119Sn coupling constant. The 3JSn,H coupling constant is about twice as large if tin and 
hydrogen are in a trans arrangement than if they are cis to each other.[115] The observed values were 
in accordance with previous studies[112d, 113b] and can be found in the experimental part (chapter 4.6).  
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Table 13: Screening of the influence of different conditions for the trans-hydrostannation.[a] 
 
Entry Catalyst Bu3SnH      Addition time Yield [%]  
1 C8a 1.15 eq. 10 min. (245) <5; (246) 69; (247) 26 
2 C8b 1.25 eq. 10 min. 246 : 247 3 : 1.2[c] 
3 C8b 1.15 eq.    60 min.[b] (246) 74; (247) 20 
[a] All reaction were carried out in CH2Cl2 at ambient temperature. [b] Addition via syringe pump. [c] Determined by crude 
NMR.  
        
The subsequent palladium-catalyzed methyl-Stille reaction afforded the desired trisubstituted alkene 
248 in 84% yield. The stoichiometry as well as the order of addition is important to ensure full 
conversion of the starting material and avoid competing proto-destannation. Application of the 
described stannylation conditions (table 13) to enyne 248 provided the desired stannane 249 as a 
10:1 mixture of regioisomers. NMR studies confirmed that again exclusively the trans-addition 
product was obtained.  
 
Scheme 59: Preparation of alkenyl stannane 249: a.) [Pd(PPh3)4], [Ph2PO2][NBu4], CuTc, MeI, DMF, 92%; b.) C8b, Bu3SnH, 
CH2Cl2, 83%. 
In view of these positive preliminary results a novel retrosynthetic strategy for the total synthesis of 
rhizoxin D was developed.  
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3.4.2 Retrosynthetic analysis of rhizoxin D 
The retrosynthetic analysis of rhizoxin D was designed in a way that several members of the family 
should be accessible. The key step of the outlined strategy should be the application of the RCDM to 
construct the 16-membered macrocyclic lactone. The retrosynthetic analysis started with the 
disconnection of the chromophoric side chain 251 which should be attached via olefination (Wittig-
Horner or HWE) at C20 – C21 (scheme 60).  
 
Scheme 60: Retrosynthetic analysis for the endgame part I. 
Construction of the (E,E)-diene (C9 - C12) should rely on the successful preliminary results described 
in the previous chapter. The C13 hydroxy group should function as a directing group for the 
ruthenium-catalyzed trans-hydrostannation of the proximal alkyne followed by a palladium-catalyzed 
methyl-Stille coupling with MeI. The second ruthenium-catalyzed trans-hydrometalation reaction of 
the distal alkyne followed by proto-demetalation should provide access to the desired (E,E)-diene 
structural motif (scheme 61). Furthermore this strategy could enable the preparation of a wide array 
of substitution patterns.  
 
Scheme 61: Retrosynthetic analysis for the endgame part II. 
The 16-membered macrocycle 252 should be obtained via RCDM of tetrayne 253, by application of 
the previously elaborated conditions (chapter 2).[79-80] The metathesis precursor should be assembled 
by esterification of the western fragment 254 with the δ-lactone containing eastern part 255. 
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Scheme 62: Retrosynthetic disconnection for the macrocyclic core of rhizoxin D. 
The retrosynthetic analysis of the western fragment (254) envisages the trans-selective 1,3-reduction 
of β-hydroxy ketone 256, derived from addition of alkenyl halogenide 257 to Weinreb amide 258. 
The Weinreb amide should be prepared by selective cleavage of the acyl-oxygen bond of the 
corresponding β-propiolactone 259.  
 
Scheme 63: Retrosynthetic analysis of the western fragment 254 part I. 
The β-propiolactone bearing already three of the four required stereogenic centers should be 
obtained via trans-selective asymmetric [2+2] cyclocondensation of aldehyde 260 with propionyl 
bromide.[116] The preparation of aldehyde 260 should be accomplished by a sequence of standard 
transformations including oxidation, asymmetric alkynylation and a second oxidation reaction. The 
suitable protected aldehyde 261 and 1,3-pentadiyne 99 were chosen as a starting point for the 
preparation of the western fragment. 
 
Scheme 64: Retrosynthetic analysis of the western fragment 254 part II. 
The eastern fragment (255) should be obtained via olefination of aldehyde 262 accessible by 
oxidative cleavage and subsequent oxidation of diol 263. The diol should be installed via OsO4-
catalyzed dihydroxylation of the cyclopentene derivative 264. 
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Scheme 65: Retrosynthetic analysis of the eastern fragment 255 part I. 
The cyclopentene motif should arise from regioselective opening of epoxide 265 with the metalated 
cyclopentene donor 266. Epoxide 265 could be synthesized from commercially available trans-crotyl 
alcohol by a sequence of standard transformations including Sharpless epoxidation, regioselective 
epoxide opening followed by mono-tosylation and treatment with base (scheme 66).[117]  
 
Scheme 66: Retrosynthetic analysis of the eastern fragment part II. 
3.4.3 Synthesis of the western fragment  
The forward synthesis commenced with the preparation of aldehyde 260, which was the first key 
intermediate in the outlined strategy. Initial attempts were based on the use of commercially 
available acetal protected ethyl ester 269. The ester was carefully reduced with DIBAL-H to the 
corresponding aldehyde 270, which was then subjected to standard conditions for the asymmetric 
1,3-diyne addition[70] producing an inseparable 1 : 1 mixture of desired product 271a together with 
olefin 271b (scheme 67).  
 
Scheme 67: Initial attempts for the synthesis of aldehyde 260: a.) DIBAL-H, CH2Cl2, -78 °C, 75%; b.) 99, Me2Zn, (R,R)-
ProPhenol, Ph3P=O, toluene, 0 °C, 54% (271a 26% , 271b 28%, calculated by NMR). 
Further exploration of this route proved to be unsuccessful since the stability of the acetal protecting 
group was insufficient for the planned transformations. Therefore ethyl ester 269 was discarded as 
starting material. A second attempt for the preparation of aldehyde 276 started from propane-1,3-
diol. Selective protection as the corresponding TES-ether 273, followed by Parikh-Doering oxidation 
provided aldehyde 274 which was subjected to asymmetric alkynylation utilizing the conditions 
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described in the total synthesis of ivorenolide A (scheme 36). The desired 1,3-diyne was obtained in 
good yield and the hydroxy group was protected as the corresponding TBS-ether 275. 
 
Scheme 68: Synthesis of aldehyde 276: a.) TESCl, Et3N, DMAP (cat), CH2Cl2, 87%; b.) SO3·Py, Et3N, DMSO/CH2Cl2 (1:1), 0 °C to 
rt, 16 h, 85%; c.) 122, Me2Zn, (R,R)-ProPhenol, Ph3P=O, toluene, 0 °C, 84%; d.) TBS-Cl, imidazole, CH2Cl2, 87%; e.) (ClCO)2, 
DMSO, -78 °C to -30 °C, 1 h then -78 °C, Et3N, 76%. 
The primary TES-ether 273 was cleaved under modified Swern conditions while the resulting alcohol 
was oxidized to aldehyde 276.[118] With aldehyde 276 in hand, preparation of the trans-configured β-
propiolactone was investigated. In 2008 Peters and co-workers reported the first trans-selective 
catalytic asymmetric [2+2] cyclocondensation reaction between aliphatic aldehydes 278 and acyl 
halides 277 furnishing 3,4-disubstituted trans-configured β-lactones (279) (scheme 69). This 
transformation represents a surrogate for the catalytic enantioselective anti-aldol reaction and was 
accomplished using chiral Lewis acid C9.[116a] 
 
Scheme 69: Working hypothesis for the formation of trans-configured β-lactones (left), chiral Lewis acid catalyst C9 (right): 
a.) C9 (cat), i-Pr2Net, CH2Cl2, -70 °C. 
[116] 
The proposed mechanism relies on the assumption that enolate 281 represents the reactive 
intermediate, which undergoes an enantioselective aldol reaction with the aldehyde activated 
through interactions with the chiral Lewis acid. The resulting acyl halide alcoholate 282 would 
decompose to the ketene intermediate 283 which, upon cyclization, forms the thermodynamically 
more stable trans-configured product 279 (scheme 69).[116] 
The streamlined preparation of the chiral Lewis acid C9 is shown in scheme 70. The sequence started 
with ortho-formylation of phenol 284,[119] followed by bromomethylation of salicylaldehyde 285[120] 
and reaction with pyridine to give pyridinium bromide 287. Condensation of (R,R)-
diaminocyclohexane with two eq. of 287 in presence of 4 Å MS afforded chiral compound L2 as deep 
orange crystals. Reaction of L2 with AlMe3 formed C9 via release of two eq. of methane.[116, 121]  
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Scheme 70: Preparation of Lewis acid catalyst C9: a.) MgCl2, (CH2O)n, Et3N, THF, 70 °C, 95%; b.) HBr, (CH2O)n, H2SO4 (cat), 70 
°C, 87%; c.) Pyridine, CH3CN, quant. d.) (R,R)-diaminocyclohexane, 4 Å MS, EtOH, quant. e.) AlMe3, CH2Cl2 quant. 
Two protocols were described for the [2+2] cyclocondensation reaction; one relies on the isolation of 
the active aluminum-complex formed from L2 and AlMe3 by precipitation with pentane. The second 
procedure relies on the in situ formation of the active species. Generation of active complex C9 was 
confirmed by reproduction of cyclocondensation of aldehyde 288 and propionylbromide (289).[116a]  
 
Scheme 71: Model reaction for the catalyst validation: a.) L2, AlMe3, CH2Cl2 3 h, then propionyl bromide, i-Pr2Net, CH2Cl2, -
70 °C (90% conversion after 3 h, calculated by GC/MS). 
Applying these reaction conditions to the cyclocondensation of aldehyde 276 and propionyl bromide 
(289) did not afford the desired product. Neither the use of the isolated nor the in situ formed 
catalyst resulted in the formation of the desired β-lactone. Increasing the temperature had no 
positive effect on the reaction. 
 
Scheme 72: Attempted preparation of the trans-configured β-lactone (291a): a.) L2, AlMe3, CH2Cl2 3 h, then propionyl 
bromide, i-Pr2Net, CH2Cl2, -70 °C. 
One possible explanation for the failure is that the bulky TBS protecting group interferes with the 
sterically demanding Lewis acid and prohibits the alignment of the aldehyde, necessary for the [2+2] 
cyclocondensation. Another conceivable explanation is that the additional oxygen functionality 
present in the aldehyde interacts with the oxophilic aluminum-center preventing the desired 
transformation. 
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Scheme 73: Mode of action of Lewis acid catalyst and conceivable explanation for the failure of the [2+2] 
cyclocondensation.[116b] 
In order to stick to the selected strategy an alternative method for the preparation of the trans-
configured β-lactone 291a was tested. In 1997 Romo and co-workers reported the use of a tandem 
Mukayama aldol-lactonization (TMAL) for the total synthesis of the lipase inhibitor (-)-panclicin D 
(293).[122] The ZnCl2 mediated reaction between thiopyridine ketene acetal 292 and aldehyde 278 led 
to the formation of trans-configured β-lactone 279. This methodology was built on early 
observations by Hirai and co-workers[123] and allowed the convenient preparation of 3,4-
disubstituted-β-lactones with high diastereoselectivity.[122, 124]   
 
Scheme 74: Tandem Mukayama aldol-lactonization (left) and (-)-panclicin D (right): a.) ZnCl2, CH2Cl2. 
This method has been extensively employed by the group of Romo and these efforts culminated in 
several total syntheses[125] and in a detailed description of the mechanism based on computational 
and experimental findings.[126] The TMAL reaction is a stereoconvergent process in terms of the 
ketene acetal geometry. The proposed mechanism is based on theoretical and experimental results 
and is in good accordance with the observed stereoselectivity (scheme 75). Coordination of ZnCl2 to 
either the (Z) or the (E)-configured acetal afforded adducts ZPre and EPre which upon addition of the 
aldehyde result in transition states E1 and Z1. The C - O bond as well as the C - C bond formation 
occurs concertedly but asynchronously, resulting in the formation of the oxetanes E2 and Z2. This 
process was found to be slightly endothermic. Subsequent cleavage of the Zn - O bond, followed by 
cleavage of the S - C bond and loss of the silyl group in the silylated intermediates E3 and Z3 give the 
trans-configured β-lactone (scheme 75).[126] 
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Scheme 75: Overall mechanistic proposal and explanation for the observed diastereoselectivity for the ZnCl2-mediated 
TMAL reaction of non chiral aliphatic aldehydes.[126] 
The (E)-thiopyridyl ketene acetal 294 was prepared by treatment of propionyl chloride (117) with  
2-mercaptopyridine in presence of Et3N. In a second step, the resulting 2-propionylthiopyridine (296) 
was deprotonated with LiHMDS and the enolate was trapped with TBS-Cl to afford the desired acetal 
294.[127] The acetal was treated with chiral aldehyde 276 in presence of stoichiometric amounts of 
freshly dried ZnCl2 to yield the desired β-lactone 291a in 62% yield as a 5:1 mixture of inseparable 
trans-diastereoisomers (scheme 76).  
 
Scheme 76: Preparation of β-lactones 291a/b via TMAL reaction (left). Possible explanation of the observed selectivity 
based on the model of 1,3-asymmetric induction (297)[128]: a.) Et3N, CH2Cl2, 30 min, 89%; b.) LiHMDS, DMF, TBS-Cl, -78 °C, 
THF, 91%; c.) ZnCl2, CH2Cl2, 3 h, 62% (5:1 d.r.).  
The relative configuration was confirmed by NOE experiments and the coupling constants (JHa,Hb ∼ 4.0 
Hz). The obtained outcome of the reaction is in accordance with the model originally proposed by 
Evans for the 1,3-asymmetric induction of β-silyl oxy aldehydes.[128] The model includes both steric 
and electrostatic interactions and relied on experimental and computational data. The proposed 
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transition state is based on the fact that steric interactions are minimized if the aldehyde adopts the 
staggered conformation 297. This also favours electrostatic interactions between the polarized 
carbonyl carbon and the β-heteroatom substituent (scheme 76).[128] 
After successful preparation of the key intermediate 291a, the alkenyl motif should be introduced. 
This transformation proved to be more challenging than expected. Initial approaches were based on 
the direct cleavage of the acyl-oxygen bond via mono-addition of the metalated species derived from 
Li/I exchange of alkenyl iodide 298a/b. The alkenyl iodides were prepared in two steps from 
commercially available but-2-yn-1-ol (299). Ti-catalyzed hydromagnesation of butynol, followed by 
iodine quench, afforded (E)-alkenyl iodide 300. This could be protected as the corresponding MOM-
ether 298a and TBS-ether 298b under standard conditions (scheme 77).[129] 
 
Scheme 77: Preparation of alkenyl iodide 298a/b: a.) Cp2TiCl2, i-BuMgCl, I2, Et2O, -78 °C to 0 °C, 5 h, 45%; b.) (a) MOM-Cl, i-
Pr2Net, CH2Cl2, 16 h, 64%; (b) TBS-Cl, imidazole, THF, 0 °C, 1 h, 68%.  
First attempts started with the Li/I exchange followed by subsequent addition to the β-lactone. The 
MOM-ether 298a proved to be unstable under the reaction conditions; therefore TBS-ether 298b 
was utilized in all later attempts. The exchange reaction was conducted at low temperature, followed 
by slow addition of the lithium reagent to the lactone. The reaction afforded the desired product 
only in low yields and the transformation lacked reproducibility. Additionally significant erosion of 
the optical purity of resulting ketone 301 was observed, which was in accordance with previous 
reports for the direct addition of alkenyllithium reagents to lactones bearing a α-stereogenic 
center.[130] Lowering the temperature from -78 °C to -90 °C as well as decreasing the addition rate 
had no beneficial effect on the outcome. Treatment of the alkenyllithium compound with anhydrous 
CeCl3 yielded a deep orange solution of an organocerium reagent, which proved to be fairly 
temperature sensitive. Addition of the organocerium compound to the β-lactone gave the desired 
product along with recovered starting material and the bis-addition product (scheme 78). 
 
Scheme 78: Initial attempts for the preparation of the α,β-unsaturated ketone 301: a.) 298b, t-BuLi, Et2O/pentane, -90 °C, 
then 291a/b, -78 °C, 20 min, 24%, b.) 298b, t-BuLi, Et2O/pentane, -78 °C, then CeCl3, 1 h, then 259a/b, -78 , 1 h, 20%. 
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Due to these unsuccessful attempts the β-lactone 291a was converted to Weinreb amide 302a by 
reaction with the aluminum-reagent prepared in situ from CH3NH(OCH3) and AlMe3 (scheme 79). At 
this stage the separation of the diastereoisomers was accomplished.    
 
Scheme 79: Preparation of the Weinreb amide (302a): a.) CH3NH(OCH3), AlMe3, CH2Cl2, 0 °C, 3 h , 78% (302b, 11%).  
Again, addition of the alkenyllithium reagent to the Weinreb amide (302a) proved to be problematic. 
Deprotonation of the hydroxy group with n-BuLi prior to the addition of the alkenyllithium reagent 
had no positive effect on the yield of the reaction. Transmetalation of the lithium species with 
MgBr2·(OEt)2 afforded the corresponding Grignard reagent, which also furnished only trace amounts 
of product. Since the direct formation of the corresponding Grignard reagent via Mg/I exchange led 
to isomeration of the olefin, the method of Oshima for the preparation of stereodefined Grignard 
reagents was tested.[131] In their report they used trialkylmagnesates for the halogen-magnesium 
exchange. The magnesium reagent prepared by this protocol afforded, upon addition to the Weinreb 
amide, again only trace amounts of the product. 
 
Table 14: Conditions for the addition of alkenyl iodide to the Weinreb amide.[a] 
 
Entry Conditions Yield [%] 
1 298b, t-BuLi, -78 °C then 302a, -78 °C 24 
2 298b, t-BuLi, -78 °C then 302a[b], -78 °C 16 
3 298b, t-BuLi, -78 °C then MgBr2·(OEt)2, then 302a, - 78 °C to 0 °C trace 
4 298b, t-BuLi, -78 °C then CeCl3·2LiCl, then 302a, -78 °C 38 (96, bsrm) 
[a] Li/I exchange was conducted in Et2O for 20 min at -78 °C, Weinreb amide was added as a solution in THF to the alkenyl 
reagent dropwise. [b]Prior treated with 0.6 eq. of n-BuLi at -78 °C and stirred for 15 min.  
        
The best results for the preparation of ketone 301 were ultimately achieved by treatment of the 
alkenyllithium reagent with CeCl3·2LiCl[132] to afford the organocerium compound, followed by 
subsequent addition of the Weinreb amide (302a). This procedure yielded the desired compound in 
38% yield together with 58% of recovered starting material (table 14). Although 5 eq. of the 
alkenylcerium reagent were employed, the reaction never reached full conversion. Increasing the 
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amount of the cerium reagent did not enhance the conversion but led to formation of side products. 
Performing the reaction at higher temperature did only result in decomposition of the organocerium 
reagent which was not stable above -60 °C. Despite the moderate yield, the good reproducibility and 
convenient recovery of starting material allowed sufficient amounts of the desired ketone 301 to be 
produced.  
The construction of the stereogenic center C17 was accomplished by Evans-Tishenko reaction 
utilizing a freshly prepared solution of SmI2 and p-nitrobenzaldehyde, which yielded the desired 1,3-
anti-diol mono-ester 303 as the only detectable isomer.[133] The advantage of this procedure 
compared to similar transformations was the concurrent protection of the C15 hydroxy group as the 
corresponding benzoate, which allowed the subsequent methylation of the C17 hydroxy group in the 
next step to be performed (scheme 80). The methylation proved more challenging than originally 
envisaged in that most of the standard conditions afforded only recovered starting material or led to 
decomposition of the substrate. In fact the use of MeI or MeOTf in presence of amine bases like i-
Pr2Net, 2,6-di-tert-butyl-4-methylpyridine or 2,6-di-tert-butylpyridine induced no conversion, 
whereas the use of t-BuOK or LiHMDS led to degradation of alcohol 303. Other methods such as 
(CH3)3SiCHN2 or Ag2O/MeI also failed to yield the desired product. Methylation was finally 
accomplished via treatment of alcohol 303 with 1,8-bis-(dimethylamino)naphthalin (Proton 
Sponge[TR]) and (CH3)3OBF4, which provided the desired product 304 in good yield (scheme 80). 
 
Scheme 80: Preparation of methyl-ether 305: a.) SmI2, p-nitrobenzaldehyde, THF, -10 °C, 2 h, 70%; b.) (CH3)3OBF4, 1,8-bis-
(dimethylamino)naphthalin, CH2Cl2, 4 h, 69% (77% bsrm.) 
The final step was the removal of the benzoate protecting group, which was achieved with the aid of 
K2CO3 to yield the desired fragment 305 in 71% yield (scheme 81).  
 
Scheme 81: Preparation of the western fragment (305): a.) K2CO3, MeOH/THF 1:1, 6 h, 71%. 
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This transformation marked the endpoint of the western fragment synthesis, which was achieved in a 
longest linear sequence of eleven steps, starting from commercially available propane-1,3-diol. The 
TMAL reaction for the preparation of the chiral β-lactone 291a was the key step in this sequence 
which allowed any auxiliary based transformations to be avoided. The complete route for the 
synthesis of the western fragment is shown in scheme 82.  
 
Scheme 82: Overview of the western fragment synthesis: a.) TESCl, Et3N, DMAP (cat), CH2Cl2, 87%; b.) SO3·Py, Et3N, 
DMSO/CH2Cl2 (1:1), 0 °C to rt, 16 h, 85%; c.) 122, Me2Zn, (R,R)-ProPhenol, Ph3P=O, toluene, 0 °C, 84%; d.) TBS-Cl, imidazole, 
CH2Cl2, 87%; e.) (ClCO)2, DMSO, , -78 °C to -30 °C, 1 h then -78 °C, Et3N, 76%; f.) 294, ZnCl2, CH2Cl2, 3 h, 62% (5:1 d.r.); g.) 
MeNH(OMe), AlMe3, CH2Cl2, 0 °C, 3 h , 78%; h.) 298b, t-BuLi, Et2O/pentane, -78 °C, 15 min, then CeCl3·2LiCl, 30 min, then 
302a, -78 °C, THF, 45 min, 38% (96% bsrm); i.) SmI2, p-nitrobenzaldehyde, THF, -10 °C, 2 h, 70%; j.) (CH3)3OBF4, 1,8-bis-
(dimethylamino)naphthalin, CH2Cl2, 4 h, 69% (77% bsrm.); k.) K2CO3, MeOH/THF 1:1, 6 h, 71%. 
3.4.4 Synthesis of the eastern fragment 
The preparation of the eastern fragment commenced with literature known Sharpless epoxidation of 
trans-crotyl alcohol (268),[134] followed by regioselective addition of the aluminum-reagent derived 
from TMS-acetylene.[135] The resulting diol 306 was selectively mono-tosylated with the aid of Bu2SnO 
and the resulting tosylate 307 was treated with DBU to yield the desired epoxide 265 (scheme 
83).[117] 
 
Scheme 83: Preparation of epoxide 265: a.) (-)-DIPD, Ti(i-PrO)4, TBHP, 3 Å MS, CH2Cl2, -20 °C to rt, 16 h, 78%; b.) TMS-
acetylene, n-BuLi, toluene, -78 °C then Et2AlCl, 0 °C then 307, 16 h, 95%; c.) Tos-Cl, Bu2SnO, Et3N, CH2Cl2, 6 h, 75%; d.) DBU, 
CH2Cl2, 3 h, 85%. 
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With the epoxide in hand, the regioselective addition of the cyclopentene moiety was investigated. 
Therefore commercially available cyclopent-3-en-1-ol (308) was transformed to the corresponding 
iodide 309. The conversion of the iodide to the alkyllithium reagent 310 was attempted with t-BuLi at 
low temperature, which only led to decomposition of the substrate (scheme 84).  
 
Scheme 84: Preparation of cyclopenten iodide 309 and bromide 311: a.) PPh3, imidazole, I2, CH2Cl2, 16 h, 81%; b.) t-BuLi, 
Et2O/pentane, -78 °C; c.) PPh3, imidazole, Br2, CH2Cl2, 16 h, 54%; 
As an alternative, the alcohol was converted to the literature known bromide 311 followed by 
treatment with freshly activated Mg to obtain the Grignard reagent.[136] The regioselective addition 
was then accomplished by reaction of the Grignard reagent with epoxide 265 in presence of a 
stoichiometric amount of CuI, which gave the desired product in good yield (scheme 85).  
 
Scheme 85: Preparation of cyclopentene derivative 264: a.) 312, Mg, Et2O, 2 h, then 265, CuI, THF, -40 °C, 40 min, 87%. 
To install the requisite 1,3-diyne, the TMS-alkyne was converted to the corresponding bromide 
followed by a copper-catalyzed coupling with propyne. Product 312 was obtained in 60% yield over 
two steps (scheme 86). 
 
 
Scheme 86: Installation of the 1,3-diyne via Cadiot-Chodkiewicz coupling: a.) NBS, AgNO3 (cat), acetone, 2 h; b.) propyne, 
CuCl, NH2OH·HCl, aq. BuNH2 (30% in water), 30 min, 60% (over two steps). 
Cyclopentene 312 was subjected to OsO4-catalyzed dihydroxylation conditions[137] to yield the 
desired cis-diol 263 as a 7.1 : 1 mixture of diastereoisomers. During the course of the reaction no 
interaction of the OsO4 with the 1,3-diyne motif was observed. The stereochemical outcome of the 
reaction was in accordance with Kishi´s empirical rule for OsO4-catalyzed dihydroxylations.[138] The 
newly formed diol lies in an anti-relationship to the directing hydroxy group at C7, which is in line 
with Kishi´s observation that osmium tetroxide approaches preferentially from the face of the double 
bond opposite to the pre-existing hydroxy group (scheme 87).[138-139] 
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.  
Scheme 87: Diyhdroxylation using Upjohn conditions: a.) OsO4 (cat), NMO, acetone/H2O (2:1), 6 h, 70% (7.7 : 1 d.r.).  
The δ-lactone was prepared by a sequence related to the one originally described by Williams and 
co-workers.[100b] The diol was treated with NaIO4 immobilized on SiO2, which produced the expected 
mixture of anomeric lactols (314). As previously described (chapter 3.3.2), in a chair like 
conformation the diequatorial alignment (A) of the side chains is sterically favored over the axial-
equatorial disposition (B). Additionally the diequatorial conformation (A) might be favored due to the 
electrostatic repulsion between the aldehyde group and the hydroxy group of the resulting lactol 
(scheme 88). The anomeric mixture was first subjected to Dess-Martin oxidation which produced the 
desired aldehyde only in trace amounts. The utilization of Yb(OTf)3-catalyzed PIDA oxidation[140] 
finally gave the desired lactone aldehyde 262 in remarkable 76% yield over two steps from diol 263 
(scheme 88). 
 
 
 
Scheme 88: NaIO4 mediated diol cleavage and subsequent PIDA oxidation: a.) NaIO4 (10% on SiO2), CH2Cl2, 20 min; b.) PIDA, 
TEMPO (cat), Yb(OTf)3 (cat), CH2Cl2, 1 h, 76% (over two steps). 
The conformation of the lactone was unambiguously assigned via coupling constants and 2D-NMR-
spectroscopy. Careful comparison of the H2 - H3 coupling constants of the obtained lactone with the 
data reported by Pattenden and co-workers confirmed the diequatorial arrangement of the side 
chains (scheme 89).[100e] 
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Scheme 89: NMR investigation of δ-lactone 262 and comparison with literature known compound 316.[100e] 
The final step of the fragment synthesis was the olefination of aldehyde 262 to install the α,β-
unsaturated carboxylic acid. The transformation was realized by the method reported by Helquist 
and co-workers in 2006, who described the Zn promoted HWE olefination of diprotic phosphonate 
reagents.[141] The reaction proceeded smoothly to the desired unsaturated carboxylic acid 255, with a 
E : Z ratio of 10 : 1.  
 
Scheme 90: Preparation of α,β-unsaturated carboxylic acid 255: a.) Zn(OTf)2, DBU, TMEDA, diethylphosphonoacetic acid, 
THF, 16 h, 73% (10: 1, E : Z). 
In total this fragment was synthesized in a longest linear sequence of eleven steps from commercially 
available trans-crotyl alcohol. The key steps were the regioselective addition of cyclopentenyl 
bromide 311 to epoxide 265, followed by the dihydroxylation/oxidation sequence for the 
construction of the δ-lactone. The complete route for the synthesis of the eastern fragment is shown 
in scheme 91. 
 
Scheme 91: Overview of the eastern fragment synthesis: a.) (-)-DIPD, Ti(i-PrO)4, TBHP, 3 Å MS, CH2Cl2, -20 °C to rt, 16 h, 
78%; b.) TMS-acetylene, n-BuLi, toluene, -78 °C then Et2AlCl, 0 °C then 267, 16 h, 95%; c.) Tos-Cl, Bu2SnO, Et3N, CH2Cl2, 6 h, 
75%; d.) DBU, CH2Cl2, 3 h, 85%; e.) 311, Mg, Et2O, 1 h, then CuI, THF, -40 °C, 1 h, 87%; f.) NBS, AgNO3 (cat), acetone, 2 h; g.) 
propyne, CuCl, NH2OH·HCl, aq. BuNH2 (30% in water), 30 min, 60% (over two steps); h.) OsO4 (cat), NMO, acetone/H2O 
(2:1), 6 h, 70% (7.7 : 1 d.r.); h.) NaIO4 (10% on SiO2), CH2Cl2, 20 min; i.) PIDA, TEMPO (cat), Yb(OTf)3 (cat), CH2Cl2, 1 h, 76% 
(over two steps); j.) Zn(OTf)2, DBU, TMEDA, diethylphosphonoacetic acid, THF, 16 h, 73% (10: 1, E : Z). 
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3.4.5 Fragment assembly and RCDM 
After the successful preparation of both fragments, their assembly was investigated next. The first 
attempt for the desired esterification of α,β-unsaturated carboxylic acid 255 with alcohol fragment 
305 was conducted under Yamaguchi conditions. The approach proved to be problematic since the 
carboxylic acid was insoluble in the solvents commonly employed for this transformation. The use of 
toluene and CH2Cl2 only resulted in recovery of the alcohol fragment and decomposition of the acid.  
 
 
Scheme 92: Attempted assembly of both fragments via Yamaguchi esterification: a.) 2,4,6-trichlorbenzoyl chloride, Et3N, 
CH2Cl2, 0 °C, then 305, DMAP, toluene, 4 h.  
Due to this unsuccessful approach an alternative strategy for the fragment assembly was envisaged. 
The metathesis precursor should be obtained via olefination of aldehyde 262 with phosphonate 317 
(scheme 93). 
 
Scheme 93: Revised retrosynthetic analysis of tetrayne 253. 
Therefore alcohol 305 was first converted to the corresponding phosphonate 318 by reaction with 
diethylphosphonoacetic acid in presence of EDC·HCl and DMAP. Product 318 was obtained in 94% 
yield. Phosphonate 318 was then treated with LiCl and DBU followed by addition of aldehyde 262, 
which afforded the desired metathesis precursor 319 (scheme 94). 
 
 
Scheme 94: Preparation of metathesis precursor 319: a.) EDC·HCl, diethylphosphonoacetic acid, 3 Å MS, DMAP, CH2Cl2, 8 h, 
94% b.) LiCl, DBU, MeCN/THF, 5 h, 50%. 
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With the metathesis precursor in hand, the RCDM key transformation was examined. The reaction 
was carried out under conditions previously used for the cyclization of precursor 129 in the total 
synthesis of ivorenolide A (chapter 2.7, scheme 36). In presence of 30 mol% of C7/L1 the reaction 
proceeded smoothly at 65 °C in 1.5 h to the desired cyclic 1,3-diyne 320. The product was obtained 
together with an impurity derived from the silanol ligand L1, which could not be removed at this 
stage. As an alternative the cyclization was performed using complex C5. In presence of 30 mol% of 
C5, the cyclic 1,3-diyne was obtained in 58% yield, without notable amounts of impurities derived 
from the employed catalyst (scheme 95). 
. 
Scheme 95: Preparation of cyclic 1,3-diyne 320: a.) C5, 5 Å MS, toluene, 65 °C, 1.5 h, 58%. 
The conversion of metathesis precursor 319 to the highly decorated cyclic product 320 proves the 
robustness and reliability of this transformation. The next step was the simultaneous removal of both 
silyl protecting groups. This transformation was accomplished with the aid of TBAF at low 
temperature (scheme 96).  
 
Scheme 96: Preparation of diol 321: a.) TBAF, THF, -50 °C to -10 °C, 71% 
The diol in hand, the second keystep, the hydroxy directed trans-hydrostannation reaction was 
examined. The use of 15 mol% of tetrameric complex C8a allowed the smooth conversion of 321 to 
the desired alkenyl stannane 322 (scheme 97). NMR-investigations confirmed the desired 
regioselectivity as well as the correct configuration of the resulting double bond. The observed  
1H – 119Sn coupling constant was in accordance with the values obtained during the model studies 
(chapter 3.4.1). 
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Scheme 97: Preparation of stannane 322: a.) Bu3SnH, C8a (cat), CH2Cl2 45 min,  
This step marks the endpoint of this work. Both keysteps were successfully applied and studies to 
finalize the total synthesis of rhizoxin D are currently ongoing in the Fürstner group. 
3.5 Summary 
In summary, a novel strategy for the total synthesis of rhizoxin D, based on RCDM, was developed. 
Preliminary studies showed that the hydroxy group directed regioselective trans-hydrostannation 
reaction of 245 allowed the preparation of alkenyl stannane 246. The subsequent palladium-
catalyzed methyl-Stille coupling followed by a second trans-hydrostannation reaction of the distal 
alkyne furnished alkenyl stannane 249 which, upon proto-destannation, would yield the (E,E)-1,3-
diene, a common motif in natural products. 
 
Scheme 98: Preparation of (E,E)-1,3-dienes via trans-selective hydrostannation. 
After the successful application of this reaction sequence on a simplified model compound a novel 
retrosynthetic strategy for the total synthesis of the antitumor polyketide rhizoxin D was developed. 
The key transformation of this strategy was the RCDM of the acyclic tetrayne 319 to afford cyclic 1,3-
diyne 320. Further disconnection of the metathesis precursor led to two different fragments (318 
and 262) exhibiting similar complexity (scheme 99).  
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Scheme 99: Revised retrosynthetic analysis of rhizoxin D. 
Fragment 318 was prepared in twelve steps from commercially available 1,3-propane diol. The TMAL 
reaction between ketene acetal 294 and chiral aldehyde 276 to afford the trans-configured β-
propiolactone 291a was the key transformation of this route (scheme 100). 
 
Scheme 100: Keystep of the western fragment synthesis a.) ZnCl2, CH2Cl2, 3 h, 62% (5:1 d.r.) 
Fragment 262 was obtained in ten steps from commercially available trans-crotyl alcohol. The 
utilized strategy relied on a regioselective epoxide opening, followed by a dihydroxylation/oxidation 
sequence (scheme 101). 
 
Scheme 101: Keysteps in the eastern fragment synthesis: a.) 311, Mg, Et2O, 1 h, then CuI, THF, -40 °C, 1 h, 87%; b.) OsO4 
(cat), NMO, acetone/H2O (2:1), 6 h, 70% (7.7 : 1 d.r.); h.) NaIO4 (10% on SiO2), CH2Cl2, 20 min; i.) PIDA, TEMPO (cat), 
Yb(OTf)3 (cat), CH2Cl2, 1 h, 76% (over two steps) 
The synthesis of both fragments was exclusively based on stereoselective transformations, the 
minimum use of protecting groups, as well as the complete avoidance of any auxiliary-based 
transformations. The assembly of both fragments was accomplished through a HWE olefination 
(scheme 102). 
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Scheme 102: Synthesis of the macrocyclic core of rhizoxin D via RCDM. 
The use of molybdenum alkylydine complex C5 allowed the conversion of tetrayne 319 to the highly 
decorated cyclic product 320. Treatment of diol 321 with Bu3SnH in the presence of C8a enabled the 
preparation of alkenyl stannane 322. 
 
Scheme 103: Cyclization of tetrayne 319 and subsequent trans-hydrostannation of diol 321. 
Studies to convert 322 to the desired natural product are currently ongoing in the Fürstner group. 
3.6 Outlook 
Previous results from the Fürstner group suggest that the catalysts used for the planned trans-
hydrostannation interferes with aromatic moieties present in the substrate. Therefore, the 
heterocycle containing polyene side chain should be attached as the last step. After the successful 
first trans-hydrostannation reaction described in chapter 3.4.5, the subsequent methyl-Stille reaction 
followed by a second trans-hydrometalation reaction should afford, after proto-destannation, the 
desired 1,3-diene. The proto-destannation could either be achieved via CuTC or by simple stirring of 
the substrate in presence of SiO2 as observed in preliminary studies (scheme 104).  
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Scheme 104: Proposed sequence for the preperation of cyclic 1,3-diene 323. 
Oxidation of the primary allylic hydroxy group in presence of a secondary alcohol has been reported 
in the total synthesis of rhizoxin by Ohno in which the application of MnO2 afforded the desired 
product.[99a] The preparation of the polyene side chain is known in the literature starting from 
commercially available 2-methyloxazole-4-carboxylate.[92a] The attachment of the chromophoric side 
chain to the macrocyclic scaffold should be accomplished via an olefination reaction to complete the 
total synthesis of rhizoxin D (scheme 105).[92a]  
 
Scheme 105: Proposed finalization of the total synthesis of rhizoxin D. 
Further modification of this strategy would allow the preparation of different members of the 
rhizoxin family which could be utilized for biological tests. Moreover the utilization of the previously 
described trans-hydrostannation methodology (chapter 3.4.1) should allow the synthesis of 
differently substituted derivatives.   
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4. Experimental 
4.1 General 
All reactions were carried out under argon in flame-dried glassware unless H2O was used as solvent. 
The following solvents and organic bases were purified by distillation over the drying agents 
indicated and were transferred under Ar: THF, Et2O (Mg/anthracene), CH2Cl2, DMSO (CaH2), pentane, 
hexane, toluene (Na/K), MeOH (Mg, stored over 3 Å MS), DMF (4 Å MS), DMSO (distilled over CaH2, 
stored over 4 Å MS). DMF, MeCN, Et3N and pyridine were dried by an adsorption solvent purification 
system based on molecular sieves. DBU, Cy2NH, i-Pr2NEt (CaH2) were distilled under Ar prior to use. 
NBS was freshly recrystallized from EtOH/H2O and p-nitrobenzaldehyde was freshly recrystallized 
from EtOH prior to use. SmI2 (0.1 M in THF) was freshly prepared prior to use according to the cited 
protocol.[100c] All other commercially available compounds (Acros, Aldrich, Alfa Aesar, Fluka, 
Fluorochem, TCI, Lancaster, Matrix Scientific,) were used as received. 
The following compounds were prepared within the department of Prof. Fürstner: C1b (Dr. A. 
Lackner), C4, C5, C7, L1, C8a, C8b, 104, Dess–Martin periodinane (DMP), [Pd(PPh3)4], Pd(PPh3)2Cl2.  
Thin layer chromatography (TLC) was performed on Macherey-Nagel precoated plates (POLYGRAM® 
SIL/UV254). Detection was achieved under UV light (254 nm) and by staining with either acidic p-
anisaldehyde or basic KMnO4 solution.  
Flash chromatography was performed with Merck silica gel 60 (40-63 μm) using predistilled or HPLC 
grade solvents. In some cases, fine silica gel (15-40 μm pore size) had to be used. 
NMR spectra were recorded on Bruker DPX 300, AMX 300, AV 400, AV 500 or AVIII 600 spectrometer 
in the solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) 
in Hz. The solvent signals were used as references and the chemical shifts converted to the TMS scale 
(CDCl3: δH = 7.26 ppm, δC = 77.13 ppm; pyridine-d5: δH = 8.74 ppm; δC = 150.35 ppm; CD3OD δH = 3.31 
ppm, δC = 49.00). Multiplets are indicated by the following abbreviations: s: singlet, d: doublet, t: 
triplet, q: quartet, quint: quintet; hept: heptet, m: multiplet. The abbreviation "br" indicates a broad 
signal. 13C NMR spectra were recorded [1H]-decoupled and the values of chemical shifts are rounded 
to one position after the decimal point. All spectra from the 500 MHz and 600 MHz spectrometers 
were acquired by co-workers of the NMR department under guidance of Dr. Christophe Farès at the 
Max-Planck-Institut für Kohlenforschung.  
IR spectra were recorded on a Spectrum One (Perkin-Elmer) spectrometer or Alpha Platinum ATR 
(Bruker) at room temperature; wavenumbers are given in cm-1.  
Mass spectrometric samples were measured by the department for mass spectrometry at the Max-
Planck-Institut für Kohlenforschung. The following equipment was used: MS (EI): Finnigan MAT 8200 
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(70 eV), ESI-MS: Bruker ESQ3000, accurate mass determinations: Bruker APEX III FT-MS (7 T magnet) 
or Mat 95 (Finnigan).  
Optical rotations were measured with a Perkin-Elmer Model 343 polarimeter at a wavelength of 589 
nm at 20 °C with a concentration (c = 1.0 = 10 mg/mL) in the indicated solvent. 
 
The following compounds were prepared according to the cited literature and the obtained 
spectroscopic data were in good agreement with those reported: 72, 74, 75, 76, 77;[31] 81, 82;[61] 
107;[77] 122;[81] 244;[114] 270;[142] 284;[119] 285;[120] 286, L2, C9;[116b] 306, 307, 265;[117] 311.[136] 
 
4.2 RCDM model studies 
Representative procedure for Ring-Closing Alkyne Metathesis of 1,3-diynes (RCDM) using C5 (GP-
1): 1,8-dioxacyclohexadeca-11,13-diyne-2,7-dione (79a). A flame dried Schlenk flask 
was charged under Ar with activated 5 Å molecular sieves (2 mg/µmol, 300mg) or a 
mixture of 4 Å/5 Å molecular sieves (2 mg/µmol of each pore size for terminal alkynes). 
The flask was then evacuated (0.01 mbar) and the molecular sieves were dried by heating with a heat 
gun (400 °C, 5 min). This procedure was repeated and after cooling to ambient temperature the flask 
was backfilled with Ar. Substrate 72 (50 mg, 0.15 mmol, 1.0 eq.) was dissolved in toluene (15 mL) and 
the solution was transferred via syringe to the flask containing the molecular sieves. The suspension 
was stirred for 1 h, before C5 (16.1 mg, 0.0015 mmol, 10 mol%) was added. The mixture was stirred 
at ambient temperature until complete conversion of starting material as indicated by TLC. The 
mixture was filtered through a short pad of SiO2, which was then rinsed with EtOAc (30 mL). The 
solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (SiO2, 10% Æ15% EtOAc in Hexane) to afford 31.3 mg (84%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 4.26 (t, J = 5.7 Hz, 4H), 2.58 (t, J = 5.7 Hz, 4H), 2.31- 2.43 (m, 4H), 1.67 
– 1.79 (m, 4H) 13C NMR (101 MHz, CDCl3): δ = 173.2, 74.4, 67.6, 60.7, 35.0, 25.7, 20.3. IR (film, cm-1): 
2960, 1728, 1282, 1230, 1171, 1128, 1011 MS: m/z calcd for C14H16O4Na 271.09405, found 
271.09408. 
 
Bis-(6-(trimethylsilyl)hexa-3,5-diyn-1-yl) adipate (80).  Adipoyl dichloride (0.22 mL, 1.5 mmol, 1.0 
eq.) was added dropwise at 0 °C to a solution of 6-(Trimethylsilyl)hexa-3,5-diyn-1-ol 
82 (500 mg, 3.0 mmol, 2.0 eq.) in CH2Cl2 (33 mL) and pyridine (1.6 mL). The mixture 
was stirred at ambient temperature for 16 h. Excess base was neutralized by addition 
of aq. HCl (0.1 N, 10 mL) and diluted with H2O (10 mL). The organic layer was separated and the 
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aqueous phase was extracted with Et2O (3 x 20 mL). The combined organic layers were dried over 
MgSO4 and the solvent was removed under reduced pressure yielding 605 mg (91%) of the title 
compound. 
1H NMR (400 MHz, CDCl3): δ = 4.16 (t, J = 6.7 Hz, 4H), 2.62 (t, J = 6.7 Hz, 4H), 2.41 – 2.28 (m, 4H), 1.74 
– 1.54 (m, 4H), 0.18 (s, 18H) 13C NMR (101 MHz, CDCl3): δ = 173.1, 88.0, 84.3, 75.3, 66.9, 61.6, 33.8, 
24.3, 19.9, -0.3(3C). IR (film, cm-1): 1738, 1251, 1181, 845 MS: m/z calcd for C24H34O4Si2Na 465.18870, 
found 465.18879. 
 
Di-(hexa-3,5-diyn-1-yl)-adipate (83). TBAF (1.0 M in THF, 0.42 mL, 0.42 mmol, 2.0 eq.) was added at  
0 °C dropwise to a solution of 80 (92.1 mg, 0.208 mmol, 1.0 eq.) in THF (6 mL) causing 
an immediate color change from yellow to dark red. Stirring was continued for 20 min 
at 0 °C before the reaction was quenched with H2O (5 mL). The organic layer was 
separated and the aqueous phase was extracted with Et2O (3 x 5 mL). The combined organic extracts 
were dried over MgSO4 and the solvent was removed under reduced pressure. The crude material 
was purified by flash chromatography (SiO2, 10% Et2O in pentane) yielding 39 mg (62%) of the title 
compound as an orange solid which rapidly decomposes on standing. 
1H NMR (400 MHz, CDCl3): δ = 4.18 (t, J = 6.6 Hz, 4H), 2.61 (td, J = 6.7, 1.2 Hz, 4H), 2.41 – 2.33 (m, 4H), 
2.00 (t, J = 1.2 Hz, 2H), 1.77 – 1.63 (m, 4H) 13C NMR (101 MHz, CDCl3): δ = 173.1, 73.9, 68.1, 66.2, 
65.5, 61.5, 33.8, 24.4, 19.8. IR (film, cm-1): 3263, 1731, 1370, 1259, 1177, 1146, 979 MS: m/z calcd for 
C18H18O4Na 321.10947, found 321.10973 
 
Cyclization: Substrate 83 (30.0 mg, 0.1 mmol, 1.0 eq.), catalyst C5 (10.1 mg, 0.01 mmol, 10 mol%), 
toluene (10 mL) according to GP-1 yielded 22.3 mg (88%) of the desired product. 
 
Cyclization: Substrate 80 (66.1 mg, 0.15 mmol, 1.0 eq.), catalyst C5 (16.1 mg, 0.015 mmol, 10 mol% + 
another 10 mol% after 12 h), toluene (15 mL), 24 h 60 °C according to GP-1. In this case the product 
was an inseparable mixture of desired and the ring contracted macrocycle[a]  
(79a : 79b, 2.3 : 1, 32.1 mg, 53% calculated by NMR purity). 
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[a] Identified by comparison with an authentic sample, cf: J. Heppekause, R. Stade, R. Goddard, A. Fürstner, J. 
Am. Chem. Soc. 2012, 132, 11045 - 11057 
 
4.2.1 Post-metathetic transformations 
4,11-Dioxa-1(2,5)-furanacyclotridecaphane-5,10-dione (84). H2O (72.0 mg, 4 mmol, 10.0 eq.) and 
SPhosAuNTf2 (15.8 mg, 0,018 mmol, 5 mol% ) were added to a solution of cyclic 1,3-
diyne 79a (90 mg, 0,362 mmol, 1.0 eq.) in THF (4 mL). The solution was heated to 60 
°C and maintained at this temperature for 16 h. The mixture was filtered through a 
short pad of SiO2 and the obtained crude material was purified by flash chromatography  
(SiO2, 15% Æ 20% EtOAc in hexane) to yield 59 mg (61%) of the title compound as a white solid. 
1H NMR (400 MHz, CDCl3): δ = 6.02 (s, 2H), 4.34 – 4.30 (m, 4H), 2.96 – 2.92 (m, 4H), 2.30 – 2.24 (m, 
4H), 1.55 – 1.49 (m, 4H) 13C NMR (101 MHz, CDCl3):173.5, 151.6, 107.4, 63.2, 34.9, 27.8, 25.1 IR (cm-
1): 1731, 1279, 1170, 1141 MS: m/z calcd for C14H18O5Na 298.10454, found 289.10404 
 
11H-4,11-Dioxa-1(4,7)-indolacyclotridecaphane-5,10-dione (85). Pyrrole (13.0 mg, 0.2 mmol, 10.0 
eq.) and [BrettPhosAu(MeCN)SbF6] (2.1 mg, 0,002 mmol, 10 mol%) were added to a 
solution of cyclic 1,3-diyne 79a (5 mg, 0,02 mmol, 1.0 eq.) in 1,2-dichloroethane (0.2 
mL). The solution was heated to 80 °C for 6 h. The mixture was filtered through a short 
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pad of SiO2, which was rinsed with EtOAc (15 mL). The solvent was removed under reduced pressure 
and the crude material was purified by flash chromatography (SiO2, 15% EtOAc in hexane). The 
product was further purified by HPLC (Kromasil, C18, 5µm, 150*21.4 mm, MeOH/H2O 80/20) yielding 
1.2 mg (21%) of the title compound as a dark green solid. 
1H NMR (600 MHz, CDCl3): δ = 8.93 (s, br N-H), 6.84 (td, J = 2.7, 1.5 Hz, 1H), 6.35 – 6.20 (m, 2H), 5.80 
(t, J = 7.2 Hz, 1H), 4.37 (t, J = 5.6 Hz, 2H), 4.31 (t, J = 5.4 Hz, 2H), 2.78 (q, J = 6.1 Hz, 2H), 2.68 (t, J = 5.7 
Hz, 2H), 2.39 – 2.33 (m, 2H), 2.30 – 2.25 (m, 2H), 1.69 – 1.62 (m, 4H) 13C NMR (600 MHz, CDCl3) δ = 
174.1, 173.5, 131.6, 118.1, 109.6, 109.0, 62.7, 61.3, 35.2, 34.7, 32.1, 29.5, 25.6, 25.4, 22.9, 20.7, 14.3, 
1.2  IR (cm-1): 2925, 2854, 1730, 1460, 1283, 1243, 1175 
 
Compound 87: Cyclic 1,3-diyne 79a (5.0 mg, 0.021 mmol, 1.0 eq.) and enyne 86 (2.71 mg, 0.042 
mmol, 2.0 eq.) were added to a solution of [Pd(PPh3)4] (2.3 mg, 0.002 mmol, 10 mol%) 
in THF (0.3 mL) and the mixture was stirred at 65 °C until TLC analysis showed 
complete consumption of 79a. The mixture was filtered through a short pad of SiO2, 
which was rinsed with EtOAc (15 mL). The solvent was removed under reduced 
pressure and the crude material was purified by flash chromatography (SiO2, 10% EtOAc in hexane) 
to yield 5.6 mg (85%) of the desired compound as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 7.29 (d, J = 7.8 Hz, 1H), 7.02 – 6.97 (m, 2H), 4.34 – 4.24 (m, 4H), 3.12 (t, 
J = 7.6 Hz, 2H), 2.79 (dd, J = 5.9, 4.9 Hz, 2H), 2.42 – 2.38 (m, 2H), 2.33 (m, 5H), 1.79 – 1.72 (m, 4H). 13C 
NMR (101 MHz, CDCl3): δ = 173.6, 173.4, 132.2, 139.4, 138.4, 129.5, 127.5, 120.8, 89.6, 80.1, 64.8, 
62.8, 34.1, 33.7, 33.4, 24.4, 24.1, 21.6, 20.4 IR (cm-1): 2924, 1732, 1458, 1340, 1238, 1144, 1066, 
1030, 1005 MS: m/z calcd for C19H22O4Na 337.14083, found 337.14103 
4.3 RCDM: Synthesis of model compound (96) and initial attempt for the total synthesis of 
ivorenolide A   
(Z)-3-Iodoacrylaldehyde (93). A 50 mL three-neck flask equipped with a thermometer, a gas inlet and 
a rubber septum was charged with ethyl-(Z)-iodoacrylate (0.64 mL, 5.0 mmol, 1.0 eq.) and 
CH2Cl2 (10 mL). The solution was cooled to -80 °C before DIBAL-H (1.0 M in CH2Cl2, 5.1 mL, 5.1 
mmol, 1.02 eq.) was added very carefully at such a rate to keep the internal temperature between  
-75 °C and -80 °C. After complete addition the mixture was stirred at -78 °C until GC/MS indicated 
complete consumption of starting ester. The reaction was cooled to -82 °C and cold MeOH (2.5 mL) 
was carefully added, followed by addition of sat. aq. Na/K-tatrate (12.5 mL). The mixture was allowed 
to warm to ambient temperature and further stirred for 30 min at this temperature. The mixture was 
filtered through a short pad of Celite®. CH2Cl2 was carefully removed under reduced pressure keeping 
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the temperature of the water bath at 0 °C. The crude aldehyde (810 mg, 86%) was not purified due to 
the high instability. Rather it was dissolved in anhydrous toluene (8.1 mL) and transferred to a 
Schlenk flask. The solution can be stored under argon in a -20 °C fridge for at least 3- 4 weeks, 
without noticeable decomposition or isomerization of the double bond. 
 
Buta-1,3-diyn-1-yltrimethylsilane (74). Bis-TMS-Butadiyne (4.0 g, 20.0 mmol, 1.0 eq.) was dissolved 
in Et2O (40 mL) and the solution was cooled to 0 °C, before MeLi (1.6 M in Et2O, 20.6 mL, 
24.0 mmol, 1.2 eq.) was added over a period of 20 min. After the addition was complete the 
solution was stirred at room temperature until GC/MS revealed complete mono-
desilylation. The mixture was cooled to -78 °C and the reaction was quenched with sat. aq. NH4Cl  
(20 mL). After warming up to room temperature, the layers were separated and the aqueous phase 
was extracted with Et2O (3 x 30 mL). The combined organic extracts were dried over MgSO4 and the 
solvent was carefully evaporated. The crude material was purified by distillation (bp. 55 °C, 60 mbar) 
to yield 1.80 g (73%) of the title compound as a colorless solution which turns yellow upon standing.  
1H NMR (400 MHz, CDCl3): δ = 2.11 (s, 1H), 0.21 (s, 9H) 13C NMR (101 MHz, CDCl3): δ = 87.5, 84.9, 
68.4, 66.8, -0.40(3C) IR (film, cm-1): 2960, 1250, 840, 759 MS: m/z calcd for C7H10Si 122.05506, found 
122.05518. 
 
(S,Z)-1-Iodo-7-(trimethylsilyl)hepta-1-en-4,6-diyn-3-ol (97). A Schlenk flask was charged with Ph3P=O 
(122.2 mg, 0,44 mmol, 20 mol%), (R,R)-ProPhenol (140.0 mg, 0,22 mmol, 10 mol%), 
and toluene (9 mL). Diyne 74 (0.66 mL, 4.40 mmol, 2.0 eq.) was added via syringe, 
followed by dimethylzinc (1.2 M in toluene, 3.65 mL, 4.40 mmol, 2.0 eq.). The 
resulting alkynylzinc solution was stirred at room temperature for 30 min, before it was cooled to  
0 °C. A cold (0 °C) solution of aldehyde 93 (4 mL of previously prepared solution, 400 mg, 2.2 mmol, 
1.0 eq.) was added over the course of 1 h. The reaction was left to proceed at 0 °C for additional 3 h. 
The reaction was then quenched at -20 °C with sat. aq. NH4Cl (10 mL) and stirred vigorously for 20 
min. The organic layer was separated and the aqueous phase was extracted with Et2O (3 x 15 mL). 
The combined organic extracts were dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude material was purified by flash chromatography (SiO2, 4% EtOAc in hexane) to 
yield 575 mg (86%, 89% ee.) of the title compound as a light yellow oil which darkens on standing.  
1H NMR (400 MHz, CDCl3): δ = 6.56 (dd, J = 7.7, 1.0 Hz, 1H), 6.38 (t, J = 7.7 Hz, 1H), 5.18 (dd, J = 7.8, 
4.2 Hz, 1H), 0.20 (s, 9H) 13C NMR (101 MHz, CDCl3): δ = 138.8, 89.1, 87.1, 85.3, 75.1, 71.0, 66.0, -
0.4(3C) IR (film, cm-1): 2960, 1683, 1611, 1251, 1130, MS: m/z calcd for C10H13IOSi 303.97812, found 
303.97804 >D@ 20 = +340.1 (c = 1.0, CHCl3).  
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The absolute configuration was determined as (S) by the advanced Mosher Ester method.[143] The ee 
of 97 was determined by integration of Ha in the spectra of the derived (S)-MTPA ester. 
 
(R)-MTPA-Ester: (S)-α-Methoxy-α-trifluoromethyl phenylacetic acid chloride (10.0 mg, 0.064 mmol, 
2.0 eq.) was added to a solution of alcohol (10.0 mg, 0.032 mmol, 1.0 eq.), pyridine (0.008 mL, 0.1 
mmol, 3.1 eq.) in CH2Cl2 (0.5 ml). The mixture was stirred for 16 h at room temperature and 
quenched with H2O (5 mL). The aqueous phase was extracted with Et2O (3 x 5 mL), the combined 
organic layers were dried over MgSO4, and the solvent was removed under reduced pressure. The 
crude product was of sufficient purity for the determination of the absolute configuration. 
1H NMR (400 MHz, CDCl3): δ = 6.78 (dd, J = 7.8, 0.9 Hz, 1H), 6.46 (t, J = 8.1 Hz, 1H), 6.24 (dd, J = 8.2, 
0.9 Hz, 1H), 0.21 (s, 9H). 
 
(S)-MTPA-Ester. Prepared analogously, using (R)-α-methoxy-α-trifluoromethyl phenylacetic acid 
chloride as the reagent. Reaction was conducted on the same scale as described above. 
1H NMR (400 MHz, CDCl3): δ = 6.74 (dd, J = 7.7, 0.9 Hz, 1H), 6.41 – 6.35 (m, 1H), 6.28 (dd, J = 8.1, 0.9 
Hz, 1H), 0.21 (s, 9H). 
 
 
Proton (R)-MTPA (S)-MTPA 
a 6.44 – 6.48 6.36 – 6.40 
b 6.22 – 6.25 6.27 – 6.29 
c 6.77 – 6.80 6.73 – 6.75 
TMS 0.205 0.209 
 
 
(S,Z)-tert-Butyl((1-iodo-7-(trimethylsilyl)hepta-1-en-4,6-diyn-3yl)oxy)dimethylsilane (90). 
TBS-Cl (313.0 mg, 2.1 mmol, 1.1 eq.), 1-methylimidazol (0.45 mL, 5.7 mmol, 3.0 eq.) 
and I2 (960.2 mg, 3.8 mmol, 2.0 eq.) were successively added at 0 °C to a solution of 
alcohol 97 (575.0 mg, 1.9 mmol, 1.0 eq.) in CH2Cl2 (8 mL). The mixture was stirred at room 
temperature until TLC indicated complete consumption of starting material. The reaction was 
quenched with sat. aq. Na2S2O3 (10 mL) and stirred until disappearance of orange color (30 min). The 
organic layer was separated and the aqueous layer was extracted with Et2O (3 x 10 mL). The 
combined organic extracts were washed with 10 mL sat aq. NaCl, dired over MgSO4 and the solvent 
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was removed under reduced pressure. The crude material was purified by flash chromatography 
(SiO2, 1% EtOAc in hexane) to afford 785 mg (98%) of the title compound as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 6.41 (dd, J = 7.5, 0.9 Hz, 1H), 6.31 (t, J = 7.6 Hz, 1H), 5.14 (dd, J = 7.6, 
0.9 Hz, 1H), 0.90 (s, 9H), 0.19 (s, 9H), 0.17 (s, 3H), 0.14 (s, 3H)  13C NMR (101 MHz, CDCl3): δ = 140.0, 
88.1, 87.4, 83.0, 76.0, 69.8, 67.1, 25.8(3C), 18.3, -0.3(3C), -4.4, -4.6. IR (film, cm-1): 2957, 2929, 2857, 
2108, 1253, 1076, 1005, MS: m/z calcd for C16H27OISi2Na: 441.05379, found 441.05374  
>D@ 20 = + 221.3 (c = 1.0, CHCl3). 
 
Hepta-3,5-diyn-1-yl 8-bromooctanoate (98). DMAP (149.1 mg, 1.11 mmol, 0.3 eq.) and DCC (1.53 g, 
7.2 mmol, 2.0 eq.) were successively added at 0 °C to a solution of 77 (400 mg, 3.7 
mmol, 1.0 eq.) and 8-bromoctanoic acid (946 mg, 4.25 mmol, 1.15 eq) dissolved 
in CH2Cl2 (20 mL). The mixture was stirred overnight at room temperature before 
the reaction was quenched with sat. aq. NaCl (20 mL) and the  organic layer was separated. The 
aqueous phase was extracted with EtOAc (4 x 15 mL). The combined organic extracts were dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude material was purified by 
flash chromatography (SiO2, 5% EtOAc in hexane) yielding 994 mg (86%) of the title compound as a 
yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 4.14 (t, J = 6.7 Hz, 2H), 3.39 (t, J = 6.8 Hz, 2H), 2.60 – 2.55 (m, 2H), 2.31 
(t, J = 7.5 Hz, 2H), 1.90 (t, J = 1.2 Hz, 3H), 1.88 – 1.79 (m, 2H), 1.65 – 1.59 (m, 2H), 1.45 – 1.39 (m, 2H), 
1.35 – 1.29 (m, 4H)  13C NMR (101 MHz, CDCl3): δ = 173.6, 74.0, 72.2, 66.9, 64.3, 61.8, 34.2, 34.1, 
32.8, 29.0, 28.5, 28.1, 24.9, 19.8, 4.3 IR (film, cm-1): 2932, 2856, 1734, 1234, 1164, 1121, MS m/z 
calcd for C15H21BrO3Na 335.06168, found 335.06172. 
 
6-(Trimethylsilyl)-hexa-3,5-diyn-1-yl(S,Z)-11-((tert-butyldimethylsilyl)oxy)hexadeca-9-en-12,14-
diynoate (99). A Schlenk flask was charged with Zn dust (32.6 mg, 0.5 mmol, 
2.0 eq.) and I2 (3.5 mg, 0.012 mmol, 5 mol%). The flask was evacuated for ca. 
30 seconds and backfilled with Ar before DMF (0.5 mL) was added. The 
resulting slurry was vigorously stirred until disappearance of the orange color (2-4 min). At this point 
alkylbromide 98 (78.3 mg, 0.25 mmol, 1.0 eq.) was added and the solution was heated to 75 °C for  
4 h. After reaching ambient temperature the remaining zinc dust was allowed to settle (20 min) 
yielding a 0.5 M solution of organozinc compound. 
A second Schlenk flask was charged with alkenyl iodide 90 (41.1mg, 0.1 mmol), PdCl2 (0.8 mg, 0.005 
mmol, 2 mol%), tri-o-tolylphosphine (4.6 mg, 0.015 mmol, 6 mol%) and THF (0.5 mL). The mixture 
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was stirred for 5 min, before an aliquot of the freshly prepared solution of organozinc compound  
(0.5 M in DMF, 0.28 mL, 0.14 mmol, 1.4 eq.) was added dropwise. The mixture was stirred for 4 h at 
ambient temperature. The reaction was quenched with sat. aq. NH4Cl (5 mL) and diluted with EtOAc 
(5 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3 x 10 mL) 
and dried over MgSO4. The solvent was removed under reduced pressure and the crude material was 
purified by flash chromatography (SiO2, 0.5% EtOAc in hexane) to yield 18.5 mg (36%) of the title 
compound. 
1H NMR (400 MHz, CDCl3): δ = 5.51 – 5.40 (m, 2H), 5.18 – 5.13 (m, 1H), 4.15 (t, J = 6.7 Hz, 2H), 2.58 
(td, J = 6.7, 1.2 Hz, 2H), 2.31 (t, J = 7.5 Hz, 2H), 2.10 – 2.01 (m, 2H), 1.90 (d, J = 1.2 Hz, 3H), 1.66 – 1.58 
(m, 2H), 1.41 – 1.22 (m, 8H), 0.88 (s, 9H), 0.18 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H) 13C NMR (101 MHz, 
CDCl3): δ = 173.7, 132.0, 129.3, 87.7, 87.4, 78.3, 74.0, 72.2, 69.0, 66.9, 64.3, 61.8, 59.5, 34.3, 29.4, 
29.3, 29.2, 29.2, 27.8, 25.9(3C), 25.0, 19.9, 18.3, 4.4, -0.3(3C), -4.4, -4.6. IR (film, cm-1): 2928, 2856, 
2105, 1738, 1251, 1165, 1072, 839 MS m/z calcd. for C31H48O3Si2Na 547.30372, found 547.30342  
>D@20 =+ 93.7 (c = 1.0, CHCl3). 
 
(S,Z)-12-((tert-Butyldimethylsilyl)oxy)oxacyclooctadeca-10-en-13,15-diyn-2-one (100).  Cyclization 
was done according to GP-1: Substrate 99 (4.1 mg, 0.0076 mmol, 1.0 eq.), 4 Å/5 Å 
MS (16 mg, each), C5 (0.7 mg, 0,0008 mmol, 10 mol%), toluene (0.76 mL), 16 h, 
rt, yielded 2.5 mg (82%) of the title compound   
1H NMR (400 MHz, CDCl3): δ = 5.53 – 5.35 (m, 2H), 5.22 – 5.18 (m, 1H), 4.24 – 4.11 (m, 2H), 2.64 (ddt, 
J = 8.1, 4.8, 1.1 Hz, 2H), 2.38 – 2.28 (m, 2H), 2.15 – 2.03 (m, 2H), 1.70 – 1.58 (m, 2H), 1.40 – 1.29 (m, 
6H), 1.24 – 1.18 (m, 2H), 0.89 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H) 13C NMR (101 MHz, CDCl3): δ = 174.0, 
131.4, 130.8, 77.3, 76.7, 69.1, 66.4, 61.6, 59.8, 35.3, 30.1, 29.7, 29.3, 29.0, 28.3, 26.1, 25.9(3C), 20.1, 
1.2, -4.5, -4.6. IR (film, cm-1): 2957, 2928, 2856, 1731, 1274, 1075 MS m/z calcd for C23H36O3SiNa 
411.23228, found 411.23259 >D@ 20 = + 39.6 (c = 1.0, CHCl3). 
 
(1R,2R,18R)-2-((tert-Butyldimethylsilyl)oxy)-9,19-dioxabicyclo[16.1.0]nonadeca-3,5-diyn-10-one 
(100b). m-CPBA (10.8 mg, 0.063 mmol, 3.5 eq.) was added at 0 °C to a solution of 
alkene 100 (7.0 mg, 0,018 mmol, 1.0 eq.) in CH2Cl2 (1 mL). The cooling bath was 
removed and the solution was stirred at room temperature for 16 h until TLC 
showed complete conversion of starting material. The reaction was quenched with sat. aq. NaHCO3 
(5 mL), and the organic layer was separated. The aqueous phase was extracted with EtOAc (3 x 5 mL) 
and the combined organic extracts were dried over MgSO4. The solvent was removed under reduced 
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pressure and the resulting crude material was purified by flash chromatography (SiO2, 3% Æ 5% 
EtOAc in hexane) yielding 5.3 mg (74%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 4.26 – 4.13 (m, 3H), 3.14 (dd, J = 7.7, 4.2 Hz, 1H), 2.96 (ddd, J = 10.6, 
4.3, 2.8 Hz, 1H), 2.70 – 2.64 (m, 2H), 2.39 – 2.34 (m, 2H), 2.09 – 1.97 (m, 2H), 1.71 – 1.57 (m, 2H), 
1.53 – 1.36 (m, 6H), 1.18 – 1.09 (m, 2H), 0.91 (s, 9H), 0.14 (d, J = 2.4 Hz, 6H) 13C NMR (400 MHz, 
CDCl3): δ = 174.0, 78.0, 73.4, 70.9, 65.7, 63.7, 61.6, 61.0, 57.0, 34.6, 30.2, 30.2, 28.9, 28.6, 27.1, 26.1, 
25.9, 25.9(3C), 20.1, -4.6, -4.7 IR (film, cm-1): 2927, 2856, 1738, 1253, 1076, 1005, MS m/z calcd for 
C23H36O4SiNa 427.22797, found 427.22751 >D@ 20 = +5.7 (c = 1.0, CHCl3). 
 
(1S,2R,18R)-2-Hydroxy-9,19-dioxabicyclo[16.1.0]nonadeca-3,5-diyn-10-one (96). TBAF (1.0 M in 
THF, 0.043 mL, 0.043 mmol, 1.5 eq.) was added dropwise at 0 °C to a solution of 
TBS-ether 100b (5.3 mg, 0.012 mmol, 1.0 eq.) in THF (0.85 mL). After stirring for 
10 min, the solution was quenched with sat. aq. NH4Cl (2 mL). The organic layer 
was separated and the aqueous phase was extracted with MTBE (3 x 5 mL). The combined organic 
extracts were dried over MgSO4 and the solvent was removed under reduced pressure. The resulting 
crude material was purified by flash chromatography (SiO2, 15% Æ 20% EtOAc in hexane) yielding  
3.0 mg (83%) of the title compound as a colorless solid. 
1H NMR (600 MHz, CDCl3): δ = 4.28 – 4.23 (m, 2H), 4.16 (ddd, J = 10.7, 6.3, 4.3 Hz, 1H), 3.39 – 3.34 (m, 
1H, OH), 3.17 (dd, J = 8.2, 4.2, Hz, 1H), 3.03 (ddd, J = 10.7, 4.2, 2.9 Hz, 1H), 2.70 – 2.66 (m, 2H), 2.40 – 
2.33 (m, 2H), 2.15 – 2.06 (m, 1H), 1.69 – 1.62 (m, 2H), 1.51 – 1.45 (m, 2H), 1.43 – 1.32 (m, 5H), 1.20 – 
1.13 (m, 2H)  13C NMR (600 MHz, CDCl3): δ = 173.7, 78.5, 72.0, 71.9, 65.4, 62.5, 61.3, 60.3, 57.5, 34.6, 
30.2, 30.0, 28.9, 28.2, 25.9, 25.8, 20.0. IR (film, cm-1): 2923, 2853, 1735, 1462, 1261, 1038, MS m/z 
calcd for C17H22O4Na 313.14065, found 313.14103 >D@20 = +17.5 (c = 0.5, CHCl3). 
 
(S)-But-3-en-2-yl 8-bromooctanoate (102).  Trimethylsulfoniumiodide (8.57 g, 42.0 mmol 3.0 eq.) 
was placed in a 250 mL Schlenk flask and THF (55 mL) was introduced. The 
suspension was cooled to -78 °C and n-BuLi (1.6 M in hexane, 25.6 mL, 40.6 
mmol, 2.9 eq.) was added. The mixture was stirred for 30 min, before (S)-2-methyloxirane 101 (0.98 
mL, 14 mmol, 1.0 eq.) in THF (5 mL) was added carefully. The cooling bath was removed and the 
solution was allowed to warm to ambient temperature. The mixture was stirred for 1.5 h, before the 
reaction was quenched with sat. aq. NH4Cl (30 mL) and the organic layer was separated. The aqueous 
layer was extracted with Et2O (3 x 30 mL) and the combined organic extracts were dried over MgSO4. 
The solvent was carefully reduced to 1/3 and the mixture was added to a stirred solution of 8-
bromooactanoic acid (3.12 g, 14 mmol, 1.0 eq.), DCC (5.72 g, 28.0 mmol, 2.0 eq.), and DMAP (0.51 g, 
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4.2 mmol, 0.3 eq.) in THF (30 mL). The mixture was stirred at room temperature overnight before the 
reaction was quenched with aq. HCl (0.5 N, 30 mL). The layers were separated and the aqueous layer 
was extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude material was purified by flash 
chromatography (SiO2, 0.5% EtOAc in hexane) to yield 2.55 g (66% over two steps) of the title 
compound as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 5.84 (ddd, J = 17.3, 10.5, 5.8 Hz, 1H), 5.40 – 5.32 (m, 1H), 5.24 (dt, J = 
17.3, 1.4 Hz, 1H), 5.13 (dt, J = 10.5, 1.3 Hz, 1H), 3.40 (t, J = 6.8 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.89 – 
1.81 (m, 2H), 1.63 (tt, J = 5.7, 2.6 Hz, 2H), 1.44 (t, J = 7.4 Hz, 2H), 1.36 – 1.32 (m, 4H) 1.31 (d, J = 6.5 
Hz, 3H)   13C NMR (101 MHz, CDCl3): δ = 173.1, 137.9, 115.8, 70.9, 34.6, 33.5, 30.4, 29.0, 28.3, 25.0, 
20.1, 7.3  IR (film, cm-1): 2931, 2856, 1733, 1453, 1372, 1237, 1179 MS: m/z calcd for C12H21O2BrNa 
299.06185 found 299.06172 >D@20 = -3.2 (c = 0.4, CHCl3). 
 
(S)-1-Oxopropan-2-yl 8-bromooctanoate (91). A 250 mL two neck flask was charged with olefin 102 
(1.5 g, 5.4 mmol, 1.0 eq.) and CH2Cl2 (50 mL) was added. The solution was 
cooled to -78 °C and O3 was bubbled through the solution until a blue color 
persisted, then O2 was bubbled through the solution until the blue color disappeared. Dimethylsulfid 
(3.9 mL, 54.0 mmol, 10.0 eq.) was added at -78 °C and the reaction was slowly warmed to ambient 
temperature over the course of 16 h. H2O (50 mL) was added and the organic layer was separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the combined organic extracts were 
washed with sat. aq. NaCl (30 mL) and dried over MgSO4. The solvent was removed under reduced 
pressure and the crude material was purified by flash chromatography (SiO2, 15% EtOAc in hexane) 
to yield 1.2 g (81%) of the title compound as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 9.54 (d, J = 0.6 Hz, 1H), 5.08 (qd, J = 7.2, 0.6 Hz, 1H), 3.19 (t, J = 7.0 Hz, 
2H), 2.42 (td, J = 7.4, 2.4 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.67 (t, J = 7.3 Hz, 2H), 1.46 – 1.30 (m, 9H) 
  13C NMR (101 MHz, CDCl3): δ =198.6, 173.2, 74.5, 34.0, 33.5, 30.4, 28.9, 28.3, 14.3, 7.3.  
IR (film, cm-1): 2934, 2857, 1737, 1236, 1174, 1074 MS: m/z calcd for C11H20O3Br 279.05883 found 
279.05905  >D@20 = -13.7 (c = 1.0, CHCl3). 
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(2S,3R)-3-Hydroxy-7-(trimethylsilyl)hepta-4,6-diyn-2-yl 8-bromooctanoate (89). A 25 mL Schlenk 
flask was charged with (R,R)-ProPhenol (27.4 mg, 0.04 mmol, 10 mol%), 
Ph3P=O (23.9 mg, 0.08 mmol, 20mol%), and toluene (2.6 mL). The solution 
was stirred for 10 min at room temperature, then ZnMe2 (1.2 M in toluene, 
1.0 mL, 1.29 mmol, 3.0 eq.) was added followed by dropwise addition of diyne 74 (0.21 mL, 1.29 
mmol, 3.0 eq.). Stirring was continued for 45 min before the solution was cooled to 0 °C. Aldehyde 91 
(120.1 mg, 0.43 mmol, 1.0 eq.) was introduced and the reaction was left to proceed at 0 °C for 16 h. 
The reaction was quenched with sat. aq. NH4Cl (10 mL) and the layers were separated. The aqueous 
layer was extracted with Et2O (2 x 15 mL) and the combined organic extracts were dried over MgSO4. 
The solvent was carefully removed under reduced pressure and the obtained crude material was 
used directly for the next step. 
TBS-Cl (56.2 mg, 0.43 mmol, 1.0 eq.), 1-methylimidazol (0.062 mL, 0.77 mmol, 1.8 eq.) and iodine 
(131.9 mg, 0.54 mmol, 1.2 eq.) were added successively to a solution of crude alcohol in CH2Cl2  
(2.5 mL). The solution was stirred until complete conversion of starting material as indicated by TLC. 
The reaction was quenched with sat. aq. Na2S2O3 (10 mL) and the organic phase was separated. The 
aqueous layer was extracted with CH2Cl2 (2 x 10 mL) and the combined organic extracts were dried 
over MgSO4. The solvent was removed under reduced pressure and the crude material was purified 
by flash chromatography (SiO2, 1% EtOAc in hexane) to yield 108 mg (49% over two steps) of the title 
compound. 
1H NMR (400 MHz, CDCl3): δ = 4.94 (qd, J = 6.4, 4.1 Hz, 1H), 4.47 (d, J = 4.1 Hz, 1H), 3.40 (t, J = 6.9 Hz, 
2H) 2.29 (t, J = 7.5 Hz, 2H), 1.85 (p, J = 7.0 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.46 – 1.41 (m, 2H), 1.36 – 
1.31 (m, 4H), 1.28 (d, J = 6.4 Hz, 3H), 0.90 (s, 9H), 0.20 (s, 9H), 0.13 (s, 3H), 0.09 (s, 3H)  
13C NMR (101 MHz, CDCl3): δ = 173.0, 87.4, 87.3, 76.0, 72.7, 70.4, 65.6, 34.5, 34.0, 32.8, 29.6, 28.5, 
28.1, 25.7(3C), 24.9, 18.3, 14.9, -0.3(3C), -4.5, -5.1. IR (film, cm-1): 2932, 2858, 1739, 1252, 842 MS: 
m/z calcd for C24H43O3Br1Si2Na 537.18335, found 537.18265 >D@20 = -17.4 (c = 0.5, CHCl3). 
 
Methyl (S)-2-((4-methoxybenzyl)oxy)propanoate (109b). Methyl-L-lactate 109 (1.04 g, 10 mmol, 1.0 
eq.) and freshly prepared PMB-trichloracetimidat (2.96 g, 10.5 mmol, 1.05 eq.) were 
dissolved in Et2O (50 mL) and the solution was cooled to -78 °C. Triflic acid (0.017 mL, 0.2 
mmol, 2 mol%) was added dropwise and the mixture was stirred for 20 min at -78 °C. The cooling 
bath was removed and the solution was allowed to warm to ambient temperature overnight. The 
reaction was quenched with sat. aq. NaHCO3 (30 mL) and the organic layer was separated. The 
aqueous layer was extracted with Et2O (3 x 30 mL) and the combined organic extracts were dried 
over MgSO4. The solvent was removed under reduced pressure and the crude material was purified 
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by flash chromatography (SiO2, 10% Et2O in pentane) to afford 2.01 g (88%) of title compound as a 
colorless oil.  
1H NMR (400 MHz, CDCl3): δ = 7.31 – 7.26 (m, 2 H), 6.90 – 6.85 (m, 2H), 4.61 (d, J = 11.3 Hz, 1H), 4.39 
(d, J = 11.3 Hz, 1H), 4.05 (q, J = 6.8 Hz, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 1.41 (d, J = 6.9 Hz, 3H)  13C NMR 
(101 MHz, CDCl3): δ = 173.9, 159.5, 129.7(2C), 129.7, 113.9(2C), 73.7, 71.8, 55.4, 52.0, 18.8  IR (film, 
cm-1): 1747, 1512, 1245, 1205, 1140, 1109, 1064, 1030, 819 MS: m/z calcd for C12H16O4Na 247.09432, 
found 247.09408 >D@20 = -85.1 (c = 1.0, CHCl3). 
 
(S)-2-((4-Methoxybenzyl)oxy)propanal (110). Methylester 109b (1.15 g, 5.12 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (25 mL) and cooled to -78 °C. To this solution was added DIBAL-H (1.0 
M in CH2Cl2, 5.64 mL, 5.64 mmol, 1.1 eq.) slowly over the course of 1 h and the reaction 
was left to proceed at -78 °C for 20 min. For work-up the reaction was quenched by slow addition of 
cold MeOH (3 mL), followed by addition of sat. aq. Na/K-tatrate (25 mL). The mixture was allowed to 
warm to room temperature and stirred for 1 h until clear phase separation was observed. The 
organic layer was separated and the aqueous phase was extracted with CH2Cl2 (2 x 20 mL). The 
combined organic extracts were dried over MgSO4 and the solvent was evaporated. The crude 
material was purfied by flash chromatography (SiO2, 15% Et2O in pentane) to yield 0.88 g (89%) of the 
aldehyde as a colorless liquid.  
1H NMR (400 MHz, CDCl3): δ = 9.63 (d, J = 1.8 Hz, 1H),  7.30 – 7.27 (m, 2H), 6.91 – 6.87 (m, 2H), 4.56 
(d, J = 3.7 Hz, 2H), 3.91 – 3.83 (m, 1H), 3.81 (s, 3H), 1.31 (d, J = 6.9 Hz, 3H) 13C NMR (101 MHz, CDCl3): 
δ = 203.8, 159.6, 129.8(2C), 129.5, 114.1(2C), 79.3, 71.9, 55.4, 15.5 IR (film, cm-1): 2837, 1732, 1612, 
1513, 1302, 1246, 1174, 1090, 1032, 820 MS: m/z calcd for C11H14O3Na 217.08357, found 217.08351 
>D@20 = -20.2 (c = 1.0, CHCl3). 
 
(3R,4S)-4-((4-Methoxybenzyl)oxy)-1-(trimethylsilyl)pent-1-yn-3-ol (111). TMS-acetylene (3.65 mL, 
25.75 mmol, 4.0 eq.) was carefully added to a solution of Et2Zn (15% in toluene, 
23.2mL, 25.75 mmol, 4.0 eq.). A reflux condenser was placed on the flask and the 
solution was heated to reflux for 1 h, during this time a large amount of grey 
precipitate was formed. After 1 h the mixture was allowed to cool down to ambient temperature, 
before (R)-BINOL (0.73 g, 2.5 mmol, 40 mol%), Ti(i-PrO)4 (1.9 mL, 6.4 mmol, 1.0 eq.) and Et2O (40 mL) 
were successively added. The suspension was stirred for 1 h at ambient temperature, before 
aldehyde 110 (1.25 g, 6.4 mmol, 1.0 eq.) dissolved in Et2O (10 mL) was introduced. The reaction was 
left to proceed overnight at room temperature before quenched with aq. Na/K-tatrate (40 mL). The 
mixture was stirred for 2 h until clear phase separation was observed. The aqueous phase was 
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extracted with Et2O (3 x 20 mL) and the combined organic extracts were washed with sat. aq. NaCl 
(20 mL) and dried over MgSO4. The solvent was removed under reduced pressure and the crude 
material was purified by flash chromatography (SiO2, 15% Et2O in pentane) to give 1.35 g (72%) of the 
title compound as a white solid. 
1H NMR (400 MHz, CDCl3): δ = 7.29 – 7.26 (m, 2H), 6.91 – 6.86 (m, 2H), 4.58 (d, J = 11.5 Hz, 1H), 4.48 
(d, J = 11.6 Hz, 1H), 4.48 – 4.43 (m, 1H), 3.81 (s, 3H), 3.65 (qd, J = 6.3, 3.7 Hz, 1H), 2.34 (d, J = 5.6 Hz, 
1H), 1.27 (d, J = 6.3 Hz, 3H), 0.17 (s, 9H)   13C NMR (101 MHz, CDCl3): δ  = 159.4, 130.3, 129.4(2C), 
114.0(2C), 103.5, 91.1, 76.5, 70.8, 65.4, 55.4, 14.6, -0.0(3C). IR (film, cm-1): 3349, 1511, 1248, 1077, 
1024, 975, 837, 760, 655, MS: m/z calcd for C16H24O3SiNa 315.13879, found 315.13869  
>D@20 = +11.4 (c = 1.0, CHCl3). 
 
(3R,4S)-1-Bromo-4-((4-methoxybenzyl)oxy)pent-1-yn-3-ol (108). NBS (402.5 mg, 2.25 mmol, 1.5 eq.) 
and AgNO3 (127.1 mg, 0.75 mmol, 0.5 eq.) were added to a solution of TMS-alkyne 
111 (440 mg, 1.5 mmol, 1.0 eq.) in acetone (12 mL). The mixture was stirred in the 
dark for 16 h. For work-up the reaction was quenched with H2O (10 mL) and diluted with Et2O (15 
mL). The organic layer was separated and the aqueous layer was extracted with Et2O (3 x 10 mL). The 
combined organic extracts were washed with sat. aq. NaCl (10 mL) and dried over MgSO4. The 
solvent was carefully removed under reduced pressure and purification of the crude material by flash 
chromatography (SiO2, 15% Et2O in pentane) yielded 342 mg (76%) of the title compound as a volatile 
liquid. 
1H NMR (400 MHz, CDCl3): δ = 7.38 – 7.21 (m, 2H), 6.94 – 6.83 (m, 2H), 4.61 (d, J = 11.5 Hz, 1H), 4.46 
(d, J = 11.5 Hz, 1H), 4.42 (dd, J = 6.7, 3.6 Hz, 1H), 3.81 (s, 3H), 3.65 (qd, J = 6.3, 3.7 Hz, 1H), 2.46 (d, J = 
6.7 Hz, 1H), 1.26 (d, J = 6.3 Hz, 3H)  13C NMR (101 MHz, CDCl3): δ = 159.5, 130.0, 129.6(2C), 114.0(2C), 
78.2, 76.3, 70.9, 66.2, 55.4, 46.2, 14.9 . IR (film, cm-1):1709, 1512, 1245, 1174, 1075, 1030, 821, 751, 
MS: m/z calcd for C13H15BrO3Na 321.00987, found 321.00969 >D@20 = -1.5 (c = 0.5, CHCl3). 
 
(2S,3R)-2-((4-Methoxybenzyl)oxy)octa-4,6-diyn-3-ol (123) GP-2. A 25 mL two-neck flask equipped 
with a pressure equalizer and a magnetic stir bar, was charged with aq. BuNH2 (30% 
in water, 8 mL) and CuCl (14.9 mg, 0.15 mmol, 15 mol%). The solution was cooled to 
0 °C before liquid propyne (0.1 mL), which had been condensed into a separate flask, 
was added via a pre-cooled syringe. A few crystals of NH2OH·HCl were added until a yellow color 
persisted. The solution was allowed to warm to ambient temperature and bromo alkyne 108 (300.2 
mg, 1.0 mmol, 1.0 eq.) was added dropwise over 5 min. During the course of the reaction several 
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portions of NH2OH·HCl were added to maintain the yellow/golden color of the reaction mixture. The 
mixture was stirred for 30 min before being transferred into a separation funnel and extracted with 
of Et2O (3 x 10 mL). The combined organic extracts were washed with sat. aq. CuSO4 (10 mL) and sat. 
aq. NaCl (10 mL), before being dried over MgSO4. The solvent was removed under reduced pressure 
and the crude material was purified by flash chromatography (SiO2, 10% Æ 20% Et2O in pentane) to 
yield 172 mg (67%) of the title compound as light yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.59 (d, J = 11.5 Hz, 1H), 
4.45 (d, J = 11.6 Hz, 1H), 4.43 – 4.41 (m, 1H), 3.81 (s, 3H), 3.65 (qd, J = 6.4, 3.7 Hz, 1H), 2.41 (s, broad 
1H, OH), 1.93 (s, 3H), 1.27 (d, J = 6.9 Hz, 3H),  13C NMR (101 MHz, CDCl3): δ =130.1, 129.6(2C), 
114.0(2C), 76.5, 72.9, 71.2, 63.9, 70.9, 65.8, 55.4, 15.0, 4.5, 1.2. (1C underneath CDCl3 peak) IR (film, 
cm-1): 2932, 1612, 1513, 1302, 1248, 1175, 1083, 822: MS: m/z calcd for C16H18O3Na 281.11486, 
found 281.11481>D@20 = -11.2 (c = 1.0, CHCl3). 
 
tert-Butyl(((2S,3R)-2-((4-methoxybenzyl)oxy)octa-4,6-diyn-3-yl)oxy)dimethylsilane (112). TBS-Cl 
(56.2 mg, 0.37 mmol, 1.23 eq.), 1-methylimidazol (72.5 mg, 0.87 mmol, 2.9 eq.) and 
iodine (132.4 mg, 0.52 mmol, 1.7 eq.) were added successively to a solution of 
alcohol 123 (80.3 mg, 0.3 mmol, 1.0 eq.) in CH2Cl2 (5 mL). The mixture was stirred at ambient 
temperature until complete conversion of starting material as judged by TLC. The reaction was 
quenched with sat. aq. Na2S2O3 (5 mL) and the organic layer was separated. The aqueous layer was 
extracted with CH2Cl2 (2 x 10 mL) and the combined organic extracts were dried over MgSO4. The 
solvent was removed under reduced pressure and the crude material was purified by flash 
chromatography (SiO2, 5% Et2O in pentane) to yield 96 mg (84%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 7.31 – 7.27 (m, 2H), 6.89 – 6.85 (m, 2H), 4.61 (d, J = 11.5 Hz, 1H), 4.53 
(d, J = 11.5 Hz, 1H), 4.33 (dq, J = 5.3, 1.0 Hz, 1H), 3.80 (s, 3H), 3.56 (qd, J = 6.2, 5.2 Hz, 1H), 1.94 (d, J = 
1.0 Hz, 3H), 1.20 (d, J = 6.3 Hz, 3H), 0.90 (s, 9H), 0.15 (s, 3H), 0.10 (s, 3H)  13C NMR (101 MHz, CDCl3): δ 
= 159.2, 130.8, 129.5(2C), 113.8(2C), 78.0, 76.5, 75.2, 71.6, 70.1, 66.9, 64.2, 55.4, 25.9(3C), 18.3, 16.4, 
4.5, -4.5, -5.0. IR (film, cm-1): 2955, 2931, 2857, 1514, 1249, 1095, 1036, 838, 779 MS: m/z calcd for 
C22H32O3Si1Na1 395.20112, found 395.20129 >D@20 = -12.7 (c = 0.4 , CHCl3). 
 
(2S,3R)-3-((tert-Butyldimethylsilyl)oxy)octa-4,6-diyn-2-ol (105). DDQ (136 mg, 0.6 mmol, 1.5 eq.) 
was added at 0 °C to a solution of PMB-ether 112 (150 mg, 0.4 mmol, 1.0 eq.) in 
CH2Cl2 (4.5 ml) and aq. pH~7 (0.5 mL) buffer. The solution was stirred at this 
temperature for 3 h. The reaction was quenched with sat. aq. NH4Cl (5 mL) and the 
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organic layer was separated. The aqueous layer was extracted with Et2O (3 x 10 mL) and the 
combined organic extracts were dried over MgSO4. The solvent was removed under reduced 
pressure and the obtained crude material was purified by flash chromatography (SiO2, 20% Et2O in 
pentane) to affford 48 mg (72%) of the title compound as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 4.29 (dq, J = 4.2, 1.0 Hz, 1H), 3.79 (qd, J = 6.3, 4.2 Hz, 1H), 1.94 (d, J = 
1.0 Hz, 3H), 1.23 (d, J = 6.3 Hz, 3H), 0.91 (s, 9H), 0.17 (s, 3H), 0.13 (s, 3H)   13C NMR (101 MHz, CDCl3): 
δ = 77.0, 73.4, 71.4, 70.9, 68.2, 63.9, 25.9(3C), 18.3, 17.7, 4.4, -4.4, -5.0 IR (film, cm-1): 2930, 2857, 
2258, 1472, 1361, 1318, 1252, 1067, 1024, 936, 913, 836, 777, 671 MS: m/z calcd for C14H24O2SiNa 
275.14379, found 275.14378>D@20 = -44.6  (c = 1.0, CHCl3). 
 
Methyl-(S,Z)-11-((tert-butyldimethylsilyl)oxy)-15-(trimethylsilyl)pentadeca-9-en-12,14 diynoate 
(113). A Schlenk flask was charged with Zn dust (65.4 mg, 1.0 mmol, 2.0 eq.) and 
iodine (12.3 mg, 0.05 mmol, 10 mol%). The flask was evacuated for ca. 30 
seconds and backfilled with Ar before DMF (0.5 mL) was added. The resulting 
slurry was vigorously stirred until disappearance of the orange color (2-4 min). Methyl-8-
iodooctanoate 107 (142.2 mg, 0.5 mmol, 1.0 eq.) was introduced via syringe and the solution was 
heated to 75 °C for 4 h. After reaching ambiente temperature the remaining zinc dust was allowed to 
settle (20 min) yielding a ca 1.0 M solution of organozinc compound. 
A second Schlenk flask was charged with alkenyl iodide 90 (81.1 mg, 0.2 mmol, 0.4 eq.), Pd(PPh3)2Cl2  
(7.1 mg, 0.01 mmol, 5 mol%), anhydrous TMEDA (0,045 mL, 0.3 mmol, 1.1 eq.) and THF (0.5 mL). The 
mixture was stirred for 5 min before an aliquot of the freshly prepared organozinc solution (1.0 M in 
DMF, 0.28 mL, 0.28 mmol, 1.4 eq.) was added dropwise and the mixture was left to proceed at 
ambient temperature for 14 h. The reaction was quenched with sat. aq. NH4Cl (5 mL) and EtOAc  
(5 mL) was added. The organic layer was separated and the aqueous layer was extracted with EtOAc  
(3 x 10 mL). The combined organic extracts were dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography (SiO2, 0.5% EtOAc 
in hexane) to yield 75.5 mg (68% yield based on NMR purity) of the title compound, together with a 
trace impurity which was best removed in the next step. 
1H NMR (400 MHz, CDCl3): δ = 5.50 – 5.41 (m, 2H), 5.17 – 5.14 (m, 1H), 3.66 (s, 3H), 2.30 (t, J = 7.6 Hz, 
2H), 2.10 – 2.00 (m, 2H), 1.67 – 1.57 (m, 2H), 1.41 – 1.33 (m, 2H), 1.34 – 1.24 (m, 6H), 0.89 (s, 9H), 
0.18 (s, 9H), 0.13 (s, 3H), 0.10 (s, 3H) 13C NMR (400 MHz, CDCl3): δ = 174.5, 132.0, 129.4, 87.7, 87.4, 
78.3, 69.1, 59.5, 51.6, 34.3, 29.4, 29.3, 29.2, 29.1, 27.8, 25.9(3C), 25.1, 18.3, -0.3(3C), -4.4, -4.6  IR 
(film, cm-1): 2952, 2930, 2857, 1742, 1252, 1075 MS: m/z calcd for C25H44O3Si2Na 471.27210, found 
471.27212 >D@20 = + 43.6 (c = 1.0, CHCl3) 
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(S,Z)-11-((tert-Butyldimethylsilyl)oxy)pentadeca-9-en-12,14-diynoic acid (106). A flask open to air 
was charged with methyl ester 113 (40.1 mg, 0.089 mmol, 1.0 eq.) and THF/H2O 
(2:1, 1 mL). LiOH (6.5 mg, 0.271 mmol, 3.0 eq.) was added and the mixture was 
stirred at room temperature for 6.5 h until TLC indicated complete consumption of starting material. 
The pH was carefully adjusted to 3 – 4 by dropwise addition of aq. HCl (0.1 N). The organic layer was 
separated and the aqueous layer was extracted with Et2O (4 x 10 mL). The combined organic extracts 
were dried over MgSO4 and the solvent was removed under reduced pressure. The crude material 
was purified by flash chromatography (SiO2, 10% Æ 15% EtOAc in hexane) yielding 25.2 mg (78%) of 
the title compound. 
1H NMR (400 MHz, CDCl3): δ = 5.52 – 5.43 (m, 2H), 5.17 – 5.14 (m, 1H), 2.35 (t, J = 7.5 Hz, 2H), 2.18 (d, 
J = 1.0 Hz, 1H), 2.10 – 2.04 (m, 2H), 1.69 – 1.59 (m, 2H), 1.45 – 1.23 (m, 8H), 0.89 (s, 9H), 0.14 (s, 3H), 
0.11 (s, 3H)  13C NMR (101 MHz, CDCl3): δ = 180.6, 132.3, 129.3, 77.0, 68.4, 67.9, 59.4, 33.9, 31.8, 
29.3, 29.2, 29.2, 29.1, 27.9, 25.9(3C), 24.8, 18.4, -4.4, -4.6. IR (film, cm-1): 2928, 2856, 1709, 1253, 
1076, 838 MS: m/z calcd for C21H34O3SiNa 385.21693, found 385.21694 >D@20 = + 62.1 (c = 1.0, 
CHCl3). 
 
Metathesis precursor (88). A Schlenk flask was charged with acid 106 (10.1 mg, 0.027 mmol, 1.0 eq.), 
alcohol 105 (8.5 mg, 0.033 mmol, 1.25 eq.) and CH2Cl2 (1 mL). The resulting 
mixture was cooled to 0 °C, before EDC·HCl (16.1 mg, 0.08 mmol, 3.0 eq.) and 
DMAP (4.5 mg, 0.036 mmol, 1.3 eq.) were introduced. The mixture was 
stirred at ambient temperature for 16 h. The reaction was quenched with H2O (5 mL) and excess base 
was neutralized with aq. HCl (0.5 N, 2 mL). The layers were separated and the aqueous phase was 
extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude material was purified via flash 
chromatography (SiO2, 1% EtOAc in hexane) to yield 9.5 mg (58%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 5.55 – 5.40 (m, 2H), 5.19 – 5.12 (m, 1H), 4.93 (qd, J = 6.4, 4.2 Hz, 1H), 
4.44 (dq, J = 4.3, 1.0 Hz, 1H), 2.29 (t, J = 7.5 Hz, 2H), 2.18 (d, J = 1.0 Hz, 1H), 2.10 – 2.02 (m, 2H), 1.93 
(d, J = 1.0 Hz, 3H), 1.96 – 1.91 (m, 2H), 1.42 – 1.28 (m, 8H), 1.27 (d, J = 6.4 Hz, 3H), 0.89 (s, 18H), 0.13 
(s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.09 (s, 3H)  13C NMR (101 MHz, CDCl3): δ = 173.2, 132.5, 129.5, 77.0, 
73.3, 72.8, 70.6, 68.4, 67.9, 65.6, 63.9, 59.4, 34.6, 29.3, 29.3, 29.2, 29.2, 27.9, 25.8(3C), 25.8(3C), 
25.0, 18.3, 18.3, 14.9, 4.5, 1.1, -4.4, -4.5, -4.6, -5.1 (one carbon of diyne underneath CDCl3) IR (film, 
cm-1): 2856, 1737, 1258, 1072, 1033, 838, 780 MS: m/z calcd for C35H56O4Si2Na 619.36095, found 
619.36094 >D@20 = + 21.2 (c = 0.3, CHCl3). 
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4.4 Total synthesis of ivorenolide B 
 
1-(Trimethylsilyl)pent-1-yn-3-one (118). A mixture of bis-trimethylsilylacetylene 119 (4.50 g, 26.5 
mmol, 1.0 eq.) and propionyl chloride 117 (2.3 mL, 26.5 mmol, 1.0 eq.) were added 
dropwise at 0 °C to a suspension of AlCl3 (3.53 g, 26.5 mmol, 1.0 eq.) in CH2Cl2 (80 ml). 
The mixture was stirred at 0 °C for 1 h, allowed to warm to ambient temperature and stirred for an 
additional hour. After cooling to -78 °C, aq. HCl (1.0 N, 20 mL) was added and the mixture was 
allowed to warm to ambient temperature. The CH2Cl2 layer was separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were dried over MgSO4, and the 
solvent was removed under reduced pressure to yield 4.01 g (97%) of the title compound as a light 
yellow liquid which was directly used for the next step. 
1H NMR (400 MHz, CDCl3): δ= 2.58 (q, J = 7.4 Hz, 2H), 1.13 (t, J = 7.4 Hz, 3H), 0.24 (s, 9H) 13C NMR 
(101 MHz, CDCl3): δ= 188.6, 102.0, 97.8, 38.8, 8.1, -0.6(3C)  IR (film, cm-1): 1681, 1253, 1130, 846 MS: 
m/z calcd for C8H14OSi 154.08125, found 154.08139. 
 
(S)-1-(Trimethylsilyl)pent-1-yn-3-ol (120). Dichloro(p-cymene)ruthenium-(II)-dimer (25.1 mg, 0.041 
mmol, 1.0 eq.), (1S,2S)-(+)-N-p-tosyl-1,2-diphenylethylenediamine (30.0 mg, 0.082 
mmol, 2.0 eq.), and KOH (32.5 mg, 0.579 mmol, 14.1 eq.) were added to a flask 
containing CH2Cl2 (1 mL). The orange mixture was stirred for 10 min, after which time a purple color 
appeared. H2O (2 mL) and CH2Cl2 (2 mL) were added, the organic layer was separated and washed 
with H2O (2 mL). The organic extracts were dried with CaH2, filtered and the solvent was evaporated 
to afford the activated catalyst (50.3 mg) as a purple solid. 
The catalyst was dissolved in i-PrOH (6 mL) and upon complete dissolution of the catalyst, the 
solution turned orange. Alkynone 118 (1.0 g, 6.5 mmol, 1.0 eq.) was added as solution in i-PrOH (3 
mL) and the mixture was stirred at room temperature for 30 min. After complete consumption of 
starting material the solvent was carefully evaporated under reduced pressure. The crude material 
was purified by flash chromatography (SiO2, 3% Et2O in pentane) to yield 902 mg (89%, 97% ee) of 
the title compound as a pale yellow liquid. The enantiomeric excess (ee) was measured by chiral 
GC/MS. See attachment below. 
1H NMR (400 MHz, CDCl3): δ = 4.31 (t, J = 6.5 Hz, 1H), 1.80 – 1.63 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H), 0.17 
(s, 9H) 13C NMR (101 MHz, CDCl3): δ = 106.7, 89.6, 64.3, 30.9, 9.6, 0.03(3C)  IR (film, cm-1): 2964, 
1250, 1014, 967, 837 MS: m/z calcd for C8H16OSiNa 179.08629, found 179.08626  
>D@20 = -4.7 (c = 1.0, CHCl3). 
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(S)-1-Bromopent-1-yn-3-ol (116). NBS (710.0 mg, 3.98 mmol, 1.65 eq.) and AgNO3 (89.0 mg, 0.52 
mmol, 20 mol%) were added to a solution of pentynol 120 (376.1 mg, 2.41 mmol, 1.0 eq.) 
in acetone (6 mL). The resulting mixture was stirred at room temperature in the dark for 2 
h. After cooling to 0 °C, the reaction was quenched with cold H2O (10 mL) and diluted with Et2O (10 
mL). The organic layer was separated and the aqueous layer was extracted with Et2O (3 x 10 mL). The 
combined organic extracts were washed with sat. aq. NaCl (10 mL), dried over MgSO4 and the solvent 
was carefully removed under reduced pressure. The crude material was purified by flash 
chromatography (SiO2, 4% Æ 5% Et2O in pentane) to afford 345 mg (88%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 4.35 (t, J = 6.4 Hz, 1H), 2.17 (s, 1H, OH) 1.77 – 1.69 (m, 2H), 1.01 (t, J = 
7.4 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 81.1, 64.8, 45.2, 30.9, 9.5. IR (film, cm-1): 3332, 2969, 2936, 
2878, 2210, 1462, 1336, 1117, 1100, 1054 MS: m/z calcd for C5H7BrONa 184.95732, found 184.95732 
>D@20 = -4.3 (c = 1.0, CHCl3). 
 
(S)-Octa-4,6-diyn-3-ol (115). Prepared according to GP-2: Bromo pentynol 116 (320.3 mg, 1.9 mmol, 
1.0 eq.), aq. BuNH2 (30% in water, 4 mL), CuCl (19.0 mg, 0.19 mmol, 10 mol%), liquid 
propyne (0.1 mL). The crude material was purified by flash chromatography (SiO2, 10% 
Æ 15% Et2O in pentane) to yield 144 mg (62%) of the title compound as a colorless oil. 
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1H NMR (400 MHz, CDCl3): δ = 4.35 (t, J = 6.8 Hz, 1H), 1.94 (d, J = 1.0 Hz, 3H), 1.89 (s, 1H, OH) 1.78 – 
1.67 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 75.8, 70.1, 66.0, 64.2, 63.8, 30.9, 
9.5, 4.5. IR (film, cm-1): 3362, 2970, 2936, 1460, 1333, 1379, 1335, 1280, 1238, 1097, 1047 MS: m/z 
calcd for C8H10ONa 145.06245, found 145.06238 >D@20 = -5.5 (c = 1.0, CHCl3). 
 
(S)-Octa-4,6-diyn-3-yl (S,Z)-11-((tert-butyldimethylsilyl)oxy)pentadeca-9-en-12,14-diynoate (114).  
A 10 mL Schlenk flask was charged with acid 106 (17.0 mg, 0.046 mmol, 1.0 
eq.), alcohol 115 (6.5 mg, 0.053 mmol, 1.15 eq.) and CH2Cl2 (1 mL). The 
mixture was cooled to 0 °C before EDC·HCl (22.1 mg, 0.115 mmol, 2.5 eq.) 
and DMAP (6.5 mg, 0.069 mmol, 1.5 eq.) were added and the mixture was stirred at ambient 
temperature for 16 h. The reaction was quenched with H2O (2 mL) and excess base was neutralized 
with aq. HCl (0.5 N). The layers were separated and the aqueous phase was extracted with EtOAc  
(3 x 5 mL). The combined organic extracts were dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude material was purified via flash chromatography (SiO2, 1% EtOAc 
in hexane) to yield 13.2 mg (62%) of the title compound.  
1H NMR (400 MHz, CDCl3): δ = 5.52 – 5.43 (m, 2H), 5.34 (td, J = 6.4, 1.0 Hz, 1H), 5.17 – 5.14 (m, 1H), 
2.35 – 2.29 (m, 2H), 2.18 (d, J = 1.0 Hz, 1H), 2.08 – 2.04 (m, 2H), 1.93 (d, J = 1.0 Hz, 3H), 1.78 (qd, J = 
7.4, 6.4 Hz, 2H), 1.65 – 1.58 (m, 2H), 1.41 – 1.35 (m, 2H), 1.30 – 1.24 (m, 6H), 1.00 (t, J = 7.4 Hz, 3H), 
0.89 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H) 13C NMR (101 MHz, CDCl3): δ = 172.8, 132.3, 129.3, 77.0, 72.4, 
70.4, 68.4, 67.9, 65.2, 63.8, 59.4, 34.4, 29.9, 29.3, 29.2, 29.2, 29.1, 28.2, 27.9, 25.9(3C), 25.0, 18.4, 
9.5, 4.4, 1.2, -4.4, -4.6 IR (film, cm-1): 2929, 2856, 1739, 1252, 1073, 837, 805 MS: m/z calcd for 
C29H42O3SiNa 489.27961, found 489.27954 >D@20 = + 18.3 (c = 1.0, CHCl3). 
 
(12S,17S,Z)-12-((tert-Butyldimethylsilyl)oxy)-17-ethyloxacycloheptadeca-10-en-13,15-diyn-2-one 
(121). Cyclization was done according to GP-1: Substrate 114 (20 mg, 0.042 
mmol, 1.0 eq.), 4 Å /5 Å MS (100 mg , each), C5 2*(8.7 mg, 0,008 mmol, 20 
mol%), toluene (4.4 mL), 22 h, rt. The crude material was purified by flash 
chromatography (SiO2, 0.3% Æ 2% EtOAc in hexane). The title compound was obtained contaminated 
with traces of triphenylsilanol 17.8 mg (comprising 14.2 mg of product, 82% calculated by NMR) 
which were best removed after the next step. 
1H NMR (400 MHz, CDCl3): δ = 5.52 – 5.42 (m, 2H), 5.28 (td, J = 6.7, 1.0 Hz, 1H), 5.21 (d, J = 4.7 Hz, 
1H), 2.39 – 2.27 (m, 2H), 2.10 – 2.01 (m, 2H), 1.83 – 1.75 (p, 2H), 1.72 – 1.60 (m, 2H), 1.44 – 1.29 (m, 
8H), 1.00 (t, J = 7.4 Hz, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H) 13C NMR (101 MHz, CDCl3): δ = 
 
 
93 
 
173.5, 132.1, 130.8, 80.9, 77.7, 69.8, 68.3, 65.3, 59.9, 34.6, 30.4, 29.7, 29.3, 28.7, 27.3, 26.5, 25.9(3C), 
18.4, 9.6, 1.2, -4.5, -4.8 .IR (film, cm-1): 2929, 2856, 1741, 1257, 1077, 909, 836 MS: m/z calcd for 
C24H38O3Si 402.25897, found 402.25902 >D@20 = - 21.4 (c = 1.0, CHCl3). 
 
(1R,2R,7S,17R)-2-((tert-Butyldimethylsilyl)oxy)-7-ethyl-8,18-dioxabicyclo[15.1.0]octadeca-3,5-diyn-
9-one (121b). Alkene 121 (15.1 mg, 0.04 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(1 mL), cooled to 0 °C and m-CPBA (26.0 mg, 0.12 mmol, 4.0 eq.) was added in 
one portion. The cooling bath was removed and the mixture was stirred at 
ambient temperature for 8 h. The reaction was quenched with sat. aq. NaHCO3 (3 mL) and stirred for 
15 min. The organic layer was separated and the aqueous phase was extracted with EtOAc (3 x 5 mL). 
The combined organic extracts were dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude material was purified by flash chromatography (SiO2, 3% Æ 5% EtOAc in hexane) 
to afford 13.1 mg (80%) of the title compound as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 5.28 (td, J = 6.7, 0.9 Hz, 1H), 4.23 (dd, J = 7.2, 0.9 Hz, 1H), 3.15 (dd, J = 
7.3, 4.3 Hz, 1H), 2.96 (ddd, J = 11.0, 4.3, 2.9 Hz, 1H), 2.47 – 2.43 (m, 1H), 2.41 – 2.37 (m, 1H), 2.04 – 
1.96 (m, 2H), 1.82 (q, J = 7.3 Hz, 2H), 1.75 – 1.61 (m, 2H), 1.46 – 1.22 (m, 8H), 1.02 (t, J = 7.4 Hz, 3H), 
0.91 (s, 9H), 0.13 (d, J = 2.2 Hz, 6H)  13C NMR (101 MHz, CDCl3): δ = 173.2, 77.9, 69.8, 69.1, 65.1, 63.9, 
61.5, 56.5, 34.5, 30.3, 30.0, 29.1, 28.0, 27.2, 26.4, 25.9(3C), 25.8, 18.4, 9.6, 1.2, -4.7, -4.8   
IR (film, cm-1): 2932, 1731, 1279, 1170 MS: m/z calcd for C24H38O4SiNa 441.24348, found 441.24316 
>D@20 = -14.3 (c = 1.0, CHCl3). 
 
Ivorenolide B (33). TBAF (1.0 M in THF, 0.043 mL, 0.043 mmol, 1.5 eq.) was added dropwise at 0 °C to 
a solution of TBS-ether 121b (12.1 mg, 0.029 mmol, 1.0 eq.) in THF (1.0 mL). 
After stirring for 30 min, the yellow solution was quenched with sat. aq. NH4Cl 
(2 mL). The phases were separated and the aqueous phase was extracted with 
EtOAc (3 x 5 mL). The combined organic extracts were dried over MgSO4 and the solvent was 
removed under reduced pressure. The crude material was purified by flash chromatography (SiO2, 
10% Æ 15% EtOAc in hexane) yielding 6.5 mg (74%) of the title compound as a colorless oil. 
1H NMR (600 MHz, C5D5N): δ = 8.42 (s, 1H, OH) 5.49 (td, J = 6.7, 0.9 Hz, 1H), 4.86 (d, J = 7.6, Hz, 1H), 
3.59 (dd, J = 7.6, 4.3 Hz, 1H), 3.08 (ddd, J = 10.8, 4.3, 2.9 Hz, 1H), 2.48 – 2.37 (m, 2H), 2.00 – 1.94 (m, 
1H), 1.81 – 1.76 (m, 2H), 1.71 – 1.64 (m, 1H), 1.63 – 1.56 (m, 1H), 1.55 – 1.51 (m, 1H), 1.48 – 1.41 (m, 
1H) 1.36 – 1.17 (m, 7H) 0.92 (t, J = 7.4 Hz, 3H)  
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13C NMR (600 MHz, C6D5N): δ = 173.0, 80.4, 78.8, 69.8, 69.8, 65.6, 62.7, 61.9, 56.7, 34.7, 30.6, 30.4, 
29.5, 28.5, 27.5, 26.8, 26.2, 9.7 IR (film, cm-1): 2928, 2857, 1741, 1462, 1236, 1085, 1041, 981 MS: 
m/z calcd for C18H24O4Na 327.15688, found 327.15668  >D@20 = - 9.3 (c = 0.2, MeOH). 
4.5 Total synthesis of ivorenolide A 
(2S,3R)-2-((4-Methoxybenzyl)oxy)octa-4,6-diyn-3-ol (123). A 25 mL Schlenk flask was charged with 
(R,R)-ProPhenol (83.2 mg, 0.13 mmol, 10 mol%), Ph3P=O (72.5 mg, 0.26 mmol, 
20mol%) and toluene (5 mL). The solution was stirred for 10 min at room 
temperature, before ZnMe2 (1.2 M in toluene, 3.2 mL, 3.86 mmol, 3.0 eq.) was 
introduced followed by dropwise addition of diyne 122 (0.25 g, 3.86 mmol, 3.0 eq.). Stirring was 
continued for 45 min at ambient temperature before the solution was cooled to 0 °C and aldehyde 
110 (0.25 g, 1.28 mmol, 1.0 eq.) was added. The reaction was left to proceed for 16 h at 0 °C. The 
reaction was quenched with sat. aq. NH4Cl (15 mL) and the layers were separated. The aqueous layer 
was extracted with Et2O (2 x 15 mL) and the combined organic extracts were dried over MgSO4. The 
solvent was carefully removed under reduced pressure and the obtained crude material was purified 
by flash chromatography (SiO2, 20% Et2O in pentane) yielding 205 mg (61%) of the title compound. 
 
1H NMR (400 MHz, CDCl3): δ = 7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.59 (d, J = 11.5 Hz, 1H), 
4.45 (d, J = 11.6 Hz, 1H), 4.43 – 4.41 (m, 1H), 3.81 (s, 3H), 3.65 (qd, J = 6.4, 3.7 Hz, 1H), 2.41 (s, broad 
1H, OH), 1.93 (s, 3H), 1.27 (d, J = 6.9 Hz, 3H),  13C NMR (101 MHz, CDCl3): δ =130.1, 129.6(2C), 
114.0(2C), 76.5, 72.9, 71.2, 63.9, 70.9, 65.8, 55.4, 15.0, 4.5, 1.2 (1C underneath CDCl3 peak) IR (film, 
cm-1): 2932, 1612, 1513, 1302, 1248, 1175, 1083, 822: MS: m/z calcd for C16H18O3Na1 281.114860 
found 281.114814>D@ 20 = -11.2 (c = 1.0, CHCl3). 
 
1-Methoxy-4-((((2S,3R)-3-(methoxymethoxy)octa-4,6-diyn-2-yl)oxy)methyl)benzene (123b). 
MOM-Cl (0.061 mL, 0.81 mmol, 1.76 eq.) and i-Pr2NEt (0.174 mL, 1.0 mmol, 2.2 
eq.) were added at 0 °C to a solution of alcohol 123 (120.0 mg, 0.46 mmol, 1.0 eq.) 
in CH2Cl2 (5 mL). The cooling bath was removed and the mixture was stirred for 16 h at room 
temperature. The reaction was quenched with H2O (10 mL), and the organic layer was separated. The 
aqueous layer was extracted with CH2Cl2 (3 x 10 mL) and the combined organic extracts were dried 
over MgSO4. The solvent was carefully removed under reduced pressure and the obtained crude 
material was purified by flash chromatography (SiO2, 10% Et2O in pentane) to afford 118 mg (85%) of 
the title compound. 
1H NMR (400 MHz, CDCl3): δ= 7.30 – 7.26 (m, 2H), 6.89 – 6.85 (m, 2H), 4.91 (d, J = 6.7 Hz, 1H), 4.65 – 
4.52 (m, 3H), 4.45 (dd, J = 4.2, 1.1 Hz, 1H), 3.80 (s, 3H), 3.67 (qd, J = 6.4, 4.2 Hz, 1H), 3.38 (s, 3H), 1.94 
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(d, J = 1.0 Hz, 3H), 1.27 (d, J = 6.4 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 159.3, 130.5, 129.5(2C), 
113.9(2C), 94.6, 76.0, 76.3, 72.0, 71.6, 71.3, 68.8, 64.0, 55.9, 55.4, 16.0, 4.5. IR (film, cm-1): 2932, 
1513, 1247, 1148, 1097, 1023, 808 MS: m/z calcd for C18H22O4Na 325.14096, found 325.14103  
>D@20 = -43.0 (c = 0.5, CHCl3). 
 
(2S,3R)-3-(Methoxymethoxy)octa-4,6-diyn-2-ol (124). DDQ (163 mg, 0.72 mmol, 2.0 eq.) was added 
at 0 °C to a solution of alcohol 123b (110 mg, 0.36 mmol, 1.0 eq.) dissolved in CH2Cl2 
(4.5 ml) and aq. pH~7 buffer (0.5 mL). The solution was stirred at 0 °C for 3 h, before 
quenched with sat. aq. NH4Cl (5 mL). The organic layer was separated and the 
aqueous layer was extracted with Et2O (3 x 10 mL). The combined organic extracts were dried over 
MgSO4. The solvent was removed under reduced pressure and the obtained crude material was 
purified by flash chromatography (SiO2, 20% Et2O in pentane) to yield 48 mg (72%) of the title 
compound as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ= 4.92 (d, J = 6.8 Hz, 1H), 4.66 (dd, J = 6.8, 0.5 Hz, 1H), 4.38 – 4.30 (m, 
1H), 4.00 – 3.91 (m, 1H), 3.39 (s, 3H), 2.32 (d, J = 5.6 Hz, 1H), 1.94 (d, J = 1.0 Hz, 3H), 1.28 (d, J = 6.4 
Hz, 3H)  13C NMR (101 MHz, CDCl3): δ = 94.6, 77.2, 72.6, 71.5, 70.5, 69.5, 63.7, 56.0, 18.3, 4.4. IR (film, 
cm-1): 3441, 2892, 2258, 1098, 1026 MS: m/z calcd for C10H14O3Na 205.08373, found 205.08351  
>D@20 = -59.1 (c = 0.5, CHCl3). 
(S,Z)-1-Iodoocta-1-en-4,6-diyn-3-ol (125). Procedure 1: A 25 mL Schlenk flask was charged with 
Ph3P=O (42.0 mg, 0.15 mmol, 20 mol%), (R,R)-ProPhenol (48.1 mg g, 0.076 mmol, 10 
mol%) and toluene (3 mL). The solution was stirred for 5 min, before diyne 122 (0.16 g, 
2.5 mmol, 3.3 eq.) and ZnMe2 (1.2 M in toluene, 1.62 mL, 1.95 mmol, 2.5 eq.) were added The 
solution was stirred for 1 h at room temperature before it was cooled to 0 °C and aldehyde 93 (1.4 
mL of previously prepared solution, 140 mg, 0.76 mmol, 1.0 eq.) was introduced. The mixture was 
stirred for 16 h at 0 °C before quenched with sat. aq. NH4Cl (5 mL). The suspension was stirred for 1 h 
at ambient temperature until clear phase separation was observed. The organic layer was separated 
and the aqueous phase was extracted with Et2O (3 x 10 mL) and the combined organic extracts were 
dried over MgSO4. The solvent was carefully removed under reduced pressure and the crude material 
was purified by flash chromatography (SiO2, 15% Et2O in pentane) to give 0.18 g (86%, 70% ee) of the 
title compound. 
 
Procedure2: A 25 mL Schlenk flask was charged with diyne 122 (0.166g, 2.6 mmol, 4.0 eq.) dissolved 
in Et2O (6 mL). (R)-BINOL (0.074 g, 0.26 mmol, 40 mol%), Cy2NH (0.006 mL, 0.0325 mmol, 5 mol%), 
and ZnEt2 (15% in toluene, 1.76 mL, 1.95 mmol, 3.0 eq.) were successively added at ambient 
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temperature and the solution was stirred for 16 h at room temperature.  
Ti(i-PrO)4 (1.9 mL, 0.65 mmol, 1.0 eq.) was added and stirring was continued for 30 min. Aldehyde 93 
(1.2 mL of previously prepared solution, 120 mg, 0.65 mmol, 1.0 eq.) was added dropwise causing a 
immediate color change from yellow to dark red. The mixture was stirred for 3 h at room 
temperature, before quenched with sat. aq. NH4Cl (5 mL). The slurry was stirred for 1 h at ambient 
temperature until clear phase separation was observed. The organic layer was separated and the 
aqueous layer was extracted with Et2O (3 x 10 mL). The combined organic extracts were dried over 
MgSO4. The solvent was carefully removed under reduced pressure and the crude matieral was 
purified by flash chromatography (SiO2, 15% Et2O in pentane) yielding 0.14 g (90%, 63% ee) of the 
title compound. 
1H NMR (400 MHz, CDCl3): δ= 6.53 (dd, J = 7.7, 1.1 Hz, 1H), 6.38 (t, J = 7.7 Hz, 1H), 5.16 (ddt, J = 6.7, 
4.0, 1.1 Hz, 1H), 2.11 (d, J = 5.0 Hz, 1H), 1.94 (d, J = 1.1 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 139.1, 
84.9, 78.6, 72.4, 71.2, 65.9, 63.6, 4.5. IR (film, cm-1): 3333, 2257, 1607, 1427, 1261, 1029, 1008, 933, 
735, 594 MS: m/z calcd for C8H7IONa 268.94355, found 268.94338 >D@20 = +275.9 (c = 1.0, CHCl3). 
The absolute configuration was determined as (S) by the advanced Mosher Ester method.[143] The ee 
of 125 was determined by integration of Ha in the spectra of the derived (S)-MTPA ester. 
 
(R)-MTPA-Ester: (S)-α-Methoxy-α-trifluoromethyl phenylacetic acid chloride (10.0 mg, 0.064 mmol, 
3.2 eq.) was added to a solution of alcohol (5.0 mg, 0.02 mmol, 1.0 eq.), and pyridine (0.063 mL, 0.08 
mmol, 4.0 eq.) in CH2Cl2 (0.5 ml). The mixture was stirred for 16 h at room temperature and 
quenched with H2O (5 mL). The aqueous phase was extracted with Et2O (3 x 5 mL), the combined 
organic layers were dried over MgSO4, and the solvent was removed under reduced pressure. The 
crude product was of sufficient purity for the determination of the absolute configuration. 
1H NMR (400 MHz, CDCl3): δ= 7.55 – 7.50 (m, 2H), 7.44 – 7.39 (m, 3H), 6.76 (dd, J = 7.8, 1.0 Hz, 1H), 
6.47 (t, J = 7.9 Hz, 1H), 6.22 (dt, J = 8.2, 1.0 Hz, 1H), 3.56 (d, J = 1.2 Hz, 3H), 1.96 (d, J = 1.2 Hz, 3H). 
 
(S)-MTPA-Ester. Prepared analogously, using (R)-α-methoxy-α-trifluoromethyl phenylacetic acid 
chloride as the reagent. Reaction was conducted on the same scale as described above. 
1H NMR (400 MHz, CDCl3): δ= 7.56 – 7.47 (m, 2H), 7.40 (qd, J = 4.2, 1.9 Hz, 3H), 6.72 (dd, J = 7.7, 0.9 
Hz, 1H), 6.39 (t, J = 7.9 Hz, 1H), 6.26 (dt, J = 8.1, 1.0 Hz, 1H), 3.60 (d, J = 1.2 Hz, 3H), 1.96 (d, J = 1.1 Hz, 
3H). 
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(S,Z)-1-Iodo-3-(methoxymethoxy)octa-1-en-4,6-diyne (126). i-Pr2NEt (0.87 mL, 5.0 mmol, 6.8 eq.) 
and MOM-Cl (0.26 mL, 3.5 mmol, 4.8 eq.) were added at 0 °C to a solution of alcohol 
125 (180 mg, 0.73 mmol, 1.0 eq.) in CH2Cl2 (5 mL). The cooling bath was removed and 
the mixture was stirred for 16 h at room temperature until complete consumption of 
starting material. The reaction was quenched with H2O (5 mL) and the organic layer was separated. 
The aqueous layer was extracted with Et2O (3 x 10 mL) and the combined organic extracts were dried 
over MgSO4. The solvent was carefully removed under reduced pressure. Purification of the crude 
material by flash chromatography (SiO2, 5% Et2O in pentane) yielded 181 mg (85%) of the title 
compound as a light yellow oil. 
1H NMR (400 MHz, CDCl3): δ= 6.53 (dd, J = 7.7, 1.1 Hz, 1H), 6.38 (t, J = 7.7 Hz, 1H), 5.16 (ddt, J = 6.7, 
4.0, 1.1 Hz, 1H), 4.87 (d, J = 6.8 Hz, 1H), 4.64 (d, J = 6.9 Hz, 1H), 3.41 (s, 3H), 1.94 (d, J = 1.1 Hz, 3H) 13C 
NMR (101 MHz, CDCl3): δ = 137.5, 93.9, 85.6, 78.0, 71.7, 70.7, 68.8, 63.7, 56.1, 4.5. IR (film, cm-1): 
2887, 2256, 1262, 1147, 1094, 1053, 1008, 964, 926, 735 MS: m/z calcd for C10H11IO2Na 312.97036, 
found 312.96960 >D@20 = +172.2 (c = 1.0, CHCl3). 
Methyl (S,Z)-11-(methoxymethoxy)hexadeca-9-en-12,14-diynoate (127). A 10 mL Schlenk flask was 
charged with Zn dust (56.1 mg, 0.86 mmol, 1.3 eq.) and anhydrous LiCl (28.0 mg, 
0.66 mmol 1.0 eq.). Vacuum (0.01 mbar) was applied and the mixture was dried 
for 5 min at 150 °C. Once the flask had reached ambient temperature and was 
flushed with Ar, THF (0.3 mL) was introduced and the slurry was heated to 60 °C before 1,2-
dibromethan (0.01 mL) was added. After stirring for 5 min, TMS-Cl (0.01 mL) was added followed by 
methyl 8-iodooctanoate 107 (187 mg, 0.66 mmol, 1.0 eq.) as a solution in THF (0.3 mL). The 
suspension was vigorously stirred for 5 h at 45 °C and at room temperature overnight. GC/MS 
revealed ~90% conversion (prolonged stirring did not further increase conversion). Stirring was 
stopped and the remaining Zn-dust was allowed to settle (~ 1 h) yielding a 1.0 M solution of 
organozinc compound. 
A second Schlenk flask was charged with Pd(PPh3)2Cl2 (3.4 mg, 0.005 mmol, 4 mol%), alkenyl iodide 
126 (40.0 mg, 0.13 mmol, 1.0 eq.), anhydrous TMEDA (0.025 mL, 0.17 mmol, 1.25 eq.) and THF (0.5 
mL). The resulting light yellow solution was stirred for 10 min at room temperature, then heated to 
50 °C before an aliquot of the freshly prepared organozinc solution (1.0 M in THF, 0.26 mL, 0.26 
mmol, 2.0 eq.) was added dropwise resulting in a color change from yellow to deep orange. The 
mixture was stirred for 1 h at 50 °C, then allowed to cool down to ambient temperature and 
quenched with sat. aq. NH4Cl (5 mL). The mixture was diluted with Et2O (10 mL) and the organic layer 
was separated. The aqueous phase was extracted with MTBE (3 x 10 mL) and the combined organic 
extracts were dried over MgSO4. The solvent was evaporated under reduced pressure and the crude 
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material was purified by flash chromatography (SiO2, 5% Æ10% EtOAc in hexane) to afford 32.8 mg 
(75%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ= 5.67 – 5.58 (m, 1H), 5.50 – 5.42 (m, 1H), 5.14 (dt, J = 8.7, 1.1 Hz, 1H), 
4.83 (d, J = 6.9 Hz, 1H), 4.60 (d, J = 6.9 Hz, 1H),  3.66 (s, 3H), 3.37 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.15 – 
2.06 (m, 2H), 1.93 (d, J = 0.9 Hz, 3H), 1.66 – 1.58 (m, 2H), 1.38 (t, J = 6.6 Hz, 2H), 1.34 – 1.25 (m, 6H) 
13C NMR (101 MHz, CDCl3): δ = 174.1, 134.5, 125.8, 93.2, 72.7, 70.3, 63.6, 61.1, 55.5, 51.3, 33.9, 29.0, 
28.9, 28.8, 27.4, 24.7, 22.2, 13.9, 4.1. IR (film, cm-1):2929, 2856, 1737, 1436, 1150, 1094, 1025, 923 
MS: m/z calcd for C19H28O4Na 343.18793, found 343.18798 >D@20 = +45.1 (c = 1.0, CHCl3). 
 
(S,Z)-11-(Methoxymethoxy)hexadeca-9-en-12,14-diynoic acid (128). A solution of LiOH (0. 5 M in 
water, 2 mL, 1.0 mmol, 9.1 eq.) was added to a solution of methyl-ester 127 
(34.0 mg, 0.11 mmol, 1.0 eq.) in THF/MeOH (2:1, 4 mL). The mixture was stirred 
at room temperature for 4 h until complete consumption of starting ester as 
indicated by TLC. The solution was carefully acidified with aq. HCl (3.0 N) and diluted with Et2O (10 
mL). The organic layer was separated and the aqueous layer was extracted with Et2O (3 x 5 mL). The 
combined organic extracts were dried over MgSO4 and the solvent was removed under reduced 
pressure affording 30 mg (89%) of the title compound as a pale yellow oil which was directly used for 
the next step. 
1H NMR (400 MHz, CDCl3): δ= 5.63 (dtd, J = 10.7, 7.5, 1.1 Hz, 1H), 5.47 (ddt, J = 10.4, 8.6, 1.5 Hz, 1H), 
5.14 (dt, J = 8.6, 1.1 Hz, 1H), 4.83 (d, J = 6.9 Hz, 1H), 4.61 (d, J = 6.9 Hz, 1H), 3.38 (s, 3H), 2.35 (t, J = 7.5 
Hz, 2H), 2.14 – 2.06 (m, 2H), 1.93 (d, J = 1.0 Hz, 3H), 1.68 – 1.59 (m, 2H), 1.42 – 1.27 (m, 7H)  13C NMR 
(101 MHz, CDCl3): δ = 179.0, 134.7, 126.0, 93.4, 77.2, 72.8, 70.5, 63.8, 61.3, 55.6, 33.8, 29.1, 28.9, 
28.9(2C), 27.5, 24.6, 4.3 IR (film, cm-1):2928, 2855, 1707, 1150, 1093, 1025, 922 MS: m/z calcd for 
C18H25O4 305.17603 found 305.17584 >D@20 = +33.6 (c = 1.0, CHCl3). 
 
(2S,3R)-3-(Methoxymethoxy)octa-4,6-diyn-2-yl (S,Z)-11-(methoxymethoxy)hexadeca-9-en-12,14-
diynoate (129). Et3N (0.02 mL, 0.14 mmol, 1.5 eq.) and Yamaguchi-
reagent (29.4 mg, 0.12 mmol, 1.25 eq.) were added at 0 °C to a solution of 
acid 128 (29.0 mg, 0.095 mmol, 1.0 eq.) in toluene (1 mL). The mixture 
was stirred at this temperature until TLC indicated complete conversion of starting material. A 
solution of alcohol 124 (17.1 mg, 0.094 mmol, 1.0 eq.) in toluene (1 mL) and DMAP (5.7 mg 0.047 
mmol, 0.5 eq.) were added and the mixture was stirred at ambient temperature for 2 h. The reaction 
was quenched at 0 °C with aq. HCl (1.0 N, 5 mL) and diluted with EtOAc (10 mL). The aqueous phase 
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was extracted with EtOAc (2 x 10 mL) and the combined organic extracts were washed with sat. aq. 
NaCl (10 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
material was purified by flash chromatography (SiO2, 10% Æ 20% Et2O in hexane) yielding 34 mg (79 
%) of the title compound.  
 
1H NMR (400 MHz, CDCl3): δ= 5.63 (dtd, J = 10.7, 7.5, 1.1 Hz, 1H), 5.46 (ddt, J = 10.3, 8.7, 1.5 Hz, 1H), 
5.14 (dt, J = 8.7, 1.1 Hz, 1H), 5.07 (qd, J = 6.5, 4.0 Hz, 1H), 4.89 (d, J = 6.8 Hz, 1H), 4.83 (d, J = 6.9 Hz, 
1H), 4.60 (d, J = 6.9, 0.6 Hz, 2H), 4.44 (dd, J = 4.0, 1.1 Hz, 1H), 3.37 (d, J = 2.0 Hz, 6H), 2.32 (t, J = 7.5 
Hz, 2H), 2.14 – 2.06 (m, 2H), 1.94 (d, J = 1.0 Hz, 3H), 1.93 (d, J = 0.9 Hz, 3H), 1.65 – 1.58 (m, 2H), 1.37 
(t, J = 6.4 Hz, 2H), 1.35 – 1.26 (m, 9H) 13C NMR (101 MHz, CDCl3): δ = 173.1, 134.9, 126.1, 94.4, 93.5, 
77.3, 77.2, 72.9, 71.9, 70.6, 70.5, 68.1, 63,9 63.7, 61.3, 55.8, 55.8, 34.5, 29.4, 29.2, 29.1, 29.1, 27.7, 
25.0, 15.4, 4.4, 4.4, 1.2. IR (film, cm-1):2928, 2855, 1707, 1150, 1093, 1025, 922 MS: m/z calcd for 
C28H38O6Na 493.25662, found 493.25606 >D@20 = -6.5 (c = 0.5, CHCl3). 
 
(12S,17R,18S,Z)-12,17-Bis(methoxymethoxy)-18-methyloxacyclooctadeca-10-en-13,15-diyn-2-one 
(130). Cyclization was done according to GP-1: Substrate 129 (10 mg, 0.021 mmol, 
1.0 eq.), 5 Å MS (45 mg), C5 (7.6 mg, 0,007 mmol, 35 mol%), toluene (2.7 mL), 3 h, 
60 °C. The crude material was purified by flash chromatography (SiO2 10% EtOAC 
in hexane) yielding 3.1 mg (39%) of the title compound. Reaction performed at 110 °C on the same 
scale delivered 2.7 mg (33%) of desired product. 
 
Procedure 2: A solution of ligand L1 (9.7 mg, 0.011 mmol) and catalyst C7 (6.5 mg, 0.01 mmol) in 
toluene (1 mL) was vigorously stirred for 10 min, to give a clear brown stock solution of the active 
catalyst (0.01 mmol/mL) which has to be used within ca 30 - 40 min before it turns dark.  
A 25 mL Schlenk flask was charged with 5 Å MS (65 mg). The flask was evacuated and the molecular 
sieves were dried for 5 min (350°C, heat gun). The flask was backfilled with Ar and substrate 129 
(15.0 mg, 0.031 mmol, 1.0 eq.) was introduced as a solution in toluene (3.4 mL). After stirring for 1 h 
at room temperature, the flask was immersed into an oil bath at 60 °C and an aliquot of the catalyst 
stock solution (0.01 mmol/mL in toluene, 0.62 mL, 0.0062 mmol, 20 mol%) was added. The mixture 
was stirred at 60 °C for 45 min before it was allowed to cool down to room temperature and filtrated 
through a pad of SiO2, which was rinsed with EtOAc (30 mL). The solvent was evaporated and the 
crude material was directly loaded on column. Purification by flash chromatography (SiO2, 10% 
EtOAC in hexane) yielded 9.7 mg (78%) of the title compound. Reaction performed at 110 °C on a 
0.0149 mmol scale delivered 9.1 mg (75%) of the title compound. 
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1H NMR (400 MHz, CDCl3): δ= 5.59 (tdd, J = 10.1, 5.8, 1.1 Hz, 1H), 5.53 – 5.44 (m, 1H), 5.19 (d, J = 8.0 
Hz, 1H), 5.07 – 5.00 (m, 1H), 4.90 (d, J = 6.9 Hz, 1H), 4.80 (d, J = 6.8 Hz, 1H), 4.61 (dd, J = 6.9, 5.6 Hz, 
2H), 4.28 (dd, J = 7.2, 0.9 Hz, 1H), 3.38 (s, 3H), 3.37 (s, 3H), 2.39 – 2.23 (m, 2H), 2.20 – 2.08 (m, 2H), 
1.75 – 1.42 (m, 4H), 1.41 – 1.28 (m, 9H) 13C NMR (101 MHz, CDCl3): δ = 173.0, 134.6, 126.5, 94.5, 
93.7, 75.8(2C), 70.7, 70.5, 69.6, 69.1, 61.7, 56.1, 55.8, 35.5, 29.7, 29.6, 28.8, 28.7, 28.1, 25.5, 17.6. IR 
(film, cm-1): 2932, 2857, 1738, 1151, 1098, 1027 MS: m/z calcd for C22H32O6Na 415.20942, found 
415.20911 >D@20 = -61.9 (0.7, CHCl3). 
 
(12S,17R,18S,Z)-12,17-Dihydroxy-18-methyloxacyclooctadeca-10-en-13,15-diyn-2-one (130b). A 
solution of bis-MOM-diol 130 (9.0 mg, 0.023 mmol, 1.0 eq.) in EtOH (1 mL) was 
treated with aq. HCl (3.0 N, 0.04 mL, 0.12 mmol, 5.0 eq.) at 70 °C for 4 h. Since 
TLC revealed incomplete conversion, additional aq. HCl (3.0 N, 0.04 mL, 0.12 
mmol, 5.0 eq.) was added and stirring continued for 6 h at 70 °C. The mixture was allowed to cool 
down to ambient temperature, before it was neutralized with sat. aq. NaHCO3 (10 mL) and diluted 
with Et2O (10 mL). The aqueous layer was extracted with MTBE (3 x 5 mL), the combined extracts 
were dried over MgSO4 and the solvent was removed under reduced pressure. The residue was 
purified by flash chromatography (SiO2, 40% Æ 50% Et2O in pentane) to give 4.4 mg (64%) of the title 
compound as a colorless oil. Small amounts of unreacted starting material were recovered and 
resubjected to MOM-cleavage under the same conditions. 
1H NMR (400 MHz, CDCl3): δ= 5.59 – 5.46 (m, 2H), 5.27 (dd, J = 6.9, 3.4 Hz, 1H), 4.92 (qd, J = 6.5, 4.6 
Hz, 1H), 4.39 – 4.29 (m, 1H), 3.17 (d, J = 8.1 Hz, 1H), 2.34 (t, J = 7.1 Hz, 2H), 2.16 – 2.10 (m, 1H), 1.75 – 
1.56 (m, 2H), 1.41 – 1.18 (m, 11H)  13C NMR (101 MHz, CDCl3): δ = 174.6, 133.6, 128.6, 79.0, 77.3, 
74.2, 70.3, 69.1, 67.0, 59.1, 35.5, 29.7, 29.6, 28.8(2C), 28.2, 25.6, 17.5 IR (film, cm-1): 3383, 2929, 
2856, 1713, 1262, 1046 MS: m/z calcd for C18H24O4Na 327.15659, found 327.15668  
>D@20 = + 61.2 (c = 0.5, CHCl3). 
 
Ivorenolide A (32). m-CPBA (8.6 mg, 0.055 mmol, 5.0 eq.) was added at 0 °C to a solution of olefin 
130b (3.4 mg, 0.011 mmol, 1.0 eq.) in of CH2Cl2 (1 mL). The mixture was stirred 
for 30 min at 0 °C, followed by stirring for 6 h at ambient temperature until TLC 
showed complete conversion of starting material. The reaction was quenched 
with sat. aq. NaHCO3 (5 mL) and the organic layer was separated. The aqueous 
layer was extracted with MTBE (3 x 10 mL) and the combined organic extracts were dried over 
MgSO4. The solvent was removed under reduced pressure and the obtained crude material was 
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purified by flash chromatography (SiO2, 30% Æ 40% Æ 50% MTBE in pentane) to afford 2.5 mg (74%) 
of the title compound as white crystals.  
1H NMR (600 MHz, C5D5N): δ = 8.27 (s, (br) 2H, OH), 5.44 (dq, J = 8.4, 6.2 Hz, 1H), 4.79 – 4.67 (m, 2H), 
3.51 (dd, J = 8.1, 4.2 Hz, 1H), 3.09 (ddd, J = 10.1, 4.3, 3.0 Hz, 1H), 2.47 – 2.37 (m, 2H), 2.01 – 1.95 (m, 
1H), 1.85 – 1.76 (m, 1H), 1.56 – 1.50 (m, 1H), 1.48 (d, J = 6.2 Hz, 3H), 1.43 (ddd, J = 11.6, 9.3, 6.2 Hz, 
2H), 1.37 – 1.20 (m, 7H)  13C NMR (151 MHz, C5D5N): δ = 172.9, 81.3, 78.5, 72.8, 70.3, 68.7, 65.5, 62.2, 
61.1, 57.0, 35.0, 30.0, 29.8, 29.1, 28.6, 26.2, 25.6, 17.7. IR (film, cm-1): 3394, 2928, 2856, 1735, 1458, 
1260, 1046, 797 MS: m/z calcd for C18H24O5Na 343.15156, found 343.15159  
>D@20 = +39.2 (0.2, MeOH). 
4.6. Preliminary studies 
7-Methylocta-3,5-diyn-2-ol (245). Prepared according to GP-2: bromo alkyne 244 (900 mg, 6.0 mmol, 
1.0 eq.), aq. BuNH2 (30% in water, 10 mL), CuCl (60 mg, 0.6 mmol, 10 mol%), 3-
methylbut-1-yne 243 (408 mg, 6.0 mmol, 1.0 eq.). Flash chromatography (SiO2, 10% 
Et2O in pentane) yielded 670 mg (81%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 4.56 (qd, J = 6.6, 0.9 Hz, 1H), 2.63 (pd, J = 6.9, 0.9 Hz, 1H), 1.90 (s, 
broad, 1H), 1.46 (d, J = 6.6 Hz, 3H), 1.18 (d, J = 6.9 Hz, 6H) 13C NMR (101 MHz, CDCl3): δ = 87.0, 77.9, 
69.1, 63.6, 58.8, 24.1, 22.4(2C), 21.1. IR (film, cm-1): 2975, 2935, 1719, 1366, 1317, 1233, 1155, 1104, 
1076, 1019 MS: m/z calcd for C9H12O 136.08886, found 136.08882. 
 
(Z)-7-Methyl-3-(tributylstannyl)oct-3-en-5-yn-2-ol (246). A 10 mL Schlenk flask was charged with 
complex C8b (3.0 mg, 0.01 mmol, 5 mol%) and freshly degassed CH2Cl2 (1 mL). Diyne 
245 (27.1 mg, 0.2 mmol, 1.0 eq.) was added in one portion and the mixture was stirred 
for 5 min before Bu3SnH (0.062 mL, 0.23 mmol, 1.15 eq.) dissolved in CH2Cl2 (1 mL) 
was added via syringe pump over the course of 1 h. After complete addition the mixture was further 
stirred for 10 min before the solvent was removed under reduced pressure and the obtained crude 
material was directly loaded on column (SiO2, 0.5% EtOAc in hexane) to yield 62.8 mg (74%) of the 
title compound. 
1H NMR (400 MHz, CDCl3): δ = 6.26 (dd, J = 2.1, 1.3 Hz, JSn-H = 111.8, 1H), 4.41 (qdd, J = 6.3, 3.5, 1.2 
Hz, 1H), 2.68 (pd, J = 6.9, 2.1 Hz, 1H), 1.58 – 1.48 (m, 6H), 1.38 – 1.27 (m, 6H), 1.22 (d, J = 6.4 Hz, 3H), 
1.19 (d, J = 6.8 Hz, 6H), 1.09 – 1.03 (m, 6H), 0.89 (t, J = 7.3 Hz, 9H) 13C NMR (101 MHz, CDCl3): δ = 
164.5, 118.1, 97.3, 79.8, 74.9, 29.3(3C), 27.6(3C), 23.9, 22.9, 21.3, 13.9 (3C), 12.4, 10.7(3C) 119Sn NMR 
(149 MHz, CDCl3): δ = -49.38 IR (film, cm-1): 2956, 2924, 2871, 2854, 1463 MS: m/z calcd for 
C21H40OSnNa 451.19948, found 451.19926. 
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(3Z,5Z)-7-Methyl-3,6-bis(tributylstannyl)octa-3,5-dien-2-ol (247). 
 
1H NMR (400 MHz, CDCl3): δ = 6.75 (dd, J = 10.6, 1.1 Hz, 1H), 6.66 (dd, J = 10.6, 1.1 Hz, 1H), 4.48 – 
4.39 (m, 1H), 2.52 (pd, J = 6.7, 1.1 Hz, 1H), 1.56 – 1.42 (m, 12H), 1.37 – 1.27 (m, 12H), 1.25 – 1.21 (m, 
3H), 1.05 – 1.00 (m, 6H), 0.89 (q, J = 7.2, 6.5 Hz, 30H) 13C NMR (101 MHz, CDCl3): δ = 160.4, 153.6, 
139.7, 136.6, 75.6, 37.6, 29.4(3C), 29.3(3C), 24.1, 23.1, 23.1, 27.5(6C), 11.4(6C), 11.2(6C) 119Sn NMR 
(149 MHz, CDCl3): δ = -50.21, -52.41 IR (film, cm-1): 2955, 2922, 2870, 2853, 1462, 1376, 1070, 878  
MS: m/z calcd for C33H67OSn2 719.32490, found 719.32400. 
(E)-3,7-Dimethyloct-3-en-5-yn-2-ol (248). Stannane 246 (42.7 mg, 0.1 mmol, 1.0 eq.) was weight into 
a Schlenk flask, vacuum (0.01 mbar) was applied for 5 min and the flask was 
backfilled with Ar. The procedure was repeated two times. A second Schlenk flask 
was charged with [Ph2PO2][NBu4] (101.2 mg, 0.22 mmol, 2.0 eq), vacuum (0.01 mbar) was applied 
and the phosphinate was carefully fused with the Bunsen burner. The phosphinate was kept for 1 h 
under vacuum, the flask was backfilled with Ar and DMF (1 mL) was introduced. The solution was 
stirred until complete dissolution of the phosphinate. An aliquot (0.22 M in DMF, 0.5 mL, 0.11 mmol, 
1.1 eq.) was added to the stannane and stirred for 5 min before [Pd(PPh3)4] (5.8 mg, 0.05 mmol, 5 
mol%) and CuTC (20.0 mg, 1.05 mmol, 1.05 eq.) were added. The mixture was stirred for 30 seconds, 
before MeI (21.3 mg, 0.15 mmol, 1.5 eq.) was added and stirring was continued for 1 h at ambient 
temperature. For work-up the solution was transferred to a separation funnel and H2O (5 mL) and 
Et2O (5 mL) were added. The layers were separated and the aqueous phase was extracted with Et2O  
(3 x 5 mL). The combined organic extracts were dried over MgSO4 and the solvent was removed 
under reduced pressure. The obtained crude material was purified by flash chromatography (SiO2, 
1% EtOAc in hexane) to afford 12.7 mg (84%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 5.53 (dt, J = 2.1, 1.2 Hz, 1H), 4.26 (qd, J = 6.5, 1.0 Hz, 1H), 2.71 (pd, J = 
6.9, 2.0 Hz, 1H), 1.86 (d, J = 1.3 Hz, 3H), 1.27 (d, J = 6.5 Hz, 3H), 1.20 (d, J = 6.9 Hz, 6H) 13C NMR (101 
MHz, CDCl3): δ = 152.4, 105.0, 100.3, 76.8, 72.0, 23.3(2C), 21.7, 21.4, 14.8. IR (film, cm-1): 2925, 1437, 
1119, 722, 694, 541 MS: m/z calcd for C10H16ONa 175.10931, found 175.10933. 
 
(3E,5Z)-3,7-Dimethyl-6-(tributylstannyl)octa-3,5-dien-2-ol (249). Complex C8b (2.2 mg, 0.007 mmol, 
10 mol%) was dissolved in freshly degassed CH2Cl2 (0.5 mL) and enyne 248 (11.0 mg, 
0.07 mmol, 1.0 eq.) was added. The mixture was stirred for 5 min followed by 
addition of Bu3SnH (0.029 mL, 0.10 mmol, 1.3 eq.) in CH2Cl2 (0.5 mL) via syringe pump over the 
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course of 1 h. After complete addition, the solution was stirred for 10 min before the solvent was 
removed under reduced pressure. The obtained residue was purified by flash chromatography (SiO2, 
2% Et2O in pentane) to yield 28 mg (89%) of the desired trans-stannane as 10 : 1 a mixture of 
regioisomers (249 : 249a).  
1H NMR (400 MHz, CDCl3): δ = 6.79 (dd, J = 10.9, 1.2 Hz, JSn-H = 116.1, 1H), 5.95 (dp, J = 11.0, 1.4 Hz, 
1H), 4.20 – 4.14 (m, 1H), 2.47 (pd, J = 6.8, 1.2 Hz, 1H), 1.73 (d, J = 1.4 Hz, 3H), 1.46 – 1.37 (m, 6H), 
1.28 – 1.23 (m, 6H), 1.21 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.8 Hz, 6H), 0.92 – 0.86 (m, 6H), 0.82 (t, J = 7.3 
Hz, 9H) 13C NMR (101 MHz, CDCl3): δ = 159.3, 139.8, 131.6, 125.7, 73.6, 38.4, 29.3(3C), 27.5(3C), 23.3, 
23.2, 21.7, 13.8(3C), 12.4, 11.2(3C). 119Sn NMR (149 MHz, CDCl3): δ = - 51.12, -54.20 IR (film, cm-1): 
2956, 2925, 2871, 1592, 1464, 1376, 1078, 670 MS: m/z calcd for C22H44OSnNa 467.23103, found 
467.23056. 
4.7. Synthesis of the western fragment 
3-((Triethylsilyl)oxy)propan-1-ol (273). TESCl (6.58 mL, 39.2 mmol, 1.0 eq.), Et3N (8.2 mL, 58.8 mmol, 
1.5 eq.) and DMAP (240 mg, 1.96 mmol, 5 mol%) were added at ambient temperature 
to a solution of 1,3-propanediol 272 (8.5 mL, 117 mmol, 3.0 eq.) in CH2Cl2 (150 mL). The mixture was 
stirred for 16 h at room temperature. For work up, EtOAc (30 mL) and H2O (30 mL) were added, and 
the organic layer was separated and washed with H2O (30 mL) and sat. aq. NaCl (30 mL). After drying 
over MgSO4, the solvent was removed under reduced pressure. The crude material was purified by 
flash chromatography (SiO2, 20% Et2O in hexane) to give 6.5 g (87%) of the title compound as a 
colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 3.89 – 3.72 (m, 4H), 2.67 (t, J = 5.2 Hz, 1H), 1.78 (p, J = 5.6 Hz, 2H), 0.96 
(t, J = 7.9 Hz, 9H), 0.65 – 0.57 (m, 6H) 13C NMR (101 MHz, CDCl3): δ = 62.7, 62.6, 34.3, 6.8, 4.4  
IR (film, cm-1): 2953, 2857, 1089, 1007, 740 MS: m/z calcd for C9H22O2SiNa 213.12818, found 
213.12813.  
 
3-((Triethylsilyl)oxy)propanal (274). Et3N (17.3 mL, 123.2 mmol, 4.0 eq.) was added at 0 °C to a 
solution of alcohol 273 (5.9 g, 30.9 mmol, 1.0 eq.) in CH2Cl2/DMSO (2:1, 112 mL). After 
stirring for 15 min at the indicated temperature, SO3·pyridine complex (15.78 g, 99.18 mmol, 3.2 eq.) 
was added as a solution in DMSO (37.5 mL) to yield a 1:1 ratio of CH2Cl2/DMSO. The mixture was 
stirred at 0 °C for 3 h and at ambient temperature for 16 h. The reaction was quenched with H2O (40 
mL) and the organic layer was separated. The aqueous phase was extracted with of Et2O (3 x 40 mL) 
and the combined organic extracts were dried over MgSO4. The solvent was removed under reduced 
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pressure and the crude material was purified by flash chromatography (SiO2, 20% Et2O in pentane) 
yielding 4.9 g (85%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 9.81 (t, J = 2.0 Hz, 1H), 3.99 (t, J = 6.1 Hz, 2H), 2.61 (td, J = 6.1, 2.0 Hz, 
2H), 0.95 (t, J =7.8 Hz, 9H), 0.64 – 0.55 (m, 6H) 13C NMR (101 MHz, CDCl3): δ = 202.1, 57.2, 46.7, 
6.8(3C), 4.4(3C). IR (film, cm-1): 2955, 2877, 1728, 1092, 1006, 729 MS: m/z calcd for C9H20O2SiNa 
211.11258, found 211.11248. 
 
(S)-1-((Triethylsilyl)oxy)octa-4,6-diyn-3-ol (274b). A 25 mL Schlenk flask was charged with Ph3P=O 
(29.5 mg, 0.1 mmol, 20 mol%), (R,R)-ProPhenol (33.8 mg g, 0.05 mmol, 10 mol%) and 
toluene (2 mL). The solution was stirred for 5 min, before diyne 122 (80% in undecane, 
0.16 g, 2.0 mmol, 4.0 eq.) and ZnMe2 (1.2 M in toluene 1.3 mL, 1.59 mmol, 3.0 eq.) 
were added. After stirring for 1 h at room temperature the mixture was cooled to 0 °C and aldehyde 
274 (100 mg, 0.053 mmol, 1.0 eq.) was added. The mixture was stirred for 16 h at 0 °C until TLC 
indicated complete conversion of starting material. For work up, the reaction was quenched with sat. 
aq. NH4Cl (5 mL) and the mixture was stirred for 1 h at ambient temperature until clear phase 
separation was observed. The organic layer was separated and the aqueous phase was extracted 
with Et2O (3 x 10 mL) and the combined organic extracts were dried over MgSO4. The solvent was 
carefully removed under reduced pressure and the crude material was purified by flash 
chromatography (SiO2, 20% Et2O in pentane) to give 112 mg (84%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 4.65 (tdd, J = 6.4, 4.1, 1.0 Hz, 1H), 4.04 (ddd, J = 10.3, 8.4, 3.7 Hz, 1H), 
3.82 (ddd, J = 10.2, 5.7, 4.3 Hz, 1H), 3.55 (d, J = 6.3 Hz, 1H), 2.07 – 1.97 (m, 1H), 1.93 (d, J = 1.0 Hz, 
3H), 1.89 – 1.80 (m, 1H), 1.01 – 0.92 (m, 9H), 0.67 – 0.55 (m, 6H) 13C NMR (101 MHz, CDCl3): δ = 77.0, 
75.5, 70.0, 63.9, 62.5, 60.8, 38.5, 6.8(3C), 5.9, 4.3(3C) IR (film, cm-1): 2955, 2913, 2877, 1080, 1014, 
743 MS: m/z calcd for C14H24O2SiNa 275.14384, found 275.14378 >D@20 = -30.8 (c = 1.0, CHCl3).  
 
(S)-9,9-Diethyl-2,2,3,3-tetramethyl-5-(penta-1,3-diyn-1-yl)-4,8-dioxa-3,9-disilaundecane (275). 
TBS-Cl (52 mg, 0.35 mmol, 1.3 eq.) and imidazole (35.4 mg, 0.53mmol, 2.0 eq.) were 
added at 0 °C to a solution of alcohol 274b (70 mg, 0.27 mmol, 1.0 eq.) in CH2Cl2 (5 
mL). The mixture was stirred for 2 h at room temperature, before it was quenched 
with H2O (5 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over MgSO4 and the solvent was 
removed under reduced pressure. The crude material was purified by flash chromatography (SiO2, 
2% Et2O in pentane) to afford 88 mg (87%) of the title compound. 
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1H NMR (400 MHz, CDCl3): δ = 4.60 (dtd, J = 7.1, 5.7, 5.1, 2.3 Hz, 1H), 3.71 (td, J = 6.4, 2.4 Hz, 2H), 
1.93 (d, J = 1.0 Hz, 3H), 1.90 – 1.80 (m, 2H), 1.01 – 0.88 (m, 18H), 0.60 (t, J = 7.9 Hz, 6H), 0.14 (s, 3H), 
0.11 (s, 3H) 13C NMR (101 MHz, CDCl3): δ =  76.6, 69.4, 67.9, 64.1, 60.2, 58.7, 41.8, 25.9(3C), 18.3, 
6.9(3C), 4.9, 4.5(3C), -4.4, -5.0. IR (film, cm-1): 2956, 2930, 2877, 1096, 1017, 837, 778, 744 MS: m/z 
calcd for C20H38 O2Si2Na 389.23038, found 389.23026 >D@20 = - 13.7 (c = 1.0, CHCl3). 
 
(S)-3-((tert-Butyldimethylsilyl)oxy)octa-4,6-diynal (276). Oxalyl chloride (0.39 mL, 4.6 mmol, 4.2 eq.) 
was added at -78 °C to a solution of DMSO (0.71 mL, 10.0 mmol, 9.2 eq.) in CH2Cl2 (10 
mL). The mixture was stirred at -78 °C for 20 min before TES-ether 275 (0.40 g, 1.1 
mmol, 1.0 eq.), dissolved in CH2Cl2 (2 mL), was slowly added and stirring was 
continued at -78 °C for 20 min. The -78 °C cooling bath was replaced by a -40 °C cooling bath and the 
solution was stirred for 1 h between -40 °C and -30 °C. The solution was cooled to -78 °C and the 
reaction was quenched with Et3N (2.27 mL, 16.4 mmol, 15.0 eq.) and allowed to warm to ambient 
temperature. The reaction was diluted with H2O (10 mL) and the organic layer was separated. The 
aqueous phase was extracted with Et2O (3 x 15 mL) and the combined organic extracts were washed 
with sat. aq. CuSO4 (2 x 10 mL), sat. aq. NaCl (15 mL), H2O (15 mL) and dried over MgSO4. The solvent 
was carefully removed under reduced pressure. The crude material was purified by flash 
chromatography (SiO2, 5% Et2O in pentane) to yield 210 mg (76%) of the title compound as a 
colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 9.80 (t, J = 2.1 Hz, 1H), 4.90 (ddd, J = 7.1, 4.7, 1.1 Hz, 1H), 2.79 (ddd, J = 
16.4, 7.0, 2.2 Hz, 1H), 2.68 (ddd, J = 16.4, 4.7, 2.0 Hz, 1H), 1.95 (d, J = 1.0 Hz, 3H), 0.87 (s, 9H), 0.17 (s, 
3H), 0.12 (s, 3H)  13C NMR (101 MHz, CDCl3): δ = 200.0, 78.0, 74.6, 70.9, 63.6, 58.7, 51.3, 25.8(3C), 
18.2, 4.5, -4.4, -5.1. IR (film, cm-1): 2955, 2930, 2857, 1728, 1254, 1093, 837, 780 MS: m/z calcd for 
C14H22O2SiNa 273.12807, found 273.12813 >D@20 = -39.2 (c = 1.0, CHCl3). 
 
S-(Pyridin-2-yl) propanethioate (297). Propionyl chloride 117 (1.17 mL, 13.5 mmol, 1.0 eq.) and Et3N 
(2.15 mL, 15.5 mmol, 1.1 eq.) were added at ambient temperature to a solution of 2-
mercaptopyridine 296 (1.5 g, 13,5 mmol, 1.0 eq. ) in THF (20 mL). The resulting thick 
slurry was stirred for 30 min and the formed precipitate was filtered off. The filtrate was collected 
and washed with sat. aq. NaHCO3 (50 mL). The solvent was removed under reduced pressure and 
2.01 g (89%) of the title compound were obtained as a yellow oil which was used directly for the next 
step. 
1H NMR (400 MHz, CDCl3): δ= 8.55 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.67 (td, J = 7.7, 1.9 Hz, 1H), 7.54 (dt, 
J = 7.8, 1.0 Hz, 1H), 7.24 – 7.19 (m, 1H), 2.66 (q, J = 7.5 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H) 13C NMR (101 
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MHz, CDCl3): δ = 197.4, 151.6, 150.5, 137.2, 130.3, 123.5, 37.7, 9.5 IR (film, cm-1): 2980, 1703, 1572, 
1562, 1449, 1420, 1082, 1011, 922, 764 MS: m/z calcd for C8H10NOS [M + H] 168.04792, found 
168.04776. 
(E)-2-((1-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)thio)pyridine (295). A 25 mL Schlenk flask was 
charged with LiHMDS (647 mg, 4.0 mmol 1.15 eq.), TBS-Cl (600 mg, 4.0 mmol, 1.15 eq), 
DMF (0.77 mL, 9.7 mmol, 3.0 eq.) and THF (10 mL). The reaction mixture was cooled to -78 
°C before pyridyl thioester 297 (538 mg, 3.2 mmol, 1.0 eq.) was added dropwise. The 
mixture was stirred for 2 h at -78 °C before it was quenched with aq. sat. NH4Cl (10 mL). The organic 
layer was separated and the aqueous layer was extracted with Et2O (2 x 20 mL). The combined 
organic extracts were dried over MgSO4 and the solvent was removed under reduced pressure. The 
crude material was purified by flash chromatography (SiO2, 10% Et2O in pentane) to yield 826 mg 
(91%) of the title compound as a colorless liquid. 
1H NMR (400 MHz, CDCl3): δ= 8.42 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.54 (ddd, J = 8.1, 7.4, 1.9 Hz, 1H), 
7.32 (dt, J = 8.1, 1.0 Hz, 1H), 7.00 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 5.45 (q, J = 6.8 Hz, 1H), 1.73 (d, J = 6.8 
Hz, 3H), 0.88 (s, 9H), 0.09 (s, 6H) 13C NMR (101 MHz, CDCl3): δ = 160.5, 149.5, 140.3, 136.6, 121.7, 
119.7, 118.1, 25.8(3C), 18.2, 12.5, -4.2(2C) IR (film, cm-1): 2930, 2858, 1635, 1574, 1450, 1418, 1308, 
1254, 1137, 1116, 1069, 862, 839 MS: m/z calcd for C14H23NOSSiNa 304.11633, found 304.11618. 
 
(3S,4S)-4-((S)-2-((tert-Butyldimethylsilyl)oxy)hepta-3,5-diyn-1-yl)-3-methyloxetan-2-one (291a). 
 A 25 mL Schlenk flask was charged with anhydrous ZnCl2 (327 mg, 2.35 mmol, 2.0 
eq.). The flask was evacuated (0.01 mbar) and the ZnCl2 was carefully fused (heat-
gun, 350°C). After reaching ambient temperature the flask was backfilled with Ar and 
the procedure was repeated before CH2Cl2 (10 mL) was introduced. The suspension was stirred for 15 
min before ketene acetal 295 (388 mg, 1.38 mmol, 1.15 eq.) was added neat via syringe. The cloudy 
grey suspension was stirred for 15 min before a solution of aldehyde 276 (300 mg, 1.2 mmol, 1.0 eq.) 
in CH2Cl2 (1.5 mL) was introduced. The mixture was stirred for 3 h at ambient temperature, which led 
to a color change from grey to dark orange. The reaction was quenched with aq. pH~7 buffer (10 mL) 
and diluted with Et2O (10 mL). The organic layer was separated and the aqueous layer was extracted 
with Et2O (3 x 15 mL). The combined organic extracts were washed with H2O (15 mL), dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude material was purified by 
flash chromatography (SiO2, 1% Æ 2% Æ 4% Æ 8% Et2O in pentane) yielding 205 mg (62%, d.r. 5.1 : 
1.0) of an inseparable mixture of trans-diastereoisomers and less than 5% of cis-isomers.  
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trans-Diastereoisomers 
1H NMR (400 MHz, CDCl3): δ= 4.61 – 4.57 (m, 1H), 4.39 (ddd, J = 7.5, 5.8, 4.0 Hz, 1H), 3.41 – 3.34 (m, 
1H), 2.25 – 2.06 (m, 2H), 1.94 (d, J = 1.0 Hz, 3H), 1.42 (d, J = 7.5 Hz, 3H), 0.90 (s, 9H), 0.16 (s, 3H), 0.12 
(s, 3H) 13C NMR (101 MHz, CDCl3): δ = 171.9, 77.8, 75.8, 74.9, 70.6, 63.6, 59.6, 51.3, 42.7, 25.9(3C), 
18.3, 12.5, 4.5, -4.4, -5.0. IR (film, cm-1): 2955, 2931, 2858, 1827, 1254, 1117, 1095, 1068, 835, 780  
MS: m/z calcd for C17H26O3SiNa 329.15448, found 329.15434 >D@20 = -45.1 (c = 1.0, CHCl3). 
 
 
 
cis-Isomers 
1H NMR (400 MHz, CDCl3): δ= 4.80 (ddd, J = 8.8, 6.5, 4.3 Hz, 1H), 4.56 (tdd, J = 6.2, 2.0, 1.0 Hz, 1H), 
3.81 (qd, J = 7.8, 6.5 Hz, 1H), 2.15 – 2.03 (m, 2H), 1.95 (d, J = 1.0 Hz, 3H), 1.30 (d, J = 7.8 Hz, 3H), 0.90 
(s, 9H), 0.15 (s, 3H), 0.12 (s, 3H)  13C NMR (101 MHz, CDCl3): δ = 172.2, 77.8, 74.7, 72.3, 71.1, 63.7, 
60.8, 47.9, 39.1, 25.9(3C), 18.3, 8.7, 4.5, -4.5, -5.0. IR (film, cm-1): 2955, 2930, 2857, 2258, 1828, 
1256, 1092, 836, 779 MS: m/z calcd for C17H26O3SiNa 329.15448, found 329.15434  
>D@20 = -45.1 (c = 1.0, CHCl3). 
 
(2S,3S,5S)-5-((tert-Butyldimethylsilyl)oxy)-3-hydroxy-N-methoxy-N,2-dimethyldeca-6,8-diynamide 
(302a). A 100 mL Schlenk flask was charged with freshly dried (two times 
azeotroped with benzene) N,O-dimethylhydroxylamin-hydrochlorid (267 mg 2.74 
mmol, 2.0 eq.) and CH2Cl2 (20 mL). The solution was cooled to 0 °C and AlMe3  
(2 M in toluene, 1.37 mL, 2.74 mmol, 2.0 eq.) was added dropwise. The mixture was stirred for 30 
min at 0 °C and then for 30 min at room temperature. The solution was cooled to 0 °C, before the 
mixture of lactones 292a/b (420 mg, 1.37 mmol, 1.0 eq.), dissolved in anhydrous CH2Cl2 (4 mL), were 
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slowly added. The cooling bath was removed and the mixture was stirred at room temperature for 3 
h before the reaction was quenched with sat. aq. Na/K-tatrate (20 mL). The mixture was further 
stirred for 1 h until clean phase separation was observed. The organic layer was separated and the 
aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic extracts were dried over 
MgSO4 and the solvent was removed under reduced pressure. Purification of the crude material 
(SiO2, 20% Æ 30% EtOAc in hexane ) yielded 395 mg (78%) of the desired isomer (302a) and 56 mg 
(11%) of the undesired isomer (302b). 
major-Isomer (302a) 
1H NMR (400 MHz, CDCl3): δ= 4.77 – 4.68 (m, 1H), 3.90 (ddd, J = 8.1, 5.6, 2.6 Hz, 1H), 3.71 (s, 3H), 
3.58 (d, J = 7.1 Hz, 1H), 3.19 (s, 3H), 2.96 – 2.83 (m, 1H), 1.93 (d, J = 1.0 Hz, 3H), 1.85 (ddd, J = 13.9, 
9.0, 2.3 Hz, 1H), 1.73 (ddd, J = 13.7, 10.2, 3.0 Hz, 1H), 1.22 (d, J = 7.0 Hz, 3H), 0.90 (s, 9H), 0.16 (s, 3H), 
0.13 (s, 3H) 13C NMR (101 MHz, CDCl3): δ = δ 177.1, 76.7, 76.6, 70.1, 69.3, 63.9, 61.6, 60.3, 43.9, 40.2, 
31.8, 25.8(3C), 18.2, 14.8, 4.3, -4.6, -5.2. IR (film, cm-1): 2956, 2929, 2857, 1641, 1462, 1389, 1252, 
1089, 996, 838, 811, 780 MS: m/z calcd for C19H33NO4SiNa 390.20767, found 390.20711  
>D@20 = -44.6 (c = 1.0, CHCl3). 
minor-Isomer (302b) 
1H NMR (400 MHz, CDCl3): δ= 4.69 (t, J = 7.5 Hz, 1H), 3.88 (dtd, J = 9.3, 6.0, 3.8 Hz, 1H), 3.71 (s, 3H), 
3.58 (d, J = 6.5 Hz, 1H), 3.20 (s, 3H), 2.98 – 2.90 (m, 1H), 1.93 (d, J = 1.0 Hz, 3H), 1.89 – 1.83 (m, 2H), 
1.21 (d, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H) 13C NMR (101 MHz, CDCl3): δ = 177.0, 
77.0, 76.0, 71.6, 70.3, 64.0, 62.3, 61.7, 44.0, 40.4, 30.4, 25.9(3C), 18.3, 14.7, 4.5, -4.4, -4.9. IR (film, 
cm-1): 2956, 2930, 2857, 1639, 1463, 1389, 1253, 1082, 994, 868, 836, 779 MS: m/z calcd for 
C19H33NO4SiNa 390.20767, found 390.20711 >D@ 20 = -51.9 (c = 1.0, CHCl3). 
 
(E)-3-Iodobut-2-en-1-ol (300). Bis-(cyclopentadienyl)titanium-(IV)-dichloride (0.57 g, 2.30 mmol,  
6 mol%) was added at 0 °C portionwise to a solution of i-BuMgBr (2 M in Et2O, 53.0 mL, 
106 mmol, 2.6 eq.) in Et2O (60 mL). The mixture was stirred at 0 °C for 10 min before a 
solution of 2-butyn-1-ol 300 (3.0 mL, 40.1 mmol 1.0 eq.) in Et2O (12 mL) was added dropwise. The 
solution was warmed to ambient temperature and stirred for 4 h until complete consumption of 
starting material was observed by TLC. The mixture was cooled to -78 °C and stirred vigorously while 
iodine (35.1 g, 138 mmol, 3.4 eq.) was added in small portions. The solution was warmed to 0 °C and 
stirred for 1 h prior to quenching with sat. aq. NH4Cl (30 mL). The mixture was diluted with Et2O (60 
mL) and water (20 mL). The organic layer was separated and the aqueous layer was extracted with 
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Et2O (3 x 30 mL). The combined organic extracts were washed with sat. aq. Na2S2O3 (50 mL) and dried 
over MgSO4. The crude material was purified by flash chromatography (SiO2, 5% Et2O in pentane) to 
yield 3.6 g (3.2 g, 45% calculated by NMR purity) of the title compound contaminated with trans-
crotyl alcohol, which was best removed in the next step.  
1H NMR (400 MHz, CDCl3): δ = 6.36 (tq, J = 6.9, 1.5 Hz, 1H), 4.05 (dq, J = 7.0, 0.9 Hz, 2H), 2.43 (dd, J = 
1.6, 0.8 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 139.8, 98.4, 59.8, 28.1 IR (film, cm-1):3300, 2917, 
1638, 1424, 1376, 1218, 1095, 1059, 99 MS: m/z calcd for C4H7OI 197.95434, found 197.95416.  
 
(E)-tert-Butyl((3-iodobut-2-en-1-yl)oxy)dimethylsilane (298b). Alcohol 301 (1.1 g, 5.5 mmol, 1.0 eq.) 
was dissolved in THF (15 mL), followed by addition of imidazole (0.74 g, 11.0 mmol, 2.0 eq.) and TBS-
Cl (0.87 g, 5.8 mmol, 1.05 eq.) at 0 °C. The mixture was stirred for 16 h at room 
temperature before the reaction was quenched with H2O (30 mL). The organic layer was 
separated and the aqueous layer was extracted with Et2O (3 x 20 mL). The combined organic extracts 
were washed with sat. aq. Na2S2O3 (20 mL) and with H2O (20 mL). The solvent was removed under 
reduced pressure and the crude material was purified by flash chromatography (SiO2, 5% Et2O in 
pentane) to yield 1.17 g (68%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 6.30 (ddt, J = 6.5, 5.0, 1.5 Hz, 1H), 4.12 (dq, J = 6.5, 0.9 Hz, 2H), 2.41 
(dd, J = 1.6, 0.8 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 6H) 13C NMR (101 MHz, CDCl3): δ = 140.8, 96.1, 60.8, 
34.3, 28.2, 26.0(3C), -5.1(2C) IR (film, cm-1): 2928, 2856, 1255, 1086, 1040, 833 MS: m/z calcd for 
C10H22IOSi [M + H] 313.04789, found 313.04847. 
 
(E)-3-Iodo-1-(methoxymethoxy)but-2-ene (298a). This compound was prepared analogously to 298b 
using alcohol 301 (300 mg, 1.5 mmol, 1.0 eq.), MOM-Cl (217 mg, 2.7 mmol, 1.8 eq.) and 
i-Pr2Net (0.57 mL, 3.3 mmol, 2.2 eq.) in CH2Cl2 (10 mL). The mixture was stirred overnight 
and standard work-up procedure was performed. The crude material was purified by flash 
chromatography (SiO2, 10% Et2O in pentane) to afford 235 mg (64%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 6.35 (tq, J = 7.0, 1.5 Hz, 1H), 4.61 (s, 2H), 4.00 (dd, J = 7.1, 0.9 Hz, 2H), 
3.37 (s, 3H), 2.45 (dt, J = 1.6, 0.8 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 137.1, 99.4, 95.5, 63.7, 55.5, 
28.2 IR (film, cm-1): 2932, 1638, 1377, 1150,1099, 1027, 981, 946, 918 MS: m/z calcd for C6H11O2INa 
264.96969 found 264.96960. 
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Preparation of the ate-complex of CeCl3·2LiCl 
A Schlenk flask was charged with anhydrous CeCl3 (1.54 g, 6.2 mmol) and anhydrous LiCl (0.53 g, 12.5 
mmol) before THF (17.5 mL) was introduced. The mixture was stirred at ambient temperature for 2 
d, before activated 4 Å MS was added. The insoluble solids were allowed to precipitate for 1 d 
yielding a ca 0.35 M clear solution of CeCl3·2LiCl which was stored under Ar. 
(9S,10S,12S,E)-10-Hydroxy-2,2,3,3,7,9,14,14,15,15-decamethyl-12-(penta-1,3-diyn-1-yl)-4,13-dioxa-
3,14-disilahexadec-6-en-8-one (301). Et2O (6 mL) was placed into a Schlenk 
flask, cooled to -78 °C and freshly titrated t-BuLi (2.25 M in pentane, 1.9 mL, 
4.3 mmol, 10.0 eq.) was added carefully. The solution was stirred for 10 min at 
-78 °C before a solution of alkenyl iodide 298b (707 mg, 2.25 mmol, 5.2 eq.) in 
Et2O (3 mL), was added dropwise over 15 min. The solution was stirred for 15 min at -78 °C, then 
transferred to a -78 °C cold solution of CeCl3·2LiCl (0.35 M in THF, 6.5 mL, 2.3 mmol, 5.3 eq.) causing 
an immediate color change to deep orange. The mixture was stirred for 45 min at -78°C before a 
solution of Weinreb amide 302a (160 mg, 0.43 mmol, 1.0 eq) in THF (2 mL) was added dropwise over 
15 min. The mixture was stirred for 45 min at -78 °C, the cooling bath was removed and the mixture 
was immediately transferred to a vigorously stirred, cold (0 °C) biphasic mixture of aq. HCl (30 mL, 
pH~ 3-4) and Et2O (30 mL). After stirring for 5 min the organic layer was separated, the aqueous layer 
was extracted with EtOAc (3 x 20 mL) and the combined organic extracts were dried over MgsO4. The 
solvent was removed under reduced pressure and the crude material was purified by flash 
chromatography (SiO2, 5% Æ 10% EtOAc in hexane) to afford 80 mg (38%) of the title compound and 
101 mg (58%) of recovered Weinreb amide 302a.   
1H NMR (400 MHz, CDCl3): δ= 6.67 (td, J = 5.1, 1.4 Hz, 1H), 4.74 – 4.70 (m, 1H), 4.45 – 4.41 (m, 2H), 
4.04 (dtd, J = 10.2, 5.9, 2.1 Hz, 1H), 3.30 (p, J = 6.8 Hz, 1H), 3.23 (d, J = 5.9 Hz, 1H), 1.93 (d, J = 1.0 Hz, 
3H), 1.83 (ddd, J = 14.0, 8.3, 2.2 Hz, 1H), 1.73 (d, J = 1.2 Hz, 3H), 1.14 (d, J = 7.2 Hz, 3H), 0.92 (s, 9H), 
0.90 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H), 0.10 (m, 6H) 13C NMR (101 MHz, CDCl3): δ = 206.4, 143.8, 135.5, 
77.0, 76.3, 70.6, 69.7, 64.0, 61.2, 60.9, 44.2, 43.1, 26.0(3C), 25.9(3C), 18.5, 18.3, 15.7, 11.7, 4.5, -4.5, -
5.1, -5.1(2C). IR (film, cm-1): 2955, 2930, 2857, 1663, 1463, 1254, 1103, 1061, 1006, 836, 778 MS: m/z 
calcd for C27H48O4Si2Na 515.29883, found 515.29834 >D@20 = -12.3 (c = 0.5, CHCl3). 
 
(R)-MTPA-Ester: (S)-α-Methoxy-α-trifluoromethyl phenylacetic acid chloride (3.5 mg, 0.014 mmol, 
2.0 eq.) was added to a solution of alcohol 301 (3.5 mg, 0.007 mmol, 1.0 eq.) and pyridine (0.002 mL, 
0.021 mmol, 3.0 eq) dissolved in CH2Cl2 (0.3 ml). The mixture was stirred for 16 h at room 
temperature and quenched with H2O (5 mL). The aqueous phase was extracted with Et2O (3 x 5 mL), 
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the combined organic layers were dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude material was purified by flash chromatography (SiO2, 5% Et2O in pentane) 
yielding 4.1 mg of desired product as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.54 – 7.47 (m, 2H), 7.43 – 7.38 (m, 3H), 6.96 – 6.91 (m, 1H), 5.46 (ddd, 
J = 9.4, 5.3, 2.1 Hz, 1H), 4.47 – 4.34 (m, 2H), 4.32 (ddd, J = 10.0, 3.1, 1.1 Hz, 1H), 3.80 – 3.73 (m, 1H), 
3.52 (d, J = 1.3 Hz, 3H), 1.93 (d, J = 1.0 Hz, 3H), 1.98 – 1.82 (m, 2H), 1.68 (d, J = 1.2 Hz, 3H), 0.92 (s, 
9H), 0.85 (s, 9H), 0.11 (s, 3H), 0.11 (s, 3H), 0.11 (s, 3H), 0.07 (s, 3H). 
 
(S)-MTPA-Ester: Compound was prepared analogously using (R)-α-methoxy-α-trifluoromethyl 
phenylacetic acid chloride as the reagent. Reaction was conducted on the same scale as described 
above. 
1H NMR (400 MHz, CDCl3): δ= 7.53 – 7.46 (m, 2H), 7.44 – 7.37 (m, 3H), 6.98 – 6.92 (m, 1H), 5.45 (ddd, 
J = 9.0, 5.4, 2.3 Hz, 1H), 4.48 – 4.34 (m, 2H), 4.21 (ddd, J = 9.7, 3.3, 1.1 Hz, 1H), 3.85 – 3.77 (m, 1H), 
3.50 (d, J = 1.1 Hz, 3H), 1.92 (d, J = 1.0 Hz, 3H), 1.90 – 1.78 (m, 2H), 1.71 (d, J = 1.2 Hz, 3H), 1.06 (d, J = 
6.9 Hz, 3H), 0.92 (s, 9H), 0.85 (s, 9H), 0.11 (s, 3H), 0.10 (s,3H), 0.10 (s, 3H), 0.07 (s, 3H). 
 
(9S,10S,12S,E)-10-Hydroxy-7,9,14,14,15,15-hexamethyl-12-(penta-1,3-diyn-1-yl)-2,4,13-trioxa-14-
silahexadec-6-en-8-one (301b). Alkenyl iodide 299a (14.5 mg, 0.06 mmol, 3.0 
eq.) was dissolved in Et2O (0.6 mL) and the solution was cooled to -78 °C. The 
solution was stirred for 5 min before freshly titrated t-BuLi (1.89 M in pentane, 
0.063 mL, 0.12 mmol, 6.0 eq.) was added dropwise and stirring was continued for 1 h at -78°C. In a 
second flask the mixture of lactones 292a/b (6 mg, 0.02 mmol, 1.0 eq.) were dissolved in Et2O (0.2 
mL) and the solution was cooled to -78 °C. The alkenyllithium solution was added dropwise in two 
batches to the solution of the lactones . After complete addition, the mixture was stirred for 45 min 
at -78 °C before the reaction was quenched with sat. aq. NH4Cl (5 mL). The mixture was allowed to 
reach room temperature and the organic phase was separated. The aqueous layer was extracted 
with Et2O (3 x 5 mL), the combined organic extracts were dried over MgSO4 and the solvent was 
removed under reduced pressure. Purification of the crude material by flash chromatography (SiO2, 
10% Æ 20 % Et2O in pentane) yielded 3.6 mg (36%) of the title compound.  
1H NMR (400 MHz, CDCl3): δ = 6.71 (td, J = 5.5, 1.4 Hz, 1H), 4.74 – 4.69 (m, 1H), 4.68 (s, 2H), 4.33 (dt, J 
= 5.4, 1.2 Hz, 2H), 4.06 (dtd, J = 10.3, 5.9, 2.1 Hz, 1H), 3.40 (s, 3H), 3.31 (p, J = 6.9 Hz, 1H), 3.20 (d, J = 
5.6 Hz, 1H), 1.93 (d, J = 0.9 Hz, 3H), 1.84 (ddd, J = 14.0, 8.1, 2.1 Hz, 1H), 1.78 (d, J = 1.2 Hz, 3H), 1.70 
(ddd, J = 13.8, 10.2, 3.3 Hz, 1H), 1.14 (d, J = 7.1 Hz, 3H), 0.90 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H)  
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13C NMR (101 MHz, CDCl3): δ = 206.2, 139.4, 137.5, 96.5, 77.1, 72.2, 70.6, 69.8, 64.9, 61.0, 55.6, 44.4, 
42.9, 25.9(3C), 18.3, 15.5, 11.9, 4.5, 1.2, -4.5, -5.1 IR (film, cm-1): 1151, 1099, 1041, 838, 811, 780 MS: 
m/z calcd for C23H38O5SiNa 445.23839, found 445.23807 >D@ 20 = -33.9 (c = 1.0 CHCl3). 
 
 (5S,7S,8R,9R,E)-9-Hydroxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-dioxa-
3,14-disilahexadec-10-en-7-yl 4-nitrobenzoate (303). A 10 mL Schlenk flask 
was charged with Sm metal (36.08 mg, 0.24 mmol) and a solution of 
diiodomethane (0,017 mL, 0.21 mmol) in THF (1.5 mL) was added. The 
resulting solution was stirred at 0 °C in the dark for 45 min yielding a dark blue 
0.1 M solution of SmI2. 
Ketone 301 (45.1 mg, 0.09 mmol, 1.0 eq.) was dissolved in THF (0.4 mL) and p-nitrobenzaldehyde 
(55.2 mg, 0.36 mmol, 4.0 eq.) was added at -10 °C. The mixture was stirred for 10 min before an 
aliquot of the freshly prepared SmI2 (0.1 M in THF, 0.95 mL, 0.095 mmol, 1.05 eq.) was added 
dropwise, resulting in the formation of a deep orange solution. The solution was stirred for 3 h at -10 
°C until complete conversion of the starting material as indicated by TLC. The reaction was quenched 
with sat. aq. NaHCO3 (5 mL), diluted with EtOAc (10 mL) and the organic layer was separated. The 
aqueous layer was extracted with Et2O (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and the solvent was removed under reduced pressure. The obtained crude material was 
purified by flash chromatography (SiO2, 8% Æ 10% Æ 15% Æ 20% Et2O in pentane) yielding 41 mg 
(70%) of the title compound as a pale yellow oil. 
1H NMR (400 MHz, CDCl3): δ= 8.32 – 8.27 (m, 2H), 8.24 – 8.19 (m, 2H), 5.64 (t, J = 6.3 Hz, 1H), 5.24 (q, 
J = 6.2 Hz, 1H), 4.44 (t, J = 6.5 Hz, 1H), 4.24 (qd, J = 13.0, 6.1 Hz, 2H), 3.93 (t, J = 4.4 Hz, 1H), 2.15 – 
2.10 (m, 3H), 2.00 (d, J = 3.5 Hz, 1H), 1.88 (d, J = 0.9 Hz, 3H), 1.67 – 1.64 (m, 3H), 0.97 (d, J = 6.9 Hz, 
3H), 0.90 (s, 9H), 0.85 (s, 9H), 0.07 (s, 12H) 13C NMR (101 MHz, CDCl3): δ = 164.7, 150.8, 150.1 136.4, 
135.7, 131.0(2C), 126.9, 123.7(2C), 77.3, 76.1, 76.1, 74.5, 70.1, 63.7, 60.2, 60.1, 39.7, 39.4, 26.1(3C), 
25.9(3C), 18.2, 13.0, 9.5, 4.4, -4.3, -5.0, -5.0, -5.2 IR (film, cm-1): 2955, 2929, 2857, 1723, 1530, 1471, 
1348, 1277, 1101, 1014, 837, 779, 720 MS: m/z calcd for C34H53NO7Si2Na 666.32538, found 
666.32528 >D@20 = -7.5 (c = 1.0 CHCl3).  
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(5S,7S,8S,9R,E)-9-Methoxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-dioxa-
3,14-disilahexadec-10-en-7-yl 4-nitrobenzoate (304). A 25 mL Schlenk 
flask was charged with Proton-sponge® (177.1 mg, 0.83 mmol, 9.0 eq.) 
and powdered 4 Å MS (80 mg). A solution of alcohol 304 (60.0 mg, 0.093 
mmol, 1.0 eq.) in CH2Cl2 (5 mL) was added and the suspension was cooled 
to 0 °C. Me3OBF4 (96.1 mg, 0.65 mmol, 7.0 eq.) was added in one portion and the mixture was stirred 
at room temperature for 3 h. For work-up, the reaction was quenched with sat. aq. NaHCO3 (5 mL). 
The organic layer was separated and the aqueous layer was extracted with EtOAc (3 x 5 mL). The 
combined organic extracts were dried over MgSO4 and the solvent was removed under reduced 
pressure. The obtained crude material was purified by column chromatography (SiO2, 5% EtOAc in 
hexane) to afford 42 mg (69%) of the title compound as a colorless oil and 4.1 mg (7%) of recovered 
303. 
1H NMR (400 MHz, CDCl3): δ= 8.31 – 8.26 (m, 2H), 8.22 – 8.17 (m, 2H), 5.55 (dd, J = 6.8, 4.8 Hz, 1H), 
5.16 (ddd, J = 10.9, 4.3, 2.0 Hz, 1H), 4.44 – 4.38 (m, 1H), 4.34 (dd, J = 13.2, 7.1 Hz, 1H), 4.19 (ddd, J = 
13.3, 4.8, 1.3 Hz, 1H), 3.24 (d, J = 7.6 Hz, 1H), 3.18 (s, 3H), 2.26 – 2.17 (m, 1H), 2.11 (ddd, J = 15.0, 
10.9, 4.4 Hz, 1H), 1.96 (ddd, J = 14.3, 8.9, 2.0 Hz, 1H), 1.86 (d, J = 0.9 Hz, 3H), 1.66 (q, J = 1.0 Hz, 3H), 
1.01 (d, J = 6.9 Hz, 3H), 0.91 (s, 9H), 0.84 (s, 9H), 0.08 (s, 6H), 0.07 (s, 3H), 0.06 (s, 3H) 13C NMR (101 
MHz, CDCl3): δ 163.8, 150.5, 135.9, 133.1, 130(2C).7, 129.7, 123.5(2C), 87.7, 76.1, 73.6, 69.8, 63.6, 
60.1, 59.8, 56.3, 38.6, 38.0, 25.9(3C), 25.7(3C), 18.3, 18.0, 11.6, 10.1, 4.2, -4.6, -5.1, -5.1, -5.2 (1C 
mising) IR (film, cm-1): 2956,2929, 2857, 1724, 1530, 1276, 1259, 1091, 1015, 835, 807, 777 MS: m/z 
calcd for C35H55NO7Si2Na 680.34088, found 680.34093 >D@20 =  -11.4 (0.75 CHCl3). 
 
(5S,7S,8S,9R,E)-9-(Methoxymethoxy)-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-
4,13-dioxa-3,14-disilahexadec-10-en-7-yl 4-nitrobenzoate (304b). A 
solution of alcohol 304 (6.2 mg, 0.009 mmol, 1.0 eq.) in CH2Cl2 (2 mL) was 
cooled to 0 °C, before i-Pr2NEt (0.031 mL, 0.18 mmol, 20.0 eq.) and MOM-
Cl (7.1 mg, 0.09 mmol, 10.0 eq.) were added. The cooling bath was 
removed and the mixture was stirred at room temperature for 18 h before the reaction was 
quenched with sat. aq. NH4Cl (5 mL) and the mixture was diluted with EtOAc (5 mL). The organic layer 
was separated and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic 
extracts were dried over MgSO4 and the solvent was removed under reduced pressure. The obtained 
crude material was purified by flash chromatography (SiO2, 4% EtOAc in hexane) to yield 6.0 mg 
(93%) of the title compound. 
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1H NMR (400 MHz, CDCl3): δ= 8.31 – 8.26 (m, 2H), 8.22 – 8.17 (m, 2H), 5.57 (td, J = 5.7, 4.9, 1.5 Hz, 
1H), 5.12 (ddd, J = 10.9, 4.2, 2.0 Hz, 1H), 4.64 (d, J = 6.7 Hz, 1H), 4.46 – 4.40 (m, 2H), 4.32 (ddd, J = 
13.3, 7.2, 0.8 Hz, 1H), 4.17 (ddd, J = 13.2, 4.7, 1.3 Hz, 1H), 3.72 (d, J = 8.8 Hz, 1H), 3.37 (s, 3H), 2.33 
(ddd, J = 8.8, 4.5, 2.4 Hz, 1H), 2.18 – 2.08 (m, 1H), 1.99 – 1.90 (m, 1H), 1.86 (d, J = 1.0 Hz, 3H), 1.71 (s, 
3H), 1.08 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.83 (s, 9H), 0.07 (s, 6H), 0.05 (s, 3H), -0.08 (s, 3H) 13C NMR 
(101 MHz, CDCl3): δ = 164.0, 150.6, 136.0, 132.8, 131.3, 130.8(2C), 123.7(2C), 93.3, 82.4, 76.1, 73.2, 
69.9, 63.7, 60.1, 59.8, 56.1, 38.2, 37.5, 26.1(3C), 25.8(3C), 18.4, 18.1, 11.6, 10.8, 4.4, -4.5, -5.0, -5.0, -
5.2 (one carbon of diyne underneath CDCl3) IR (film, cm-1): 2954, 2930, 2857, 1724, 1530, 1347, 1277, 
1098, 1033, 837, 778, 720 MS: m/z calcd for C36H57NO8Si2Na 710.35138, found 710.35150  
>D@20 = - 21.2 (0.4 CHCl3). 
 
(5S,7S,8S,9R,E)-9-Methoxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-dioxa-
3,14-disilahexadec-10-en-7-ol (305). Benzoate 304 (42.1 mg, 0.064 mmol, 1.0 
eq.) was dissolved in THF/MeOH (1:1, 1.5 mL) and K2CO3 (14.2 mg, 0.10 mmol, 
1.6 eq.) was added at 0 °C. The cooling bath was removed and the mixture 
was stirred at ambient temperature for 6 h. The solvent was removed under 
reduced pressure and the crude material was directly purified by flash chromatography (SiO2, 10% Æ 
20% Et2O in pentane) to yield 23 mg (71%) of the title compound.  
1H NMR (400 MHz, CDCl3): δ= 5.50 (tt, J = 6.2, 1.3 Hz, 1H), 4.73 (ddd, J = 7.2, 3.5, 1.1 Hz, 1H), 4.27 
(ddt, J = 6.0, 2.9, 0.9 Hz, 2H), 3.88 (tdd, J = 6.6, 4.5, 2.2 Hz, 1H), 3.61 (d, J = 4.7 Hz, 1H), 3.36 (d, J = 4.4 
Hz, 1H), 3.24 (s, 3H), 1.94 (d, J = 1.0 Hz, 3H), 1.86 – 1.69 (m, 3H), 1.56 (s, 3H), 0.90 (s, 18H), 0.89 (m, 
3H), 0.17 (s, 3H), 0.13 (s, 3H), 0.07 (s, 6H) 13C NMR (101 MHz, CDCl3): δ = 133.4, 127.8, 86.9, 77.0, 
76.2, 70.5, 69.9, 64.0, 61.7, 60.0, 56.9, 42.2, 41.0, 26.1(3C), 25.9(3C), 18.5, 18.2, 13.3, 11.0, 4.5, -4.5, -
5.0(2C), -5.2 IR (film, cm-1): 2929, 2857, 1463, 1255, 1061, 940, 835, 776, 665 MS: m/z calcd for 
C28H52O4Si2Na 531.32944, found 531.32964 >D@20 = - 5.1 (c = 0.2, CHCl3). 
 
4.8. Synthesis of the eastern fragment 
((2R,3R)-3-Methyloxiran-2-yl)methanol (267). A jacketed Schlenk flask was charged with 4 Å MS (2 g) 
and CH2Cl2 (100 mL). D-(-)-diisopropyl tartrate (702 mg, 3.0 mmol, 6 mol%) and Ti(i-PrO)4 
(568 mg, 2 mmol, 4 mol%), were added and the mixture was cooled to -20 °C. A solution of trans-
crotyl alcohol 268 (19 : 1 trans/cis, 3.6 g, 50 mmol, 1.0 eq.) in CH2Cl2 (12.5 mL) was added and the 
suspension was stirred for 30 min, followed by addition of TBHP (5.5 M in decane, 13.63 mL, 75 
mmol, 1.5 eq.). The mixture was stirred at -20 °C for 16 h, before the reaction was quenched with 
dimethylsulfide (7.3 mL, 100 mmol, 2.0 eq.). Stirring was continued for 10 h at room temperature 
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and the mixture was filtered through a short pad of Celite®. Purification via flash chromatography 
(SiO2, 20% Et2O in pentane) yielded 3.44 g (78%) of the title compound.  
1H NMR (400 MHz, CDCl3): δ = 3.90 (ddd, J = 12.6, 5.6, 2.5 Hz, 1H), 3.61 (ddd, J = 12.6, 7.2, 4.4 Hz, 1H), 
3.04 (qd, J = 5.3, 2.3 Hz, 1H), 2.89 (dt, J = 4.7, 2.4 Hz, 1H), 2.02 (ddd, J = 8.6, 6.3, 2.6 Hz, 1H), 1.33 (d, J 
= 5.2 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 61.8, 59.7, 52.1, 17.2 IR (film, cm-1): 3405, 1451, 1383, 
1102, 1037, 988, 864 MS: m/z calcd for C4H8O2Na 111.04178 found 111.04165  
>D@20 = + 42.3 (1.0 CHCl3). 
 
(2S,3R)-3-Methyl-7-(trimethylsilyl)hepta-4,6-diyne-1,2-diol (306b). A 25 mL Schlenk flask was 
charged with TMS-diyne 74 (550 mg, 4.5 mmol, 3.0 eq.) and toluene (8 mL). The 
solution was cooled to -78 °C and n-BuLi (1.6 M in hexane, 2.5 mL, 4.0 mmol, 2.6 
eq.) was added. Stirring was continued for additional 30 min and the -78 °C cooling 
bath was replaced with a 0 °C cooling bath. Et2AlCl (0.9 M in toluene, 4.4 mL, 4.0 mmol, 2.6 eq.) was 
added and the mixture was stirred for 30 min before a solution of epoxide 267 (132 mg, 1.5 mmol, 
1.0 eq.) in toluene (2 mL) was added dropwise. The reaction was left to proceed overnight at ambient 
temperature before it was quenched with aq. HCl (1.0 N, 5 mL) and the mixture was diluted with Et2O 
(10 mL). The organic layer was separated and the aqueous layer was extracted with Et2O (3 x 15 mL). 
The combined organic extracts were dried over MgSO4 and the solvent was removed under reduced 
pressure. Purification by flash chromatography (SiO2, 30% Æ 40% Et2O in pentane) yielded 210 mg 
(67%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 3.85 (ddd, J = 10.8, 6.2, 3.0 Hz, 1H), 3.70 (ddd, J = 11.1, 6.9, 4.3 Hz, 1H), 
3.61 (ddt, J = 7.0, 5.3, 3.5 Hz, 1H), 2.69 (p, J = 7.0 Hz, 1H), 2.37 (s, broad, 1H, OH), 1.89 (s, broad, 1H, 
OH), 1.27 (d, J = 7.0 Hz, 3H), 0.18 (s, 9H) 13C NMR (101 MHz, CDCl3): δ = 87.9, 85.1, 79.9, 74.6, 67.9, 
64.7, 30.3, 16.6, -0.3(3C) IR (film, cm-1): 3358, 2960, 1251, 844, 760 MS: m/z calcd for C11H18O2SiNa 
233.09672, found 233.09683 >D@20= +9.6 (c = 0.4, CHCl3). 
 
(2S,3R)-2-Hydroxy-3-methyl-7-(trimethylsilyl)hepta-4,6-diyn-1-yl4-methylbenzenesulfonate (307b). 
Bu2SnO (20 mg, 0.081 mmol, 10 mol%) was added to a stirred solution of diol 307b 
(180 mg, 0.86 mmol, 1.0 eq.) in CH2Cl2 (5 mL). The mixture was stirred for 5 min 
before Et3N (0.13 mL, 0.95 mmol, 1.1 eq.) and Tos-Cl (180 mg, 0.95 mmol, 1.1 eq.) 
were added and the reaction was left to proceed overnight at room temperature. The reaction was 
quenched with sat. aq. NH4Cl (5 mL) and the layers were separated. The organic layer was extracted 
with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried over MgSO4 and the solvent was 
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removed under reduced pressure. The crude material was purified by flash chromatography (SiO2, 
5% Æ 15% EtOAc in hexane) to afford 250 mg (80%) of the title compound as colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.84 – 7.78 (m, 2H), 7.40 – 7.34 (m, 2H), 4.29 (dd, J = 10.5, 3.0 Hz, 1H), 
4.08 (dd, J = 10.5, 6.4 Hz, 1H), 3.72 (dtd, J = 11.0, 6.0, 3.0 Hz, 1H), 2.69 – 2.57 (m, 1H), 2.46 (s, 3H),   
1.24 (d, J = 7.0 Hz, 3H), 0.19 (s, 9H)  13C NMR (101 MHz, CDCl3): δ = 145.3, 132.5, 130.1(2C), 128.2(2C), 
87.7, 85.5, 78.7, 72.4,72.0, 68.3, 30.0, 21.8, 16.5, -0.3(3C) . IR (film, cm-1): 2960, 1361, 1251, 1190, 
1176, 960, 846, 555 MS: m/z calcd for C18H24O4SSiNa 387.10565, found 387.10568  
>D@20 = +32.2 (c = 0.5, CHCl3). 
 
Trimethyl((R)-5-((S)-oxiran-2-yl)hexa-1,3-diyn-1-yl)silane (265b). DBU (0.19 mL, 1.3 mmol, 2.0 eq.) 
was added at 0 °C to a stirred solution of tosylate 307b (240 mg, 0.68 mmol, 1.0 eq.) 
in CH2Cl2 (10 mL). The mixture was stirred for 6 h at room temperature before H2O (10 
mL) was added and the layers were separated. The aqueous layer was extracted with 
Et2O (2 x 10 mL) and the combined organic extracts were washed with sat. aq. NaCl (10 mL) and dried 
over MgSO4. The solvent was removed under reduced pressure and the crude material was purified 
by flash chromatography (1% Et2O in pentane) to yield 95 mg (75%) of the title compound as a 
volatile colorless liquid.  
1H NMR (400 MHz, CDCl3): δ = 2.93 (ddd, J = 6.4, 3.8, 2.5 Hz, 1H), 2.79 (dd, J = 4.8, 3.8 Hz, 1H), 2.68 
(dd, J = 4.8, 2.5 Hz, 1H), 2.49 (p, J = 6.9 Hz, 1H), 1.33 (d, J = 7.0 Hz, 3H), 0.19 (s, 9H)  13C NMR (101 
MHz, CDCl3): δ = 87.8, 85.2, 78.3, 67.6, 54.5, 46.4, 30.0, 17.5, -0.3(3C) IR (film, cm-1): 2961, 2935, 
2227, 2108, 1251, 909, 839, 760 MS: m/z calcd for C11H16OSi 192.09720, found 192.09704  
>D@20 =  + 4.2 (c = 0.3, CHCl3). 
 
(S)-2-((R)-Hepta-3,5-diyn-2-yl)oxirane (265c). NBS (231 mg, 1.3 mmol, 1.3 eq.) and AgNO3 (25.4 mg, 
0.15 mmol, 15 mol%) were added to a stirred solution of 265 (168 mg, 1.0 mmol, 1.0 
eq.) in acetone (6 mL). The mixture was stirred at room temperature in the dark for 2 
h. After cooling to 0 °C, the reaction was quenched with H2O (10 mL) and the mixture was diluted 
with Et2O (10 mL). The organic layer was separated and the aqueous layer was extracted with Et2O  
(3 x 10 mL). The combined organic extracts were washed with sat. aq. NaCl (10 mL), dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude bromo alkyne was directly 
used in the next step.  
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Prepared according to GP-2: Crude bromo alkyne (130 mg, 0.73 mmol, 1.0 eq.), aq. BuNH2 (30% in 
water, 4 mL), CuCl (6.9 mg, 0.07 mmol, 10 mol%), liquid propyne (0.1 mL). The crude material was 
purified by flash chromatography (SiO2, 10% Et2O in pentane) to yield 41 mg (40%) of the title 
compound as a volatile liquid. 
1H NMR (400 MHz, CDCl3): δ = 2.91 (ddd, J = 6.4, 3.8, 2.6 Hz, 1H), 2.78 (dd, J = 4.9, 3.9 Hz, 1H), 2.67 
(dd, J = 4.9, 2.5 Hz, 1H), 2.51 – 2.39 (m, 1H), 1.91 (d, J = 1.1 Hz, 3H), 1.32 (d, J = 7.0 Hz, 3H)  13C NMR 
(101 MHz, CDCl3): δ = 75.3, 74.9, 67.6, 64.1, 54.7, 46.4, 29.9, 17.7, 4.3 IR (film, cm-1): 2982, 2932, 
1722, 1455, 1258, 1073, 1025, 922, 882, 828 MS: m/z calcd for C9H10O 134.07333, found 134.07317 
>D@20 =  + 59.7 (c = 0.5 CHCl3). 
 
4-Iodocyclopent-1-ene (309). A 50 mL flask was charged with triphenylphosphine (1.62 g, 6.18 mmol, 
1.3 eq.), imidazole (420 mg, 6.18 mmol, 1.3 eq.) and CH2Cl2 (15 mL). After stirring for 5 min the 
solution was cooled to 0 °C. Iodine (1.56 g, 6.18 mmol, 1.3 eq.) was added in three portions 
every 5 min. Stirring was continued for 15 min at 0 °C, before a solution of alcohol 309 (400 mg, 4.75 
mmol, 1.0 eq.), in CH2Cl2 (2 mL) was added with a syringe pump over the course of 45 min. The 
mixture was stirred overnight and diluted with pentane (50 mL) which resulted in the formation of 
large amounts of precipitate. The precipitate was filtered off and the procedure was repeated 
yielding 750 mg (81%) of the desired product as a light yellow liquid. 
1H NMR (400 MHz, CDCl3): δ = 5.75 (d, J = 0.8 Hz, 2H), 4.54 (tt, J = 6.8, 4.4 Hz, 1H), 3.03 – 2.80 (m, 4H) 
13C NMR (101 MHz, CDCl3): δ = 129.6(2C), 46.7(2C), 22.9 IR (film, cm-1): 2826, 1428, 1200, 1126, 896, 
730 MS: m/z calcd for C5H7I 193.95940 found 193.95925. 
 
(2R,3R)-1-(Cyclopent-3-en-1-yl)-3-methyl-5-(trimethylsilyl)pent-4-yn-2-ol (264). A solution of freshly 
prepared cyclopent-3-enylmagnesiumbromide (1.3 M in Et2O, 4.0 mL, 5.22 mmol, 
1.8 eq.) was added at -40 °C to a stirred suspension of CuI (552 mg, 2.9 mmol, 1.0 
eq.) in THF (20 mL). The mixture was stirred for 30 min, while the suspension turned from light grey 
to dark grey. A solution of epoxide 265 (500 mg, 2.9 mmol, 1.0 eq.) in THF (3.5 mL) was added 
dropwise and the solution was stirred for 2 h between -40 °C and -30 °C. The reaction was quenched 
with sat. aq. NH4Cl (15 mL) and the organic layer was separated. The aqueous layer was extracted 
with Et2O (3 x 20 mL) and the combined organic extracts were dried over MgSO4. The solvent was 
removed under reduced pressure and the crude material was purified by flash chromatography (SiO2, 
10% Et2O in pentane) to yield 620 mg (87%) of the title compound as a colorless liquid.  
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1H NMR (400 MHz, CDCl3): δ = 5.74 – 5.62 (m, 2H), 3.65 – 3.55 (m, 1H), 2.64 – 2.40 (m, 4H), 2.08 – 
1.93 (m, 2H), 1.72 (d, J = 5.7 Hz, 1H), 1.61 (ddd, J = 8.0, 4.8, 3.0 Hz, 2H), 1.15 (d, J = 7.0 Hz, 3H), 0.15 
(s, 9H) 13C NMR (101 MHz, CDCl3): δ = 130.2, 129.7, 108.8, 86.9, 73.2, 40.3, 39.7, 38.6, 34.4, 34.3, 
15.6, 0.3 (3C) IR (film, cm-1): 3360, 3054, 2959, 2932, 2165, 1249, 1055, 839, 759 MS: m/z calcd for 
C14H24OSiNa 259.14885, found 259.14886 >D@20 = + 16.1 (c =0.4, CHCl3). 
 
(2R,3R)-1-(Cyclopent-3-en-1-yl)-3-methylocta-4,6-diyn-2-ol (312). NBS (266 mg, 1.5 mmol, 1.2 eq.) 
and AgNO3 (20 mg, 0.12 mmol, 10 mol%) were successively added in the dark to a 
solution of TMS-alkyne 264 (300 mg, 1.26 mmol, 1.0 eq.) in acetone (7 mL). The 
solution was stirred for 2 h before it was diluted with Et2O/pentane (2:3, 30 mL). The organic layer 
was washed three times with H2O (10 mL) and the solvent was carefully removed under reduced 
pressure. The crude bromo alkyne was directly used in the next step.  
Prepared according to GP-2: Crude bromo alkyne (306 mg, 1.26 mmol, 1.0 eq.), aq. BuNH2 (30% in 
water, 6 mL), CuCl (11.2 mg, 0.12 mmol, 10 mol%), liquid propyne (0.1 mL). The crude material was 
purified by flash chromatography (SiO2, 10% Et2O in pentane) to yield 140 mg (60% over two steps) of 
the title compound. 
1H NMR (400 MHz, CDCl3): δ = 5.73 – 5.63 (m, 2H), 3.59 (dd, J = 9.0, 4.5 Hz, 1H), 2.64 (ddt, J = 6.7, 5.6, 
1.4 Hz, 1H), 2.58 – 2.43 (m, 3H), 2.01 (tddd, J = 16.8, 8.3, 3.9, 2.4 Hz, 2H), 1.92 (d, J = 1.1 Hz, 3H), 1.66 
– 1.62 (m, 2H), 1.18 (d, J = 7.0 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 130.2, 129.7, 78.0, 74.5, 73.4, 
67.6, 64.3, 40.4, 39.6, 38.5, 34.3, 34.0, 15.8, 4.3 IR (film, cm-1): 3393, 2931, 2842, 1451, 1070, 1038, 
971 MS: m/z calcd for C14H18ONa 225.12475, found 225.12498 >D@ 20 = + 9.2 (c =0.4, CHCl3). 
 
(1R,2S)-4-((2R,3R)-2-Hydroxy-3-methylocta-4,6-diyn-1-yl)cyclopentane-1,2-diol (263). NMO (140.7 
mg, 1.2 mmol, 1.7 eq.) and OsO4 (4% in water, 0.12 mL, 0.002 mmol, 4 mol%) 
were added successively to a stirred solution of alkene 313 (140 mg, 0.69 
mmol, 1.0 eq.) in acetone/H2O (2:1, 5 mL), which resulted in a color change to 
light yellow. The mixture was stirred at ambient temperature until complete conversion of the 
starting material was reached, as judged by TLC. The reaction was quenched with sat. aq. Na2S2O3 (5 
mL) and the mixture was stirred for 30 min before it was diluted with EtOAc (10 mL). The organic 
layer was separated and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were washed with H2O (10 mL), dried over MgsO4 and the solvent was removed 
under reduced pressure. The crude material was purified by flash chromatography (SiO2, 2% MeOH in 
EtOAc) to afford 110 mg (70%, 7.7 : 1 d.r.) of the title compound as a white solid. 
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1H NMR (400 MHz, CD3OD): δ = 4.04 (ddd, J = 4.7, 3.4, 1.6 Hz, 2H), 3.36 (ddd, J = 9.7, 7.0, 2.6 Hz, 1H), 
2.59 – 2.47 (m, 1H), 2.44 (tq, J = 7.0, 1.1 Hz, 1H), 1.94 – 1.84 (m, 2H), 1.88 (d, J = 1.1 Hz, 3H), 1.61 
(ddd, J = 13.9, 10.0, 2.6 Hz, 1H), 1.53 – 1.40 (m, 3H), 1.17 (d, J = 7.0 Hz, 3H) 13C NMR (101 MHz, 
CD3OD): δ = 78.9, 74.8, 74.8, 74.6, 74.4, 68.2, 65.1, 43.1, 39.4, 38.2, 35.2, 32.2 17.3, 3.5 IR (film, cm-1): 
3302, 1933, 2914, 1343, 1134, 1111, 1078, 1040, 1026, 986, 882, 869, 716 MS: m/z calcd for 
C14H20O3Na 259.13021, found 259.13046 >D@20 = + 17.1 (c =0.4, CHCl3). 
 
2-((2R,4S)-2-((R)-Hepta-3,5-diyn-2-yl)-6-oxotetrahydro-2H-pyran-4-yl)acetaldehyde (262). NaIO4 
(10% on SiO2, 2.56 g, 1.2 mmol, 2.85 eq.) was added to a vigorously stirred 
suspension of diol 263 (100 mg, 0.42 mmol, 1.0 eq.) in CH2Cl2 (8 mL). The reaction 
mixture was stirred at ambient temperature for 20 min before it was filtered 
through a short pad of SiO2. The SiO2 was rinsed with Et2O (50 mL) and the filtrate 
was evaporated under reduced pressure to yield a 1:1 mixture of anomers which were used directly 
for the next step.  
PIDA (283 mg, 0.88 mmol, 2.1 eq.) and TEMPO (9.3 mg, 0.06 mmol, 14 mol%) were added to a 
solution of the anomeric mixture in CH2Cl2 (4 mL). The yellowish solution was cooled to 0 °C and 
Yb(OTf)3 (20.4 mg, 0.03 mmol, 7 mol%) was added. The cooling bath was removed and the mixture 
was stirred at ambient temperature for 1 h. The reaction was diluted with CH2Cl2 (4 mL) and 
quenched with sat. aq. Na2S2O3 (4 mL). The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried over MgSO4 and the 
solvent was evaporated under reduced pressure. The crude material was purified by flash 
chromatography (SiO2, 40% EtOAc in hexane) to yield 75 mg (76% over two steps) of the title 
compound as a colorless gum. 
1H NMR (400 MHz, CDCl3): δ = 9.79 (s, 1H), 4.16  (ddd, J = 11.5, 6.9, 3.3 Hz, 1H), 2.85 – 2.75 (m, 2H), 
2.60 – 2.53 (m, 3H), 2.26 (dtd, J = 13.7, 3.1, 1.7 Hz, 1H), 2.14 (dd, J = 17.5, 10.5 Hz, 1H), 1.92 (d, J = 1.1 
Hz, 3H), 1.39 (dt, J = 13.7, 11.5 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H) 13C NMR (101 MHz, CDCl3): δ = 199.5, 
169.7, 81.9, 75.2, 75.2, 68.6, 64.1, 49.8, 35.9, 32.9, 32.0, 25.8, 17.0, 4.3 IR (film, cm-1): 2918, 1724, 
1385, 1235, 1082 MS: m/z calcd for C14H16O3Na 255.09900 found 255.09916  
>D@20 = -18.6 (c =0.35, CHCl3). 
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(E)-4-((2R,4R)-2-((R)-Hepta-3,5-diyn-2-yl)-6-oxotetrahydro-2H-pyran-4-yl)but-2-enoic acid (255). 
Diethylphosphonoacetic acid (12.4 mg, 0.062 mmol, 1.1 eq.) was added to a 
suspension containing Zn(OTf)2 (43.6, 0.12 mmol, 2.0 eq.), TMEDA (7.7 mg, 0.067 
mmol, 1.2 eq.), DBU (33.5 mg, 0.22 mmol, 4.0 eq.) and THF (1 mL). The 
suspension was cooled to 0 °C and aldehyde 262 (13 mg, 0.056 mmol, 1.0 eq.) was added. The 
cooling bath was removed and the suspension was stirred for 16 h at ambient temperature, while it 
became a clear yellow solution. The reaction was quenched with sat. aq. NH4Cl (5 mL) and the 
organic layer was separated. The aqueous layer was extracted with CH2Cl2 (3 x 5 mL) and the 
combined organic extracts were dried over MgSO4. The solvent was carefully removed under reduced 
pressure and the crude material was purified by flash chromatography (SiO2, 50% MeOH in EtOAc) to 
give 10 mg (70%) of the title compound as a white powder.  
1H NMR (400 MHz, CD3OD): δ = 6.70 – 6.59 (m, 1H), 5.90 (d, J = 15.6 Hz, 1H), 4.28 (ddd, J = 11.7, 6.2, 
2.8 Hz, 1H), 2.93 – 2.80 (m, 1H), 2.76 – 2.64 (m, 1H), 2.28 – 2.13 (m, 4H), 1.89 (d, J = 1.1 Hz, 3H), 1.44 
– 1.28 (m, 2H) 1.24 (d, J = 7.1 Hz, 3H) 13C NMR (101 MHz, CD3OD): δ = 173.5(2C), 141.5, 130.5, 83.5, 
76.3, 75.5, 69.1, 64.7, 39.2, 36.6, 33.6, 32.4, 31.9, 16.8, 3.5 IR (film, cm-1): 3377, 2919, 1719, 1655, 
1544, 1418, 1252, 1171, 1033 MS: m/z calcd for C16H18O4Na 297.10943, found 297.10973  
>D@20 = +2.1 (c =0.1, MeOH). 
4.9. Fragment assembly and RCDM 
(5S,7S,8S,9R,E)-9-Methoxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-dioxa-
3,14-disilahexadec-10-en-7-yl 2-(diethoxyphosphoryl)acetate (318). 
Diethylphosphono acetic acid (22.1 mg, 0.11 mmol, 2.8 eq.) was added to a 
flask containing CH2Cl2 (1 mL) and 3 Å MS (beads). The solution was cooled 
to 0 °C before EDC·HCl (13.4 mg, 0.072 mmol, 1.8 eq.) was added and the 
solution was stirred for 15 min. A solution of alcohol 305 (20.1 mg, 0.039 mmol, 1.0 eq.) in CH2Cl2 (0.5 
mL) was added, the cooling bath was removed and DMAP (1.5 mg, 0.013 mmol, 30 mol%) was 
introduced. The yellow solution was stirred for 8 h at ambient temperature. The solvent was 
removed under reduced pressure and the crude material was purified by flash chromatography (SiO2, 
10% Æ 15% EtOAc in hexane) to afford 25.3 mg (94%) of the title compound as a colorless oil. 
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1H NMR (400 MHz, CDCl3): δ = 5.53 – 5.48 (m, 1H), 4.98 – 4.89 (m, 1H), 4.42 – 4.35 (m, 1H), 4.31 (dd, J 
= 13.2, 7.1 Hz, 1H), 4.22 – 4.09 (m, 5H), 3.19 (d, J = 7.0 Hz, 1H), 3.17 (s, 3H), 2.93 (dq, J = 21.8, 14.3 Hz, 
2H), 2.10 – 2.01 (m, 1H), 1.93 (d, J = 1.0 Hz, 3H), 1.89 (td, J = 9.2, 8.3, 3.3 Hz, 2H), 1.61 – 1.58 (m, 3H), 
1.34 (t, J = 7.1 Hz, 6H), 0.94 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 0.87 (s, 9H), 0.12 (s, 3H), 0.07 (s, 6H), 0.05 
(s, 3H) 13C NMR (101 MHz, CDCl3): δ = 164.9, 133.2, 129.3, 87.5, 76.5, 73.3, 63.8, 62.8, 62.6, 59.9, 
59.9, 56.5, 38.5, 38.3, 35.3, 34.0, 26.1(3C), 25.9(3C), 18.5, 18.3, 16.4, 16.3, 16.3, 11.9, 9.8, 4.5, -4.5, -
5.1(2C), -5.2 IR (film, cm-1): 2955, 2929, 2856, 1735, 1471, 1463, 1255, 1090, 1048, 1024, 834, 777 
MS: m/z calcd for C34H63O8PSi2Na 709.36890, found 709.36914 >D@20 = -10.0 (c = 0.2, CHCl3). 
 
 Metathesis precursor (319). LiCl (3.8 mg, 0.09 mmol, 2.5 eq.) was added to a Schlenk flask 
containing a solution of phosphonate 317 (25 mg, 0.036 mmol, 1.0 
eq.) in MeCN (1 mL). The mixture was stirred at ambient 
temperature for 20 min before DBU (6 mg, 0.039, 1.1 eq.) was added 
and the reaction was cooled to 0 °C. Stirring was continued for an 
additional 15 min before a solution of aldehyde 262 (10.5 mg, 0.045 
mmol, 1.25 eq.) in THF (0.6 mL) was added. The cooling bath was removed and the mixture was 
stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the crude 
material was purified via flash chromatography (SiO2, 5% EtOAc in hexane) to yield 15 mg (54%) of 
title compound and 3.5 mg (12%) of recovered 317. 
1H NMR (400 MHz, CDCl3): δ = 6.83 (dt, J = 15.4, 7.3 Hz, 1H), 5.87 (dt, J = 15.5, 1.5 Hz, 1H), 5.51 (ddd, J 
= 8.2, 5.0, 1.4 Hz, 1H), 4.91 (ddd, J = 10.7, 4.3, 2.4 Hz, 1H), 4.39 – 4.28 (m, 2H), 4.17 (ddd, J = 13.2, 4.7, 
1.2 Hz, 1H), 4.10 (ddd, J = 11.7, 7.0, 3.0 Hz, 1H), 3.16 (s, 3H), 3.14 – 3.18 (m, 1H) 2.81 (ddt, J = 8.0, 6.9, 
1.1 Hz, 1H), 2.68 (td, J = 11.0, 10.4, 1.9 Hz, 1H), 2.28 – 2.18 (m, 3H), 2.16 – 2.08 (m, 3H), 1.93 (d, J = 
1.0 Hz, 3H), 1.91 (d, J = 1.1 Hz, 3H), 1.94 – 1.80 (m, 2H), 1.64 – 1.61 (s, 3H) 1.41 – 1.31 (m, 1H), 1.28 
(d, J = 7.0 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.86 (s, 9H), 0.09 (s, 3H), 0.07 (s, 6H), 0.00 (s, 
3H) 13C NMR (101 MHz, CDCl3): δ = 169.9, 165.3, 144.4, 133.3, 129.7, 124.4, 88.1, 81.8, 76.9, 76.7, 
75.2, 75.2, 71.8, 69.5, 68. 6.64.1, 63.9, 59.9, 59.7, 56.4, 38.7, 38.3, 37.9, 36.0, 32.9, 32.0, 30.8, 
26.1(3C), 25.8(3C), 18.5, 18.1, 17.0, 11.6, 10.1, 4.5, 4.3, -4.5, -5.0(2C), -5.2 IR (film, cm-1): 2929, 2856, 
1718, 1250, 1089, 1048, 835, 778 MS: m/z calcd for C44H68O7Si2Na 787.43961, found 787.43958  
>D@20 = -10.0 (c =0.2, CHCl3). 
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Macrocycle (320). Procedure 1: A solution of ligand L1 (9.7 mg, 0.011 mmol) and catalyst C7 (6.5 mg, 
0.01 mmol) in 1 mL toluene was vigorously stirred for 10 min to give a clear 
brown stock solution of the active catalyst (0.01 mmol/mL) which has to be 
used within ca 30 - 40 min before it turns dark. 
A 10 mL Schlenk flask was charged with 5 Å MS (25 mg). The flask was 
evacuated (0.01 mbar) and the molecular sieves were dried for 5 min (350°C, 
heat gun). The flask was backfilled with Ar and substrate 318 (6.0 mg, 0.0078 mmol, 1.0 eq.) was 
introduced as a solution in toluene (3.5 mL). After stirring for 1 h at room temperature, the flask was 
immersed into an oil bath at 65 °C and an aliquot of the catalyst stock solution (0.01 mmol/ mL in 
toluene, 0.23 mL, 0.0023 mmol, 30 mol%) was added. The mixture was stirred at 65 °C for 1.5 h. The 
reaction was allowed to cool to ambient temperature and filtrated through a pad of silica, which was 
rinsed with EtOAc (30 mL). Purification of the crude material by flash chromatography (SiO2, 10% Æ 
15% Æ 20% EtOAC in hexane) yielded 2.9 mg (50% calculated by NMR) of the title compound 
contaminated with an impurity from the silanol ligand. 
Procedure 2: Cyclization was done according to GP-1: Substrate 319 (6.0 mg, 0.0078 mmol, 1.0 eq.), 
5Å MS (25 mg), C5 (2.5 mg, 0,0024 mmol, 30 mol%), toluene (3.5 mL), 1 h, 65 °C. Purification by flash 
chromatography (SiO2, 10% Æ 15% Æ 20% EtOAC in hexane) yielded 3.1 mg (58%) of the title 
compound as a white solid. 
1H NMR (600 MHz, CDCl3): δ = 6.84 (ddd, J = 15.8, 10.2, 5.7 Hz, 1H), 5.92 (d, J = 15.7 Hz, 1H), 5.45 (t, J 
= 6.0 Hz, 1H), 4.75 (dd, J = 9.3, 3.8 Hz, 1H), 4.34 – 4.28 (m, 2H), 4.21 (dd, J = 13.3, 5.2 Hz, 1H), 4.02 
(ddd, J = 11.2, 7.4, 4.0 Hz, 1H), 3.17 (s, 3H), 3.16 (d, J = 6.2 Hz, 1H), 2.75 (p, J = 7.1 Hz, 1H), 2.72 (dq, J 
= 17.6, 2.6, 1.9 Hz, 1H), 2.49 (dt, J = 12.1, 3.9 Hz, 1H), 2.46 – 2.39 (m, 1H), 2.24 (dd, J = 17.4, 10.9 Hz, 
1H), 2.09 (td, J = 10.0, 2.8 Hz, 2H), 2.08 – 1.99 (m, 1H), 1.95 (q, J = 10.5 Hz, 1H), 1.83 (dd, J = 14.4, 4.0 
Hz, 1H), 1.66 (s, 3H), 1.34 – 1.29 (m, 1H), 1.25 (d, J = 7.2 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 
0.90 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.07 (s, 6H) 13C NMR (101 MHz, CDCl3): δ = 170.3, 165.6, 144.4, 
134.6, 129.8, 126.3, 88.6, 82.3, 80.6, 78.7, 72.6, 69.6, 68.8, 63.2, 59.8, 56.4, 39.2, 38.0, 37.6, 36.4, 
34.0, 30.7, 29.7, 26.1(3C), 25.8(3C), 18.5, 18.2, 16.6, 11.4, 9.9, -4.3, -4.8, -5.0, -5.0 IR (film, cm-1): 
2927, 2855, 1718, 1463, 1258, 1083, 837, 779 MS: m/z calcd for C38H62O7Si2Na 709.39287, found 
709.39263 >D@20 = +4.0 (c =0.1, CHCl3). 
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Macrocyclic diol (321). TBAF (1.0 M in THF, 0.012 mL, 0.012 mmol, 2.8 eq.) was added at -50 °C to a 
solution of macrocycle 320 (3 mg, 0.0044 mmol, 1.0 eq) in THF (0.4 mL). The 
solution was allowed to warm to -10 °C over 2 h and maintained at this 
temperature for 3 h. The mixture was diluted with Et2O (2 mL) and quenched 
with H2O (2 mL). The organic layer was separated and the aqueous layer was 
extracted with Et2O (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude material was purified by 
flash chromatography (SiO2, 60% Æ 70% Æ 80% EtOAc in hexane, then 20% MeOH in EtOAc) to 
afford 1.4 mg (71%) of the title compound. 
1H NMR (400 MHz, CDCl3): δ = 6.85 (ddd, J = 15.7, 10.1, 5.6 Hz, 1H), 5.93 (d, J = 16.1 Hz, 1H), 5.57 (dt, 
J = 5.9, 0.9 Hz, 1H), 4.78 (ddd, J = 9.2, 3.9, 1.2 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 4.26 (d, J = 6.6 Hz, 2H), 
4.02 (ddd, J = 11.3, 7.4, 4.0 Hz, 1H), 3.19 (d, J = 8.6 Hz, 1H), 3.17 (s, 3H), 2.80 – 2.69 (m, 2H), 2.51 
(ddd, J = 8.9, 7.4, 3.4 Hz, 1H), 2.46 – 2.38 (m, 1H), 2.25 (dd, J = 17.3, 10.7 Hz, 1H), 2.15 – 1.91 (m, 6H), 
1.71 (dt, J = 1.5, 0.8 Hz, 3H), 1.34 – 1.29 (m, 1H) 1.24 (d, J = 5.8 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H). 
Stannane (322). A stock solution of stannane was prepared by dissolving Bu3SnH (0.004 mL, 0.014 
mmol) in freshly degassed CH2Cl2 (2 mL). A stock solution of catalyst was 
prepared by dissolving [Cp*RuCl4] C8a (2 mg, 0.013 mmol) in freshly degassed 
CH2Cl2 (1 mL). 
Diol 321 (1 mg, 0.0022 mmol, 1.0 eq.) was transferred to a Schlenk flask and 
dried by applying vacuum (0.01 mbar) for 15 min. An aliquot of the catalyst stock solution (0.1 mL of 
the prepared solution, 0.0004 mmol, 15 mol%) was added causing a color change to deep purple. The 
solution was stirred for 1 min before Bu3SnH (0.4 mL of the prepared solution, 0.0025 mmol, 1.15 
eq.) was added over the course of 30 min. After complete addition the reaction was further stirred 
for 5 min. The solvent was removed under a stream of argon and the crude material was purified by 
flash chromatography (SiO2, 50% Æ 60% EtOAc in hexane) to afford 1.1 mg (66%) of the title 
compound. 
1H NMR (600 MHz, CDCl3): δ = 6.78 (ddd, J = 15.7, 11.0, 5.0 Hz, 1H), 5.99 (d, J = 3.1 Hz, JSn-H = 105.6 
Hz, 1H), 5.77 (d, J = 15.7 Hz, 1H), 5.62 (td, J = 6.5, 0.8 Hz, 1H), 4.73 (dd, J = 9.8, 3.3 Hz, 1H), 4.28 (t, J = 
7.3 Hz, 2H), 4.08 – 4.00 (m, 1H), 3.91 – 3.85 (m, 1H), 3.21 (d, J = 9.1 Hz, 1H), 3.18 (s, 3H), 2.79 (ddd, J 
= 17.9, 5.4, 2.3 Hz, 1H), 2.67 – 2.62 (m, 1H), 2.61 (ddd, J = 14.3, 5.4, 2.8 Hz, 1H), 2.56 – 2.50 (m, 2H), 
2.19 – 2.11 (m, 1H), 2.12 – 2.04 (m, 1H), 1.88 (dt, J = 14.9, 10.2 Hz, 1H), 1.82 – 1.74 (m, 3H), 1.73 (d, J 
= 1.2 Hz, 3H), 1.15 – 1.04 (m, 6H), 0.98 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 7.3 Hz, 9H) 119Sn NMR (149 MHz, 
CDCl3): -52.1 13C NMR (101 MHz, CDCl3): δ = 169.9, 166.2, 165.4, 145.1, 137.0, 91.6, 89.1, 83.7, 81.6, 
73.8, 59.0, 56.2, 39.2, 38.0, 37.0, 36.2, 34.0, 33.1, 30.3, 29.2 (3C), 27.6 (3C), 16.7, 14.1, 13.8 (3C), 
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11.0, 10.9 (3C), 10.2 IR (film, cm-1): 2924, 2853, 1988, 1718, 1657, 1082 MS: m/z calcd for 
C38H62O7SnNa 773.34099, found 773.34090. 
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Atom Chemical Shift J COSY HSQC HMBC
1 C 58.95 1
H2 4.28 2 1 2, 3
2 C 128.68 2 1, 4, 25
H 5.62 1 2 4, 25
3 C 137.01 1, 25
4 C 89.10 4 2, 26, 25, 24
H 3.21 9.10(5) 5 4 2, 26, 24, 25, 5
5 C 39.21 5 4, 24
H 2.08 9.10(4) 4, 24, 6 5
6 C 73.80 6 7a, 24
H 4.73 5, 7a, 7b 6 22, 8, 24
7 C 36.21 7b, 7a
Ha 1.88 6, 8 7 9, 6, 8
Hb 1.79 6, 8 7 9, 8
8 C 81.58 8 10, 6, 7a, 7b
H 4.03 7a, 7b 8 10
9 C 166.19 10, 7a, 7b
10 C 119.14 10 8
H 5.99 10 9, 12, 8
11 C
12 C 91.56 10, 23
13 C 34.03 13 23
H 2.65 14, 23 13
14 C 83.72 14 17b, 23
H 3.89 13, 17b, 17a 14
15 C 169.89 16a, 16b
16 C 36.96 16a, 16b
Ha 2.79 16b, 18, 17a 16 15, 17
Hb 2.15 16a 16 15, 18, 19
17 C 33.13 17a, 17b 16a, 19a, 19b
Ha 2.61 14, 17b, 16a, 18 17
Hb 0.97 14, 17a 17 14
18 C 30.29 18 16b
H 1.88 19b, 16a, 17a 18
19 C 37.96 19a, 19b 21, 16b
Ha 2.53 20, 19b 19 17
Hb 1.78 20, 19a, 18 19 20, 21, 17
20 C 145.10 20 19b
H 6.78 15.70(21) 21, 19a, 19b 20 22
21 C 125.55 21 19b
H 5.77 15.70(20) 20 21 22, 19
22 C 165.39 20, 21, 6
23 C 16.65 23
H3 1.29 13 23 12, 14, 13
24 C 10.17 24 4, 6
H3 0.98 5 24 6, 4, 5
25 C 11.01 25 2, 4
H3 1.73 25 2, 3, 4
26 C 56.24 26 4
H3 3.18 26 4
31 31' 31''C 10.93 31 31' 31''
H2 1.09 32 32' 32'' 31 31' 31''
32 32' 32'' C 29.21 32, 32' 32''
H2 1.56 31,33, 31', 33' 31'', 33'' 32, 32' 32''
33 33' 33'' C 27.56 33, 33', 33''
H2 1.36 32, 34, 32', 34', 32'', 34'' 33, 33', 33''
34 34' 34'' C 13.76 34, 34', 34''
H3 0.93 33, 33', 33'' 34, 34', 34''  
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6. List of abbreviations  
9-BBN  9-borabicyclo(3.3.1)nonane 
Ac  acetyl  
AIBN  azobisisobutyronitrile 
aq  aqueous 
Ar  aryl  
BINOL  1,1´-bi-2-naphtol 
Bn  benzyl 
Br  broad 
brsm  based on recovered starting material 
Bu  butyl 
Bz  benzoyl 
cat.  catalytic 
CI  chemical ionization 
CBS  Corey-Bakshi-Shibata 
CC50  concentration of the compound that reduced cell viability to 50% 
ConA  concavalin A 
COSY  correlation spectroscopy 
m-CPBA meta-chloroperoxybenzoic acid  
Cp  cyclopentadienyl 
Cp*  1,2,3,4,5-pentamethylcyclopentadienyl 
CsA  cyclosporin A 
Cy  cyclohexyl 
Δ  reflux temperature 
dba  dibenzylideneacetone  
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC  dicyclohexylcarbodiimide 
DCE  1,2-dichloroethane 
d  doublet 
DDQ  2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEPT  distorsionless enhancement by polarization transfer 
DIBAL-H diisobutylaluminium hydride 
DMAP  N,N-dimethyl 4-aminopyridine 
DMF  dimethylformamide 
DMP  Dess-Martin Periodinane 
DMS  dimethyl sulfide 
DMSO  dimethylsulfoxide  
d.r.  diasteromeric ratio  
EDC·HCl 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EE  ethoxy ethyl 
ee  enantiomeric excess 
ent  enantiomeric 
ESI  electronspray ionization 
Et  ethyl 
g  gram 
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GC  gas chromatography  
h   hour 
IBX  2-iodoxybenzoic acid 
HMBC  heteronuclear multiple quantum coherence 
HMPA  hexamethylphosphoramide 
HSQC  heteronuclear single quantum coherence 
HPLC  high pressure liquid chromatography 
HWE  Horner-Wadsworth-Emmons olefination 
IC50  half maximal inhibitory concentration 
IR  infrared spectroscopy 
KHMDS  potassium hexamethyldisilazide 
l  liter 
LDA  lithium diisopropylamide 
LiHMDS lithium hexamethyldisilazide 
mol  molar 
m  multiplet 
Me  methyl 
mg  milligram 
min  minute  
mL  milliliter 
MOM  methoxy methyl 
MTBE  tert-butylmethylether 
Ms  methanesulfonyl 
MS  mass spectrometry 
MS  molecular sieves 
N  normal (mol/kg) 
NBS  N-bromosuccinimide 
NMI  N-methylimidazole 
NMR  nuclear magnetic resonance 
NOE  nuclear overhauser effect 
Ph  phenyl 
PIDA  phenyliodine-(III)-diacetate 
PG  protecting group 
PKS  polyketide synthase 
PMB  para-methoxybenzyl 
PNB  para-nitrobenzoate 
PPTS  pyridinium-para-toluenesulfonate 
Pr  propyl 
ProPhenol 2,6-Bis((2-(hydroxydiphenylmethyl)pyrrolidin-1-yl)methyl)-4-methylphenol 
q  quartet 
quant.  quantitative 
RCAM  ring-closing alkyne metathesis 
RCDM  ring-closing alkyne metathesis of 1,3-diyne 
RCM  ring-closing (olefin)metathesis 
rt  room temperature 
s  singlet 
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sm  starting material 
sat.  saturated 
t  triplet 
TBAF  tetra-n-butylammonium fluoride 
TBDPS  tert-butyldiphenylsilyl 
TBS  tert-butyldimethylsilyl 
Tc  thiophene-2-carboxylate 
TEMPO  (2,2,6,6-tetramethyl-piperidin-1-yl)oxyl 
TES  triethylsilyl 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
TMS  trimethylsilyl 
Tol  tolyl 
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8. Appendix 
8.1 Spectra of synthetic ivorenolide B 
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8.2 Spectra of synthetic ivorenolide A 
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8.3 Spectra of macrocycle 320 
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